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VASCULOGENESIS IN THREE DIMENSIONAL (3D) COLLAGEN MATRICES 
IN VITRO AND IN VIVO 
 
Human cord blood (CB) derived circulating endothelial colony forming cells 
(ECFCs) display a hierarchy of clonogenic proliferative potential and possess de 
novo vessel forming ability upon implantation in immunodeficient mice. Since 
survival of ECFC post-implantation is a critical variable that limits in vivo 
vasculogenesis, we tested the hypothesis that activation of Notch signaling or co-
implantation of ECFC with human platelet lysate (HPL) would enhance cultured 
ECFC vasculogenic abilities in vitro and in vivo. Co-implantation of ECFCs with 
Notch ligand Delta-like 1 (DL1) expressing OP9 stromal cells (OP9-DL1) 
decreased apoptosis of ECFC in vitro and increased vasculogenesis of ECFC in 
vivo. The co-culture of ECFC with HPL diminished apoptosis of ECFC by altering 
the expression of pro-survival molecules (pAkt, pBad and Bcl-xL) in vitro and 
increased vasculogenesis of human EC-derived vessels both in vitro and in vivo. 
Thus, activation of the Notch pathway by OP9-DL1 stromal cells or co-
implantation of ECFC with HPL enhances vasculogenesis and augments blood 
vessel formation by diminishing apoptosis of the implanted ECFC. The results 
from this study will provide critical information for the development of a cell 
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therapy for limb and organ re-vascularization that can be applied to recovery of 
ischemic tissues in human subjects. 
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CHAPTER 1. INTRODUCTION 
1.1. Development Of Blood Vessels 
During organogenesis, the development of the vascular system is one of the 
earliest events for the proper formation of vertebrate embryos and the system 
must remain responsive to growth and regeneration signals for the survival of 
adult tissues and organs (Hannan & Little, 1998; Jin, Beis, Mitchell, Chen, & 
Stainier, 2005; Lamalice, Le Boeuf, & Huot, 2007; Risau & Flamme, 1995; Wilting 
& Christ, 1996). Blood vessels deliver oxygen and nutrients, carry away 
metabolic waste products and serve as the principle interface for the circulating 
immune cell response to microbes that have invaded tissues (Adams & Alitalo, 
2007). The vascular system, composed of functional arteries, veins, and 
capillaries, originates via two fundamental processes: vasculogenesis and 
angiogenesis (Figure 1.1.) (Adams & Alitalo, 2007; Lamalice et al., 2007; Risau, 
1997).   
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Figure 1.1. A schematic diagram of vascular development during 
embryonic development. During embryogenesis, angioblasts are derived from 
mesoderm. Angioblasts give rise to the primary capillary plexus via 
vasculogenesis before circulation is established. Subsequently, the primary 
capillary plexus is quickly expanded, recruits mural cells and is remodeled into 
primary vessels. Primary vessels may be further remodeled through sprouting 
and intussusceptive angiogenesis and ultimately this leads to the formation of a 
well-organized arterial, capillary, and venous bed. Reprinted with permission 
from “Molecular regulation of angiogenesis and lymphangiogenesis” by Adams et 
al., 2007, Nat Rev Mol Cell Biol, 8:464-478 (Adams & Alitalo, 2007).  
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Vasculogenesis 
During early embryogenesis, on mouse embryonic day (E) 6.5, gastrulation 
begins with the formation of the primitive streak and leads to formation of three 
principle germ layers: ectoderm, mesoderm, and endoderm (Hannan & Little, 
1998; Risau & Flamme, 1995; Wilting & Christ, 1996; Zorn & Wells, 2009). The 
first step of blood vessel formation is the differentiation of vascular endothelial 
cells (ECs), which cover the entire inner surface of all blood vessels. A subset of 
the primitive mesodermal cells is committed to differentiate into not only the first 
ECs, called angioblasts but also into hemangioblastic cells in the yolk sac 
(Adams & Alitalo, 2007; Carmeliet, 2000; Coultas, Chawengsaksophak, & 
Rossant, 2005; Lamalice et al., 2007; Risau, 1997). The angioblasts migrate and 
aggregate to form blood islands, which are the earliest discernible vascular 
structures that give rise to a primitive vascular network in the yolk sac (Adams & 
Alitalo, 2007; Carmeliet, 2000; Carmeliet et al., 1996; Coultas et al., 2005; 
Ferrara, 1999; Ferrara et al., 1996; Hannan & Little, 1998; Lamalice et al., 2007; 
Risau, 1997; Risau & Flamme, 1995; Shalaby et al., 1997; Wilting & Christ, 1996). 
Fusion of blood islands and subsequent endothelial cell differentiation lead to 
formation of primitive capillary structures driven by certain growth factors binding 
to their EC surface receptors (Adams & Alitalo, 2007; Carmeliet, 2000; Carmeliet 
et al., 1996; Coultas et al., 2005; Ferrara, 1999; Ferrara et al., 1996; Lamalice et 
al., 2007; Risau, 1997; Shalaby et al., 1997).  
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EC migration and fusion of the blood islands leads to remodeling into tubular 
structures that give rise to the first primitive vascular plexus (Adams & Alitalo, 
2007; Carmeliet, 2000; Coultas et al., 2005; Lamalice et al., 2007; Risau, 1997). 
These vascular plexuses remodel into a network of interconnected tubules that 
provide perfusion of tissues (Adams & Alitalo, 2007; Carmeliet, 2000; Coultas et 
al., 2005; Lamalice et al., 2007; Risau, 1997). The process of EC lumen and 
tubule formation (morphogenesis) is critical to establish blood flow and stabilize 
vessel networks during vascular development (Aplin, Fogel, Zorzi, & Nicosia, 
2008; Davis, Koh, & Stratman, 2007; Davis & Senger, 2005; Holderfield & 
Hughes, 2008; Koh, Stratman, Sacharidou, & Davis, 2008). During capillary 
morphogenesis, individual ECs generate vesicles after endocytosis (intracellular 
vacuolation) and interconnect with neighboring cells (fusion) to form multicellular 
lumens and tubes (Figure 1.2.) (Bayless & Davis, 2002, 2003; Bayless, Salazar, 
& Davis, 2000; Davis et al., 2007). The intracellular vacuolation process may be 
observed in ECs without contact with neighbor ECs in 3D collagen matrices 
(Davis, Bayless, & Mavila, 2002). Many studies have investigated the cellular 
mechanisms of EC lumen formation in 3D collagen matrices in vitro (Davis & 
Camarillo, 1996; Ilan, Mahooti, & Madri, 1998; Kanzawa, Endo, & Shioya, 1993; 
Koh, Mahan, & Davis, 2008; Korff & Augustin, 1999; Matsumura, Wolff, & 
Petzelbauer, 1997; Ment, Stewart, Scaramuzzino, & Madri, 1997; Ng, Helm, & 
Swartz, 2004; Salazar, Bell, & Davis, 1999; Schechner et al., 2000; Sieminski, 
Hebbel, & Gooch, 2004; Vernon & Sage, 1999; S. Yang, Graham, Kahn, 
Schwartz, & Gerritsen, 1999). These studies have reported that matrix-integrin
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cytoskeleton signaling plays a critical role in EC tube formation (Davis & 
Camarillo, 1996; Ilan et al., 1998; Koh, Mahan, et al., 2008; S. Yang et al., 1999). 
In response to α2β1 integrin and extracellular matrix (ECM) interactions, Rho 
GTPase family members Rac1 and Cdc42 are activated to initiate vacuole 
formation by embedded cells in 3D collagen matrices (Bayless & Davis, 2003; 
Bayless et al., 2000; Davis & Camarillo, 1996; Koh, Mahan, et al., 2008). After 
formation of multicellular structures, ECs remodel the surrounding matrix to 
create vascular guidance tunnels through membrane type 1-metalloproteinase 
(MT1-MMP) dependent proteolysis in 3D collagen matrices (Stratman et al., 
2009). The tunnels allow EC migration throughout the networks and by recruiting 
pericytes to the newly formed vascular networks, and the new vessels become 
stabilized. Pericytes stimulate ECs to deposit basement membrane matrices 
containing collagen type IV, laminins, and fibronectin (Davis & Senger, 2005; Y. 
Liu & Senger, 2004; Stratman et al., 2009). The deposition of basement 
membrane matrices contributes to the development of vascular tube maturation, 
stabilization, and EC quiescence (Davis & Senger, 2005; Y. Liu & Senger, 2004; 
Stratman et al., 2009).  
 
Growth factors in vasculogenesis 
The fibroblast growth factor (FGF) family is composed of 22 FGF ligands that 
bind to four tyrosine kinases receptors (FGFRs) and share a conserved 
sequence of 120 amino acids (Ornitz & Itoh, 2001). FGF has been reported to be 
necessary for the differentiation of mesoderm (Amaya, Musci, & Kirschner, 1991; 
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Cornell & Kimelman, 1994a, 1994b; Feldman, Poueymirou, Papaioannou, 
DeChiara, & Goldfarb, 1995; Flamme & Risau, 1992; LaBonne & Whitman, 1994; 
Pajusola et al., 1994; Slack, Darlington, Heath, & Godsave, 1987). Expression of 
dominant negative mutants of FGF receptor (FGFR) in early Xenopus embryos 
abolishes wild-type receptor function and fails to induce mesoderm in response 
to FGF (Amaya et al., 1991). The embryos display defects in gastrulation and 
posterior development. Overexpression of a wild-type receptor could rescue 
these defects (Amaya et al., 1991). FGFR1 deficient mice die at E9.5-E12 and 
show defects in cell migration through the primitive streak (Deng et al., 1994; 
Yamaguchi, Harpal, Henkemeyer, & Rossant, 1994). Adenovirus-driven 
dominant-negative FGFR1 expression results in significant defects in blood 
vessel development and maintenance in mouse embryos cultured in vitro (S. H. 
Lee, Schloss, & Swain, 2000). FGFR2-/- embryos die at E10.5 because of defects 
in the placenta and limb buds (De Moerlooze et al., 2000; Eswarakumar et al., 
2002; Xu et al., 1998). Cultured FGF-4 null murine embryos display severely 
impaired proliferation of the inner cell mass, whereas growth and differentiation 
of the inner cell mass is rescued in the presence of FGF-4 protein (Feldman et al., 
1995). These reports suggest that the FGF/FGF-receptor system may be a 
crucial signal transduction pathway for mesoderm induction in vivo. However, 
FGF2-/- mice and FGF1-/-/FGF2-/- double knockout (DKO) mice display normal 
vascularization (Miller, Ortega, Bashayan, Basch, & Basilico, 2000; Tobe et al., 
1998; Zhou et al., 1998). Analysis of mice lacking individual FGF family members 
revealed a wide range of phenotypes from early embryonic lethality to very mild 
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defects. These observations may reflect the extensive redundancy of FGF family 
members and the contribution of other growth factors including vascular 
endothelial growth factor (VEGF) to vascular development.  
 
The VEGF family belongs to the platelet-derived growth factor (PDGF) family and 
consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placenta growth 
factor (PIGF) (Achen et al., 1998; Ferrara, 1996; Jeltsch et al., 1997; Olofsson et 
al., 1996; Petrova, Makinen, & Alitalo, 1999). Alterative splicing of human VEGF-
A mRNA gives rise to five different isoforms of 121, 145, 165 (the most abundant 
form), 189, and 206 amino acid residues (Ferrara, 1996). In this manuscript, 
“VEGF” stands for VEGF-A. VEGF binds to two distinct receptor tyrosine kinases, 
VEGF receptor 1 (VEGFR1 or Flt-1) and VEGF receptor 2 (VEGFR2 or Flk-1) 
(Neufeld, Cohen, Gengrinovitch, & Poltorak, 1999; Petrova et al., 1999).  
 
Several studies have reported cross talk between FGF2 and VEGF family 
members during vasculogenesis (Auguste et al., 2001; Gabler, Plath-Gabler, 
Killian, Berisha, & Schams, 2004; Kanda, Miyata, & Kanetake, 2004; Seghezzi et 
al., 1998). Expression of dominant-negative FGFR1 or FGFR2 in glioma cells 
causes a decrease in tumor vascularization by downregulating VEGF expression 
(Auguste et al., 2001). While FGF2 modulates VEGF expression in ECs 
(Seghezzi et al., 1998), anti-VEGF-A neutralizing antibodies reduce FGF2-
induced vasculogenesis (Seghezzi et al., 1998). Flt-1 blocking antibodies or 
expression of a dominant negative Flt-1 leads to a significant reduction of FGF2-
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induced EC extensions and capillary morphogenesis (Kanda et al., 2004). Thus, 
pro-angiogenic effects of FGF2 are stimulated by VEGF/VEGFR signaling in ECs 
(Gabler et al., 2004).  
 
VEGF/VEGFR signaling is essential for embryonic vascular development 
(Carmeliet, 2000). In the presence of VEGF, embryonic stem cell-derived 
endothelial structures generated in vitro lead to improved survival of ECs and to 
the formation of primitive endothelial tubes, whereas FGF2 enhances only 
survival of angioblasts (Kazemi et al., 2002). In embryoid bodies in which 
VEGF/VEGFR function is blocked, FGF2 stimulation promotes formation of EC 
clusters, but fails to stimulate EC development into primitive vessels (Magnusson 
et al., 2004). In contrast, in FGFR1-/- embryoid bodies, VEGF stimulates 
formation of a vascular plexus (Magnusson et al., 2004). Thus, FGF2 is a 
downstream target of VEGF signaling and FGF2 and VEGF may have differential 
roles in vasculogenesis.  
 
Deletion of a single VEGF allele (VEGF+/-) or both alleles (VEGF-/-) is embryonic 
lethal (E8.5) as a result of failure to form the primary capillary plexus (Carmeliet 
et al., 1996; Ferrara et al., 1996). In addition, VEGF receptors (Flt-1 and Flk-1) 
play a critical role in vascular development. Flk-1 is expressed on angioblasts 
and ECs in avian and murine embryos and plays a critical role in differentiation of 
mesoderm to endothelial and hematopoietic lineages in early development 
(Dumont et al., 1995; Eichmann, Marcelle, Breant, & Le Douarin, 1993; Flamme, 
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Breier, & Risau, 1995; Fong, Rossant, Gertsenstein, & Breitman, 1995; Millauer 
et al., 1993; Roman & Weinstein, 2000; Yamaguchi, Dumont, Conlon, Breitman, 
& Rossant, 1993). Flk-1 deficient mice (Flk-1-/-) display defects in blood island 
formation and development of hematopoietic and ECs at E7.5 (Shalaby et al., 
1995). The Flk-1 deficient embryos die by E8.5 (Shalaby et al., 1997; Shalaby et 
al., 1995). VEGF receptor 1 (Flt-1) deficient mice display abnormal vasculature 
and embryonic death marked by disruption of endothelial cell assembly and loss 
of blood island integrity (Breier, Albrecht, Sterrer, & Risau, 1992; de Vries et al., 
1992; Fong et al., 1995; Millauer, Shawver, Plate, Risau, & Ullrich, 1994; Millauer 
et al., 1993; Shalaby et al., 1995). Thus, VEGF signaling is required for vascular 
development. 
 
Angiogenesis 
After the primary vascular plexus is formed by vasculogenesis, blood vessels are 
expanded and remodeled rapidly through generating more ECs that form new 
capillaries by sprouting or splitting from the existing vessels (intussusceptive 
angiogenesis) (Fig. 1.2.) (Adams & Alitalo, 2007; Carmeliet, 2000; Carmeliet et 
al., 1996; Coultas et al., 2005; Ferrara, 1999; Ferrara et al., 1996; Lamalice et al., 
2007; Risau, 1997; Shalaby et al., 1997). This process, referred to as 
angiogenesis, is defined as the formation of new vessels from the pre-existing 
primary plexus. In many regions such as the yolk sac, central nervous system 
(CNS), and retina, angiogenic sprouting occurs and is characterized by leading 
EC tip cells and trailing stalk cells controlled by Notch signaling (Fig. 1.2./1.3.) 
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(Breier & Risau, 1996; Gerhardt et al., 2003; Kurz, Gartner, Eggli, & Christ, 1996; 
Noguera-Troise et al., 2006; Ridgway et al., 2006).  
 
During sprouting angiogenesis, tip cells lead the way in a branching vessel and 
stalk cells elongate the sprout to form lumenized tubular structures (Fig. 1.3.) 
(Gerhardt et al., 2003; Kume, 2009). ECs stimulated by VEGF compete for tip 
cell position via Dll4/Notch signaling. In tip cells, Dll4 expression is induced more 
than in neighboring stalk cells to suppress the same response in adjacent ECs 
via activated Notch signaling (Hellstrom et al., 2007; Leslie et al., 2007; 
Siekmann & Lawson, 2007; Suchting et al., 2007). Dll4 expression is induced in 
response to VEGF/Flk-1 signaling in tip cells whereas Dll4 expression activates 
Notch signaling in adjacent cells to reduce the expression of Flk-1 to suppress 
the tip cell phenotype (Lobov et al., 2007; Noguera-Troise et al., 2006; Sainson 
et al., 2005; Siekmann & Lawson, 2007; Suchting et al., 2007). Thus, the tip cell 
phenotype suppression enhances the stalk cell phenotype. Jagged1 also 
enhances angiogenesis and antagonizes the effects of Dll4-mediated Notch 
signaling in stalk cells during sprouting angiogenesis (Benedito et al., 2009). 
Jagged1 loss of function mutants in the retina decreases sprouting while 
Jagged1 overexpression enhances angiogenesis and increases the number of tip 
cells (Benedito et al., 2009). Therefore, Dll4 expression corresponds to elevated 
VEGF-mediated signaling in tip cells, whereas Notch activation suppresses pro-
angiogenic response in their neighboring stalk cells. 
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Angiogenic sprouting of ECs from existing blood vessels is not the only 
mechanism that contributes to vascular growth. Intussusception (Figure 1.1.) is a 
separate mechanism that leads to local expansion of blood vessels. This process 
is the splitting of vessels through the insertion of tissue pillars (Djonov & 
Makanya, 2005). Little is known about the process but the process is proposed to 
involve EC proliferation, cell movement, ECM degradation, and the deposition of 
new ECM molecules (Djonov & Makanya, 2005).  
 
 
Figure 1.2. Human EC tube morphogenesis in 3D collagen matrices in vitro. 
Vasculogenesis (left panels); ECs were suspended in 3D collagen matrices and 
EC formed vacuoles that coalesced into lumens (cross-section). Angiogenesis 
(right panels); ECs were plated on top of the collagen matrices. The black arrows 
indicate the monolayer of ECs. The white arrows indicate EC tubes and sprouts 
(tip cells) from tube-like structures on the monolayer. Bar=25µm. Reprinted with 
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permission from “Mechanisms controlling human endothelial lumen formation 
and tube assembly in three-dimensional extracellular matrices” by Davis et al., 
2007, Birth Defects Res C Embryo Today, 81:270-285 (Davis et al., 2007). 
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Figure 1.3. Endothelial tip and stalk cells in angiogenesis. VEGF from 
surrounding tissue binds to VEGF receptor on tip cells and stimulate expression 
of Dll4. Dll4 activates Notch signaling (particularly Notch1) in stalk cells to reduce 
stalk cell sensitivity to VEGF stimulation and suppress the tip-cell phenotype. In 
contrast, Jagged1 expressed in stalk cells prevents expression of Dll4 that 
activate Notch1 in neighboring ECs (stalk or tip cells) to increase tip cell numbers. 
Antagonistic interaction between Dll4 and Jagged1 in ECs is mediated by Fringe 
(glycosyltransferase), which enhances Notch activation in response to Dll4 and 
reduces Notch activity in response to Jagged1. Reprinted with permission from 
“Novel insights into the differential functions of Notch ligands in vascular 
formation” by Kume, 2009, J Angiogenes Res 1:8 (Kume, 2009).   
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Notch signaling in angiogenesis 
Notch receptors and their ligands are essential for sprouting angiogenesis during 
mouse development (Hellstrom et al., 2007; Lobov et al., 2007; Noguera-Troise 
et al., 2006; Ridgway et al., 2006; Sainson et al., 2005; Suchting et al., 2007). 
Notch signaling is evolutionarily conserved and involved in various 
developmental processes. Notch receptor family members and Notch ligands are 
expressed throughout early vascular development (Gridley, 2007, 2010). The 
mammalian Notch signaling pathway is composed of four Notch receptors 
(Notch1-4) and five ligands (Jagged1 and 2 and Delta-like (Dll) 1, 3, and 4) 
(Gridley, 2007, 2010). All of the ligands are transmembrane and interact with 
Notch receptors on adjacent cell surfaces by cell-cell interactions. After ligand 
binding, the Notch receptor is cleaved by γ-secretase and the Notch intracellular 
domain (NICD) is released into the cytoplasm. The NICD translocates into the 
nucleus and forms a transcriptional activation complex that promotes 
downstream target gene transcription. Both Notch ligands and receptors are 
expressed in vascular endothelial cells and Notch signaling is known to be 
involved in vascular development (Alva & Iruela-Arispe, 2004; Gridley, 2010; 
Hofmann & Iruela-Arispe, 2007; Phng & Gerhardt, 2009; Roca & Adams, 2007). 
Notch1 is broadly expressed in many tissues including vascular ECs while 
Notch4 expression is restricted to vascular ECs (Krebs et al., 2000; J. Wu & 
Bresnick, 2007; J. Wu et al., 2005), and Notch3 is predominantly expressed in 
vascular smooth muscle cells (Joutel et al., 2000). Notch ligands (Jagged1, 
Jagged2, Dll1, and Dll4) are expressed in vascular ECs (Beckers, Clark, Wunsch, 
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Hrabe De Angelis, & Gossler, 1999; Krebs et al., 2000; Villa et al., 2001). Notch1-
/-, Notch1-/-/Notch4-/-, Jagged-1-/-, and Dll1-/- mice display vascular defects (Hrabe 
de Angelis, McIntyre, & Gossler, 1997; Huppert et al., 2000; Kotani et al., 1999; 
Xue et al., 1999). Of interest, Notch1-/- and Notch1-/-/Notch4-/- mouse embryos 
form a normal vascular plexus but fail to remodel the plexus to form conduit 
blood vessels at E9.5 (Huppert et al., 2000; Krebs et al., 2000). Similar to the 
Notch1-/- and Notch1-/-/Notch4-/- mouse, deletion of the Dll4 gene reveals vascular 
remodeling defects (Duarte et al., 2004; Gale et al., 2004). Reduced level of Dll4 
or blocking of Notch signaling promotes the formation of tip cells that lead to 
sprouting, branching, and fusion of endothelial tubes (Leslie et al., 2007; 
Siekmann & Lawson, 2007). When Dll4 and Notch signaling is compromised in 
zebrafish development, endothelial sprouts failed to display angiogenic motility 
and this caused excessive branching (Leslie et al., 2007; Siekmann & Lawson, 
2007). Thus, Notch signaling is essential for angiogenic vascular morphogenesis 
and capillary plexus remodeling.  
 
1.2. Endothelial Colony Forming Cells (ECFCs) 
Recruitment of circulating endothelial progenitor cells (EPCs) to growing 
endothelial sprouts may combine vasculogenic and angiogenic mechanisms. The 
dorsal aorta and cardinal vein in the early embryo are formed by vasculogenesis, 
which is direct assembly of angioblasts and ECs. Similarly, in the adult organism, 
EPCs play critical roles in the formation of new vessels or the recovery of 
damaged vascular endothelium through angiogenesis and vasculogenesis 
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(Asahara et al., 1997; Rafii, Lyden, Benezra, Hattori, & Heissig, 2002; Shi et al., 
1998). While the majority of circulating human ECs are senescent sloughed cells 
undergoing anoikis (Woywodt, Erdbruegger, & Haubitz, 2006), reports over 5 
decades have reported evidence that some circulating mammalian ECs attach 
and proliferate to form colonies of endothelium that coat intravascular suspended 
biomaterials (Stump, Jordan, Debakey, & Halpert, 1963). In 1997, Asahara 
reported that circulating endothelial progenitors could be isolated from human 
adult peripheral blood and lead to revascularization in vivo in response to acute 
tissue ischemia (Asahara et al., 1997). EPCs have been subsequently reported 
to contribute to new vessel formation in adult subjects (Asahara et al., 1997; Shi 
et al., 1998). This process is termed neovasculogenesis or postnatal 
vasculogenesis: the formation of new vessels by circulating ECs in the adult 
(combination of angiogenesis and vasculogenesis).  
 
We have isolated endothelial colony forming cells (ECFCs) from human 
peripheral blood and cord blood (Au, Daheron, et al., 2008; Ingram et al., 2004; 
Melero-Martin et al., 2007). Human mononuclear cells (MNCs) are placed on rat-
tail collagen I coated dishes and the nonadherent cells are removed after one 
day. Between 5 and 14 days, colonies of ECs appear and are identified as typical 
cobblestone morphology in endothelial cell growth medium. ECFCs express cell 
surface proteins (KDR, CD34, vWF, eNOS, VE-cadherin, and others) similar to 
those on primary ECs, but ECFCs do not express hematopoietic cell markers 
such as CD45, AC133, CD11b, and CD14 (Ingram et al., 2004; Yoder et al., 
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2007). ECFCs derived from human adult and cord blood are able to incorporate 
DiI-labeled acetylated-low density lipoprotein (acLDL) (Ingram et al., 2004). They 
are highly proliferative and form capillary-like structures in vitro (Ingram et al., 
2004). They can proliferate at a clonal level and be replated into secondary and 
tertiary ECFCs (Ingram et al., 2004). When single ECFCs were plated in defined 
conditions, they displayed a complete hierarchy of clonal proliferative potential 
(Figure 1.4. a and b). The highest proliferative potential (HPP)-ECFCs, formed 
the largest colonies and displayed replating potential, low proliferative potential 
(LPP)-ECFCs formed smaller colonies without replating potential, endothelial 
clusters that gave rise only to non-proliferating mature cells, and non-proliferative 
ECs lack ECFC activity. Most importantly, in contrast to colony forming unit-Hill 
(CFU-Hill) and any other putative EPCs, ECFCs are able to form human blood 
vessel de novo in vivo when implanted in immunodeficient mice (Yoder et al., 
2007) (Figure 1.4. C). The human ECFC-derived capillary plexus inosculates with 
the murine vessels to become the part of the host blood vascular system (Yoder 
et al., 2007) (Figure 1.4. D). Thus, only ECFCs display characteristics of high 
proliferative potential and in vivo vessel forming ability.  
 
Blood vessel damage increases the number of circulating EPCs in patients with 
peripheral artery disease (PAD) (Hill et al., 2003; Rafii & Lyden, 2003; Urbich & 
Dimmeler, 2004). Some studies suggest that certain subsets of circulating EPCs 
may monitor the status of endothelium and be recruited into a site of vascular 
injury to facilitate angiogenesis (Urbich & Dimmeler, 2004; Werner et al., 2005). 
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Especially, ECFCs have shown promise for tissue regeneration.  In mouse 
vascular injury models, ECFCs are recruited and incorporate into injured vessels 
or ischemic tissue (Schwarz et al., 2012). Several studies have reported that 
ECFCs enhance vascular repair, improve blood flow after ischemic retinopathy, 
limb ischemia, myocardial infarction, and stroke (X. T. Huang et al., 2013; Kang, 
Coggins, Xiao, Rosenzweig, & Bischoff, 2013; Medina, O'Neill, Humphreys, 
Gardiner, & Stitt, 2010; Moubarik et al., 2011; Schwarz et al., 2012; Stroncek, 
Ren, Klitzman, & Reichert, 2012).  ECFCs also engraft and re-endothelialized 
denuded vascular segments or implanted grafts (Stroncek et al., 2012). Thus, 
introduction of ECFCs into patients could have major therapeutic benefits. 
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Figure 1.4. Quantitation of the clonogenic and proliferative potential of 
single ECs derived from cord blood and adult peripheral blood (PB) and 
vessel formation properties of ECFCs. (a) The percentage of single ECFCs 
dividing at least once after 14 days culture. (b) Representative photomicrographs 
(50x magnification) of the different size of endothelial cell clusters or colonies. (c) 
Formation of functional blood vessels in vivo (arrow indicates murine red blood 
cells in the lumen of human vessel) when implanted into immunodeficient mice. 
(d) Moreover, these vessels inosculate with the murine vessels and become the 
part of host vascular system. Reprinted with permission from “Identification of a 
novel hierarchy of endothelial progenitor cells using human peripheral and 
umbilical cord blood” by Ingram et al., 2004, Blood, 104:2752-2760 and 
“Redefining endothelial progenitor cells via clonal analysis and hematopoietic 
stem/progenitor cell principals” by Yoder et al., 2007, Blood, 109:1801-1809 
(Ingram et al., 2004; Yoder et al., 2007). 
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1.3. Akt Signaling  
Protein kinase B (PKB), also known as Akt is a member of the serine/threonine 
family of protein kinases and is comprised of three isoforms, Akt1, Akt2, and Akt3. 
Akt is critical for neovasculogenesis since it is a downstream target of pro-
angiogenic growth and survival factors including VEGF (Fujio & Walsh, 1999; 
Gerber et al., 1998). Activation of Akt leads to a number of changes in EC 
behavior including enhanced angiogenesis, vasculogenesis, growth, and 
regulation of apoptosis/cellular survival (Llevadot & Asahara, 2002).  
 
Akt phosphorylates endothelial nitric oxide (NO) synthase (eNOS), enhances 
endothelial NO synthesis, and influences postnatal vessel growth (Dimmeler et 
al., 1999; Fulton et al., 1999). Akt signaling can mediate the endothelial response 
to angiogenic stimuli, including NO production and VEGF-induced migration in 
ECs and EPCs (Morales-Ruiz et al., 2000). Endothelial-specific Akt1 loss causes 
significant retinal vascular defects (M. Y. Lee et al., 2014). Global Akt1 deletion in 
murine pups increases neonatal mortality but some pups are viable despite 
growth retardation because of compensation from other Akt isoforms. 
Interestingly, both Akt1-/-/Akt2-/- double knockout (DKO) and Akt1-/-/Akt3-/- DKO 
mice die during the embryonic or postnatal period (Peng et al., 2003; Z. Z. Yang 
et al., 2005). Furthermore, triple knockout mice (Akt+/-/Akt2-/-/Akt3-/-) are viable 
with impaired growth (Dummler et al., 2006). These studies suggest a single Akt1 
allele is sufficient for embryonic development and postnatal survival.  
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Akt has been known to promote the expression of anti-apoptotic B-cell lymphoma 
2 (Bcl-2) proteins, such as B-cell lymphoma extra large (Bcl-xL) through the 
activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) (I. Kim et al., 2000; Zong, Edelstein, Chen, Bash, & Gelinas, 1999). 
Constitutive activation of Akt signaling protects cardiomyocytes against apoptosis 
(Fujio, Nguyen, Wencker, Kitsis, & Walsh, 2000). In addition, chronic activation of 
Akt pathway in ECs promotes cell survival of endothelial cells (ECs) and 
stimulates vasculogenic activity of ECs in absence of growth factors and serum 
(Seandel et al., 2008). 
 
1.4. Human Platelet Lysate (HPL) 
Human platelet lysate (HPL) contains various cytokines, chemokines, and growth 
factors that are involved in various cellular events, particularly cellular migration, 
proliferation, differentiation, extracellular matrix organization and remodeling, cell 
survival, and angiogenesis/neovascularization (tissue repair) (Aarabi, Longaker, 
& Gurtner, 2007; Crowley, Dempsey, Horwitz, & Horwitz, 1994; Fekete et al., 
2012; Gurtner, Werner, Barrandon, & Longaker, 2008; Langer et al., 2009; Shih 
et al., 2011; Singer & Clark, 1999). Chemokines in HPL including stromal-derived 
growth factor 1 (SDF-1), stimulate recruitment, adhesion, and proliferation of 
CD34+ progenitor cells, mesenchymal stromal cells (MSC), smooth muscle 
progenitors, and endothelial progenitors (de Boer et al., 2006; Langer et al., 
2009; Lev et al., 2006; Zernecke et al., 2005). Growth factors in HPL, especially, 
VEGF, FGF, and angiopoietin-1, stimulate Akt to enhance cell survival and 
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ensure adequate vascular development in cardiovascular functions (Carmeliet et 
al., 1999; Fujio & Walsh, 1999; Gerber et al., 1998; I. Kim et al., 2000; Kontos et 
al., 1998; Papapetropoulos et al., 2000). In addition, other molecules such as 
SDF-1, hepatocyte growth factor (HGF), and sphingosine-1-phosphate promote 
survival signals for vascular ECs and smooth muscle cells (SMCs) at injured 
vascular sites (Hisano et al., 1999; Nakamura, Teramoto, & Ichihara, 1986; 
Stellos & Gawaz, 2007). HPL also contains platelet microparticles (PMPs) that 
are membrane vesicles carrying platelet-derived products, including chemokines, 
cytokines, and various bioactive lipids and are elevated in patients with 
atherosclerosis, acute vascular syndromes, and diabetes mellitus (Barry, Pratico, 
Savani, & FitzGerald, 1998; Mause, von Hundelshausen, Zernecke, Koenen, & 
Weber, 2005; Rozmyslowicz et al., 2003; VanWijk, VanBavel, Sturk, & 
Nieuwland, 2003). PMPs have been reported to activate Akt via phosphorylation 
and improve endothelial regeneration in murine vascular injured model (Mause et 
al., 2010). Moreover, PMPs phosphorylate and activate Akt that inactivate pro-
apoptotic molecule B-cell lymphoma 2-associated death promoter (BAD) and 
stimulate anti-apoptotic pathways in a human monocytic leukemia cell line (Datta 
et al., 1997; Vasina et al., 2013). However, incubation of ECs and SMCs with 
PMPs from septic patients results in stimulation of apoptosis in the cells via 
production of reactive oxygen species (Gambim et al., 2007; Janiszewski et al., 
2004). Therefore, HPL obtained from normal healthy subjects is involved in 
regulation of apoptosis and cell survival in numerous cells involved in the repair 
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of injured tissues, whereas HPL from septic patients may harbor deleterious 
signals to cell survival.  
 
1.5. Apoptosis 
Apoptosis is a highly conserved and essential cellular process in tissue 
development and homeostasis (Prindull, 1995). Characteristic apoptotic features 
are cell membrane blebbing, cell shrinkage, chromatin condensation, and DNA 
fragmentation, finally ending with the engraftment by tissue macrophages or 
other neighboring cells (Savill & Fadok, 2000). Apoptosis generally culminates 
with the sequential activation of caspases, the cysteine proteases for cleavage of 
proteins (Duprez, Wirawan, Vanden Berghe, & Vandenabeele, 2009; Sprick & 
Walczak, 2004; Taylor, Cullen, & Martin, 2008). Cells undergo apoptosis through 
two major pathways: the extrinsic pathway (death receptor pathway) is initiated 
by ligand binding to membrane receptors of the death receptor family, whereas 
the intrinsic pathway (mitochondrial pathway) is mediated by intracellular and 
extracellular stresses (Duprez et al., 2009; Sprick & Walczak, 2004; Taylor et al., 
2008; Wyllie, 2010).  
 
The extrinsic pathway involves the transmembrane death receptors of the tumor 
necrosis factor (TNF) receptor superfamily including FasR, TNFR1, and death 
receptors (DRs) (Duprez et al., 2009; Sprick & Walczak, 2004; Taylor et al., 
2008; Wyllie, 2010). Death ligand stimulation leads to oligomerization of the 
receptors and recruitment of the adaptor protein, Fas-associated death domain 
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(FADD) and initiator caspases such as caspase-8 and -10 to form a death-
inducing signaling complex (DISC). This leads to the activation of effector 
caspases, typically caspase-3. The intrinsic pathway is mediated by various 
physiochemical stresses such as chemotherapeutic agents, alterations in 
temperature, osmolality, DNA damaging agents, free radical generation 
compounds, removal of nutrients, and oxygen deprivation (Duprez et al., 2009; 
Sprick & Walczak, 2004; Taylor et al., 2008; Wyllie, 2010). The pathways lead to 
the same type of apoptotic response that causes release of cytochrome c (Cyt-C) 
from mitochondria into the cytoplasm and activation of caspase-3 (Duprez et al., 
2009; Sprick & Walczak, 2004; Taylor et al., 2008). Caspase-3 is activated to 
cleaved caspase-3 to generate all the biochemical and morphologic hallmarks of 
cell apoptosis. Thus, the activation of the two pathways converges by activating 
common effector caspase cascades. 
 
In normal cells, Akt activation (phospho-Akt, pAkt) by various growth factors 
stimulates cell survival via protection of mitochondrial integrity and inhibition of 
Cyt-C release (Gottlob et al., 2001; Plas, Talapatra, Edinger, Rathmell, & 
Thompson, 2001; Uchiyama, Engelman, Maulik, & Das, 2004; Wyllie, 2010). Akt 
has also been reported to promote the expression of the anti-apoptotic Bcl-2 
proteins, such as Bcl-xL that inhibits activation of Bcl-2-associated X protein 
(Bax/Bak) to prevent permeablization of the mitochondrial membrane (Jones et 
al., 2000; Zong et al., 1999).  However, in apoptotic cells, pro-apoptotic members 
(Bax, Bak, and Bad) are activated and induce the release of Cyt-C from 
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mitochondria by binding and inactivating anti-apoptotic proteins (Gustafsson & 
Gottlieb, 2007; Scorrano & Korsmeyer, 2003).  
 
1.6. Summary 
Formation of the vascular system, composed of functional arteries, veins, and 
capillaries, originates via two fundamental processes: vasculogenesis and 
angiogenesis (Adams & Alitalo, 2007). Angiogenesis is a well-studied process, 
controlled by a number of well-known angiogenic mediators and pathways in 
both developing embryo and postnatal life (Adams & Alitalo, 2007). However, 
identifying the molecular mechanisms that regulate and facilitate vasculogenesis 
has been less well examined. 
  
We and others have identified rare viable circulating ECFC (Au, Daheron, et al., 
2008; Ingram et al., 2004; Melero-Martin et al., 2007). Human cord blood (CB) 
derived circulating ECFC display a hierarchy of clonogenic proliferative potential 
and posses de novo vessel forming ability upon implantation in immunodeficient 
mice. Human ECFC-derived vessels form after implantation in NOD/SCID mice, 
but inosculation and perfusion by the host circulatory system does not occur until 
3-4 days after implantation (P. Allen, K. T. Kang, & J. Bischoff, 2013). We have 
previously reported that only 1-3% of the total implanted human CB ECFC were 
alive following implantation in vitro and in vivo (H. Kim, Huang, et al., 2015). Thus, 
one fundamental question we wish to examine is how to improve cell survival of 
ECFC and promote vasculogenesis of ECFC in in vitro and in vivo models. Since 
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systemic blood flow is required to stabilize newly formed vessels, the overall 
focus of this dissertation is on the methods and mechanisms to enhance 
vasculogenesis of ECFC implanted in vivo to form a stable perfused capillary 
network that can be perfused by the host circulatory system. 
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CHAPTER 2. NOTCH LIGAND DELTA-LIKE 1 (DLL1) PROMOTES IN VIVO 
VASCULOGENESIS IN HUMAN CORD BLOOD DERIVED ENDOTHELIAL 
COLONY FORMING CELLS (ECFCS) 
 
The following chapter is reprinted with permission from “Notch ligand Delta-like 1 
promotes in vivo vasculogenesis in human cord blood-derived endothelial colony 
forming cells” by Kim et al., 2015, Cytotherapy, 17(5):579-92 (H. Kim, Huang, et 
al., 2015). 
 
2.1. Introduction 
The Notch signaling pathway is an evolutionarily conserved pathway that is 
involved in a variety of developmental processes (Ables, Breunig, Eisch, & Rakic, 
2011; Niessen & Karsan, 2008; Radtke, Fasnacht, & Macdonald, 2010). Notch 
family members and Notch ligands are expressed in endothelial cells (ECs) 
throughout early vascular development (Kume, 2009; Rocha & Adams, 2009; 
Swift & Weinstein, 2009). Notch1, Notch4, Jagged2, Dll1, and Dll4 are 
specifically expressed in arterial endothelium (Kume, 2009; Takeshita et al., 2007) 
and these molecules play critical roles in arterial specification (Adams & Alitalo, 
2007; Alva & Iruela-Arispe, 2004; Rossant & Howard, 2002; Shawber & 
Kitajewski, 2004; Siekmann, Covassin, & Lawson, 2008; Sorensen, Adams, & 
Gossler, 2009). VEGF is one of the most potent and ubiquitous vascular growth 
factors that affect many aspects of EC biology. Recently, VEGF-A has been 
found to interact with the activated Notch pathway to determine and maintain 
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arterial EC fate (Lawson, Vogel, & Weinstein, 2002; Sorensen et al., 2009; Zhong, 
Childs, Leu, & Fishman, 2001). Less is known of how Notch signaling may 
influence the vasculogenic properties of human vessel forming cells. 
 
In Notch1 and 4 deficient mouse embryos, embryos failed to remodel the plexus 
to form large and small blood vessels, although the primary vascular plexus 
forms normally. These data indicate that Notch signaling plays a critical role in 
angiogenic vascular morphogenesis and remodeling (Huppert et al., 2000; Krebs 
et al., 2000). Different human endothelial cell lines have been used to study, the 
regulation of Notch signaling in human vascular development. Most studies have 
utilized human umbilical vein endothelial cells (HUVECs) or human 
arterial/microvascular endothelial cells to investigate the roles of the Notch 
signaling pathway on their angiogenic and vasculogenic behavior. Notch1 
activation has been implicated both in promoting and in inhibiting cell death in a 
cell type specific manner (Beverly, Felsher, & Capobianco, 2005; Jehn, Bielke, 
Pear, & Osborne, 1999; MacKenzie, Duriez, Wong, Noseda, & Karsan, 2004; 
Sade, Krishna, & Sarin, 2004). Notch1 activation in cultured monocytes plated 
upon immobilized Deltaext-myc has been reported to induce apoptosis (Ohishi et al., 
2000). On the other hand, activation of Notch 1 and a downstream mediator, 
HES1, in human iliac artery endothelial cells (HIAECs) caused growth 
suppression but improved cell survival of the cultured cells. Also, activated 
Notch1 in HIAECs formed more stabilized networks and cord formation on 
Matrigel substrate in the presence of VEGF (Z. J. Liu et al., 2003). Dll1-
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dependent Notch signaling mediated by EphrinB2 induced branching 
morphogenesis and network formation by human arterial endothelial cells 
(HAECs) plated on Matrigel (Limbourg et al., 2007). These reports indicated that 
Notch1 signaling plays a role in regulating endothelial cell survival, network, and 
cord formation in vitro, but limited evidence has been presented to examine how 
in vitro Notch activation preconditioning might influence angiogenic or 
vasculogenic behavior when cells are implanted in vivo.  
 
We have successfully isolated circulating endothelial colony forming cells 
(ECFCs) from human umbilical cord blood (CB) and identified a hierarchy of 
proliferative potential in ECFC through the use of single cell clonogenic and 
functional assays (L. Huang, Critser, Grimes, & Yoder, 2011; Ingram et al., 2004). 
Human cord blood ECFCs form a human capillary plexus in immunodeficient 
mice after subcutaneous implantation in collagen-fibronectin matrices and upon 
inosculation with murine vessels, become a part of the systemic host circulation 
(L. Huang et al., 2011; Yoder et al., 2007). We recently determined that all viable 
circulating ECFC in human cord blood (CB) and adult peripheral blood can be 
enriched and identified as endothelial cells expressing CD34, CD146, CD105, 
CD31, but not CD45 or CD133 (Mund, Estes, Yoder, Ingram, & Case, 2012). 
These circulating viable endothelial cells represent those rare circulating ECFC 
that are known to colonize and re-endothelialize implanted biomaterials in human 
subjects (Hirschi, Ingram, & Yoder, 2008; Stump et al., 1963). 
 
	   31 
The use of circulating CB ECFC to study human vessel formation within 
immunodeficient mice permits analysis of human vasculogenesis and 
determination of key regulatory molecules controlling human vessel formation in 
vivo in a unique model system. For example, use of cultured CB ECFC with adult 
bone marrow mesenchymal stromal cells (MSC) can recreate a hematopoietic 
and leukemic stem cell niche in vivo (Y. Chen et al., 2012). Since Notch pathway 
activation plays such a key role in establishing the murine embryonic vascular 
system, we hypothesized that in vitro preconditioning of human CB ECFC with 
Notch ligand may enhance in vivo vasculogenic activity. We demonstrate that 
preconditioning of ECFC with Notch activation in vitro is insufficient to promote in 
vivo vasculogenesis, however, provision of the Notch ligand Dll1 by OP9 stromal 
cells in vivo activates Notch1 signaling in ECFC and enhances human blood 
vessel formation.  
 
2.2. Materials And Methods 
Media and supplements 
Human endothelial serum free medium (SFM, Invitrogen) was supplemented with 
20 ng/ml human recombinant basic fibroblast growth factor (hrbFGF, Invitrogen), 
10 ng/ml human recombinant epidermal growth factor (hrEGF, R&D), 10 ng/ml 
human recombinant vascular endothelial growth factor 165 (rhVEGF-
A/rhVEGF165, R&D), 10 ng/ml rhVEGF121 (R&D), 10 ng/ml stem cell factor (SCF, 
R&D), 5 ng/ml stromal cell derived factor 1alpha (SDF1α, R&D), 10 ng/ml 
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interleukin 6 (IL6, R&D) and 1.5% human cord plasma (HCP), to create serum 
reduced medium (SRM).  
 
Isolation and culture of human umbilical cord blood (CB) derived ECFCs  
Human CB samples (50–100 mL) were collected in heparin-coated syringes from 
healthy newborns (38–40 weeks gestation). The Institutional Review Board at 
Indiana University School of Medicine reviewed and approved this study with 
exempt IRB status. UCB was diluted 1:1 with Dulbecco's phosphate buffered 
saline (DPBS, Invitrogen) and overlaid onto Ficoll-Paque PLUS (GE Healthcare). 
Cells were centrifuged for 30 minutes at room temperature (RT) at 1500 rpm. 
Mononuclear cells (MNCs) were isolated and washed with DPBS. For outgrowth 
of ECFC colonies, MNCs were resuspended in SRM. 3 x 107 MNCs were seeded 
onto each well of 6-well tissue culture plates pre-coated with Type I rat-tail 
collagen (BD Biosciences Pharmingen) and cultured as previously described 
(Ingram et al., 2004). ECFC colonies appeared around 4 days of culture and 
were noted to form colonies of adherent cells with cobblestone morphology. After 
approximately 10 days of culture, the ECFC-derived ECs were released from the 
culture dish by TrypLE™ Express (Gibco) and replated onto 25 cm2 tissue 
culture flasks pre-coated with Type I rat-tail collagen for subsequent passage. 
Characterization of human UCB ECFC derived ECs was conducted using 
monoclonal antibodies and fluorescence-activated cell sorter (FACS) analysis as 
previously described (Ingram et al., 2004). 
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Immobilization of Delta1ext-IgG protein 
Delta1ext-IgG protein is the extracellular domain of human delta-like 1(Dll1) fused 
to the Fc domain of human IgG1 (Varnum-Finney et al., 2000). Non-tissue 
culture-treated plates were coated with decreasing concentrations of Delta1ext-IgG 
(20, 10, 5, 2.5, 1.25, 0.625, and 0.3125 µg/mL) or the same concentration of 
human IgG (Sigma-Aldrich), diluted in PBS together with 5 µg/mL fibronectin 
fragment CH-296 (Takara Shuzo). The plates were incubated overnight at 4°C, 
washed with PBS 3 times, and further incubated with 2% bovine serum albumin 
(BSA) dissolved in PBS at 37°C for 1 hour. Thereafter, plates were washed with 
PBS 3 times and were then ready for plating cells. 
 
RNA isolation and conventional/quantitative RT-PCR 
Total cellular RNA was extracted with an RNeasy Micro extraction kit (Qiagen) as 
described by the manufacturer. RT reactions were performed using an 
Omniscript RT Kit (Qiagen). Conventional PCR was conducted by using Go Tap 
Flexi DNA Polymerase (Promega) according to the manufacturer’s instructions. 
The primer sequences are shown in Table 2.1. The PCR cycle profile was 94°C 
for 5 minutes, 94°C for 30 seconds, 53 or 57°C (depending on the different 
primers) for 30 seconds, 72°C for 45 seconds, and 32 cycles with a final 72°C for 
7 minute. PCR products were added to wells in a 2% agarose/ethidium bromide 
gel and exposed to electrophoresis current. Migrating bands were photographed 
under UV light. Quantitative PCR was performed using FastStart Universal SYBR 
Green Master 2x (Rox) (Roche). The relative standard curve of each gene 
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amplification was first generated to determine the amplification efficiency (Eff). 
ATP5B was used as a housekeeping gene. To compare gene expression levels 
among treated and control ECFCs, results were presented as the ratio of the 
expression of each gene to ATP5B expression. For Delta1ext-IgG or γ-secretase 
inhibitor L685458 treatment effects on ECFCs, gene expression levels in non-
treated cells at Day 0 were analyzed as controls. Results were expressed as a 
fold change (in logarithmic scale) in comparison to the control. The quantitative 
analysis was performed according to Pfaffl’s method (Pfaffl, 2001). The primer 
sequences are shown in Table 2.2. 
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Table 2.1. Primers used for conventional RT-PCR 
Gene Forward Reverse Tm size 
(bp) 
VEGF 
 
R1 
AGTTTAAAAGGCACCCAGCA 
 
ACGAGCTCCCTTCCTTCAGT 
 
55 362 
VEGFR2 GAGGGACTTGGACTGGCTTT 
 
GATTTGAAATGGACCCGAGA 
 
55 302 
VEGFR3 TGAACATCACGGAGGAGTCA 
 
TCAGGCTTGTTGATGAATGG 
 
55 337 
NRP1 GAAAAATGCGAATGGCTGAT 
 
AATCCGGGGGACTTTATCAC 
 
53 335 
NRP2 CAAACACTGTGGGAACATCG 
 
TGTCCAGCCAATCGTACTTG 
 
55 338 
DLL1 TGTGCCTCAAGCACTACCAG ACACACGAAGCGGTAGGAGT 55 353 
DLL4 TATTGGGCACCAACTCCTTC 
 
ACATAGTGGCCGAAGTGGTC 
 
55 349 
NOTCH1 GGCCAGAACTGTGAGGAAAA 
 
GCAGTAGAAGGAGGCCACAC 
 
57 327 
NOTCH4 TCTCCCTCTCCATTGACACC 
 
TGGAAGCACTCGTTGACATC 
 
55 323 
HEY2 TGGGGAGCGAGAACAATTAC 
 
GCACTCTCGGAATCCTATGC 
 
55 329 
EFNB2 (C) TTATTTGCCCCAAAGTGGAC 
 
CCTGGTTGATCCAGCAGAAC 
 
55 347 
EPHB4 GAGCTGTGTGGCAATCAAGA 
 
ACTTTGCAGACGAGGTTGCT 
 
55 345 
COUPTFII AACACATCGAGTGCGTGGT 
 
CAGGTACGAGTGGCAGTTGA 
 
55 311 
PECAM1 GCAAAATGGGAAGAACCTGA 
 
ACAGTTGACCCTCACGATCC 
 
55 316 
VECAD TGGACAAGGACACTGGTGAA TCTTGCAGAGTGACCAGCAC 
 
55 382 
ACTB GCCAGCTCACCATGGATGAT GTCTCAAACATGATCTGGGTC 57 388 
 
Reprinted with permission from “Notch ligand Delta-like 1 promotes in vivo 
vasculogenesis in human cord blood-derived endothelial colony forming cells” by 
Kim et al., 2015, Cytotherapy, 17(5):579-92. Table 2.1. was drawn by my co-
worker, Lan Huang (H. Kim, Huang, et al., 2015). 
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Table 2.2. Primers used for quantitative RT-PCR 
Gene Forwards Reverse Eff 
VEGFR1 GCTTCTGACCTGTGAAGCAA 
 
CTCGTGTTCAAGGGAGTGGT 
 
1.987 
 VEGFR2 GAACATTTGGGAAATCTCTTGC CGGAAGAACAATGTAGTCTTTG
C 
1.917 
VEGFR3 AGACAAGAAAGCGGCTTCAG TTGGGAGTCAGGGTGTGC 1.860 
 NRP1 GTTGTGTCTTCAGGGCCATT 
 
AATCCGGGGGACTTTATCAC 
 
2.036 
 NRP2 TCTGCGCTACGAGATCTTCA GTGCAGTCCAAGTTGTGTGG 1.862 
DLL4 GACCACTTCGGCCACTATGT TTGCTGCAGTAGCCATTCTG 1.967 
NOTCH1 CTTCAATGACCCCTGGAAGA 
 
GAAGTGGAAGGAGCTGTTGC 
 
1.950 
NOTCH4 CTGCTGCTGCTGCTATGTGT GTCAGGAAACTGGCACGTCT 1.833 
HES1 TGCTTCACTGTCATTTCCAGA 
 
GAAAGTCTGAGCCAGCTGAA 
 
1.958 
HEY2 CTTGTGCCAACTGCTTTTGA TCATGAAGTCCATGGCAAGA 1.912 
EFNB2 TCTTTGGAGGGCCTGGAT CCAGCAGAACTTGCATCTTG 1.986 
EPHB4 TTTGGCTCCTTCGAGCTG GGCCAAGATTTTCTTCTGGTG 1.880 
COUPTF
II 
CCAAGAGCAAGTGGAGAAGC TCCACATGGGCTACATCAGA 1.988 
ATP5B CCACTACCAAGAAGGGATCTATCA GGGCAGGGTCAGTCAAGTC 1.960 
 
Reprinted with permission from “Notch ligand Delta-like 1 promotes in vivo 
vasculogenesis in human cord blood-derived endothelial colony forming cells” by 
Kim et al., 2015, Cytotherapy, 17(5):579-92. Table 2.2. was drawn by my co-
worker, Lan Huang (H. Kim, Huang, et al., 2015). 
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Notch ligand and receptor cell surface expression on ECFC  
Relative levels of Notch ligands and receptors on ECFCs were determined by 
flow cytometry. ECFCs were harvested by cell dissociation buffer enzyme-free 
Hanks’-based reagent (Gibco). Cells (0.5 x 106) were suspended in staining 
buffer (PBS, 0.5% bovine serum albumin BSA, and 2mM EDTA) and stained 
using purified anti-human Notch4 (clone MHN4-2, Isotype mouse IgG1κ, 
BioLegend), Biotin anti-human Notch1 (clone mN1A, BioLegend), anti-human 
Delta-like protein 1 (Dll1) conjugated to phycoerythrin (PE) (clone MHD 1-314, 
BioLegend), anti-human Delta-like protein 4 (Dll4) conjugated to APC (clone 
MHD 4-46, BioLegend), and anti-human CD31 antibody conjugated to 
phycoerythrin-cyanine7 (PE-Cy7) (clone WM-59, eBiosciences) for 15 minutes at 
room temperature in the dark. After staining with purified and biotin conjugated 
primary antibodies, cells were stained with secondary antibody, goat anti-mouse 
alexa fluor 488 (Invitrogen), streptavidin-allophycocyanin (APC) (eBioscience), 
and with propidium iodide (PI) (eBiosciences) for 15 minutes at room 
temperature in the dark. For negative controls, we used fluorescence minus one 
(FMO) controls, as we have previously described (Mund et al., 2012). Stained 
cells were analyzed by FlowJo software. 
 
Western blot 
Protein extracts were prepared as described previously (Z. Yang et al., 2009), 
electrophoresed using sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE), transferred to nitrocellulose, and probed with 
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purified anti-human CoupTFII (clone H7147, R&D), anti-human Hey2 (ab167280, 
Abcam), and anti-human β-actin (mAbcam 8226, Abcam). For Notch receptors, 
proteins were transferred to immobilon-P membrane, PVDF, 0.45 µm, (Millipore) 
and probed with purified anti-human Notch1 (clone C-20, Santa Cruz 
Biotechnology), anti-human Notch2 (clone 25-255, Santa Cruz Biotechnology), 
and anti-human Notch4 (clone H-225, Santa Cruz Biotechnology). 
 
Implantation of human cord blood derived ECFCs into NOD/SCID mice  
Cellularized matrix implants were cast as previously described (L. Huang et al., 
2011; Yoder et al., 2007). Cultured ECFCs (2 x 106 cells/mL) were suspended in 
a solution containing 1.5 mg/mL rat-tail collagen I (BD Biosciences), 100 µg/mL 
human fibronectin (Chemicon), 1.5 mg/mL sodium bicarbonate (Sigma), 25 mM 
HEPES (Cambrex), 10% FBS, and 30% SFM, pH-adjusted to 7.4. Then 250 µL 
of the cell suspension was pipetted into one well of a 48-well tissue culture plate, 
allowed to polymerize at 37°C for 30 minutes, and covered with 500 µL SRM for 
overnight incubation at 37°C in 5% CO2. Matrices were implanted into the flanks 
of anesthetized 6-9 week old NOD/SCID mice. After 14 days, the mice were 
sacrificed; the grafts were excised and analyzed by histology and 
immunohistochemistry (N=6) as previously described (L. Huang et al., 2011; 
Yoder et al., 2007). ECFCs were also co-implanted with OP9 or OP9-DL1 
stromal cells in some studies. OP9-DL1 cells represent murine bone marrow 
stromal OP9 cells that have been engineered to constitutively express the Notch 
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ligand Dll1 (Schmitt & Zuniga-Pflucker, 2002). ECFCs and OP9 or OP9-DL1 
were implanted at 4:1 ratios as above. 
 
Histology and immunohistochemistry 
Sections were stained as previously described (Yoder et al., 2007). Briefly, 
paraffin-embedded tissue sections were deparaffinized and then either directly 
stained with hematoxylin and eosin (H&E) or immersed in retrieval solution (Dako) 
for 20 minutes at 90–99°C. Slides were incubated at room temperature for 30 
minutes with anti-human CD31 antibody (clone JC70/A, Abcam) and rat anti-
mouse smooth muscle alpha actin (αSMA) (clone 1A4, Sigma) followed by a 10-
minute incubation with LASB2 link-biotin and streptavidin-HRP (Vector 
Laboratories), then developed with DAB (Vector Laboratories) solution for 5 
minutes. Slides were analyzed by microscope under 40x magnification using a 
Leica DM 4000B microscope (Leica Microsystems) with attached Spot-KE digital 
camera (Diagnostic Instruments).   
 
Assessment of apoptosis of ECFCs in 3D collagen matrices 
Apoptosis was assessed by examining the percentage of human CD31 positive 
ECFCs that bound Annexin V and propidium iodide and was performed as per 
the manufacturer’s instruction (Apoptosis Detection kit, eBioscience). OP9 or 
OP9-DL1 cells were co-implanted with ECFCs (1:1) in collagen matrices at 
indicated time points as above. Collagen matrices were prepared as described 
previously (Critser, Kreger, Voytik-Harbin, & Yoder; Yoder et al., 2007). Briefly, 2 
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x 106 cells/mL were implanted in collagen solution with endothelial cell growth 
medium (EGM-2, Lonza). Matrices were recovered from one to three days later 
and incubated in 250 µl Collagenase Type I (0.25%) (Stemcell technology) for 20 
minutes at 37°C. Cell dissociation buffer was added to stop the enzymatic 
reaction (Invitrogen). Cells were centrifuged at 500 g for 5 minutes at room 
temperature. Cell pellets were suspended in staining buffer and stained with anti-
human CD31 antibody conjugated to PE for 15 minutes (clone WM-59, BD 
Biosciences Pharmingen). Cells were incubated in binding buffer for 20 minutes 
and stained for Annexin V-APC and propidium iodide (PI) for 30 minutes at room 
temperature in the dark. Stained cells were analyzed by FlowJo software. 
 
Caspase-1 and -3/7 assays in 3D collagen matrices 
Relative levels of active caspase-1 and -3/7 activities were determined by flow 
cytometry using fluorescein-labeled inhibitors of caspases (FLICA) reagent 
according to the manufacturer’s instructions (FLICA 660 Caspase-3/7 assay kit 
and FLICA 660 in vitro Caspase-1 Detection kit, Immunochemistry Technology). 
Collagen matrices and cells were prepared as previously described in 
assessment of apoptosis above. Cells recovered from matrices were suspended 
in staining buffer and stained with anti-human CD31 antibody conjugated to PE 
(clone WM-59, BD Biosciences Pharmingen) for 15 minutes. Cells were 
incubated with the FLICA 660-DEVD-FMK caspse-3/7 inhibitor or FLICA 660-
YVAD-FMK caspase-1 inhibitor reagent for 20 minutes at room temperature in 
the dark. Unbound reagents were removed by two washes in wash buffer. The 
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cells were stained with PI to assess viability. The cells were analyzed by LSR II 
flow cytometer (BD Biosciences Pharmingen) using FlowJo software.    
 
Statistical analysis 
Results are expressed as mean ± the standard error of the mean (SEM) for the 
study variables. The change of gene expression after rhVEGF-A, Delta1ext-IgG, or 
γ-secretase inhibitor L685458 induction in ECFC was assessed by Student’s 
paired t-test. The vessel number and size distribution were evaluated by 
Students unpaired t-test. A statistically significant difference was set at P<0.05. 
The quantification of western blot data points, the number of αSMA+ vessels, the 
assessment of apoptosis of ECFCs, and results of caspase-1 and -3/7 assays in 
3D collagen matrices were assessed by One-way ANOVA, *P<0.05, **P<0.001, 
or ***P<0.0001.  
 
2.3. Results 
Cultured human cord blood ECFC expresses multiple Notch pathway 
transcripts 
We examined cultured human cord blood ECFCs to determine if Notch 
ligand/receptor or downstream genes activated by Notch ligand binding were 
evident at baseline conditions, along with some typical endothelial transcripts. 
Cultured ECFCs expressed a variety of the Notch pathway related transcripts 
(Figure 2.1. a). ECFCs displayed several typical endothelial cell surface markers 
such as platelet endothelial cell adhesion molecule-l (PECAM-I, CD31) and 
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vascular endothelial-cadherin (VE-Cad), which are typical of an EC identity and 
these cells have all been shown to give rise to cultures of ECs that display in vivo 
human vessel forming potential (Ingram et al., 2005; Yoder et al., 2007). We also 
demonstrated protein expression of Notch ligands and Notch receptors on 
ECFCs by flow cytometry (Figure 2.1. b). While Dll1 was not detected on ECFCs, 
Notch1 (2.7 ± 0.5%), Notch4 (2.9 ± 0.3%), and Dll4 (4.6 ± 0.9%) were expressed 
on subsets of ECFCs. N=3.  
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Figure 2.1. The expression of Notch pathway related transcripts in cultured 
ECFCs. (a) Human cord blood (CB) derived ECFCs expressed numerous Notch 
pathway related transcripts and EC gene markers such as PECAM-I and VE-
Cadherin. (b) Notch ligands and receptors were expressed on a subset of ECFCs. 
The representative histograms show comparison between fluorescence minus 
one (FMO) control (red) and Notch molecules (blue) on ECFCs. Reprinted with 
permission from “Notch ligand Delta-like 1 promotes in vivo vasculogenesis in 
human cord blood-derived endothelial colony forming cells” by Kim et al., 2015, 
Cytotherapy, 17(5):579-92. Figure 2.1. (a) was performed by my co-worker, Lan 
Huang. Figure 2.1. (b) was from my original work (H. Kim, Huang, et al., 2015). 
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Delta1ext-IgG induces known Notch downstream target gene transcripts in 
human cord blood ECFCs in a dose-dependent manner 
Previous studies have indicated that Notch signaling is required for blood vessel 
formation during embryo development (Duarte et al., 2004; Gale et al., 2004; 
Lawson et al., 2001; Rocha & Adams, 2009; Swift & Weinstein, 2009). In this 
study, the engineered Notch ligand, Delta1ext-IgG, consisting of the extracellular 
domain of Dll1 fused to the Fc portion of human IgG, was used to activate Notch 
signaling in the ECFC. An enzyme-linked immunoabsorbant assay was utilized to 
confirm that the concentration of ligand coated on the tissue culture plate surface 
correlated with the amount of ligand bound as previously described (Delaney, 
Varnum-Finney, Aoyama, Brashem-Stein, & Bernstein, 2005). The linear 
relationship between the amount of immobilized ligand and activation of Notch 
signaling was measured by the expression of the Notch downstream target gene 
Hey2 (Figure 2.2. a and b). After 3 days of culture, cells were harvested and the 
expression of Hey2 was examined by quantitative PCR. Expression of Hey2 
increased as the concentration of Delta1ext-IgG increased, which indicated that 
human CB derived ECFCs were capable of responding to Notch ligand Dll1 
stimulation.  
 
We next evaluated whether Delta1ext-IgG influences other Notch related gene 
expression patterns in human CB ECFCs. Early passaged (2-4) ECFCs (N=5) 
were cultured in wells coated with Delta1ext-IgG at concentrations ranging from 
0.312 to 20 µg/mL or with the same concentration of human IgG as the control 
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attachment ligand. Dll4, Notch 1, and Notch4 mRNA expression over 14 days of 
culture were unchanged in the ECFC treated with Delta1ext-IgG (Figure 2.3.). It is 
noteworthy that mRNA for the arterial-like endothelial gene markers Hey2 and 
EphrinB2 were significantly upregulated after 3 days of Delta1ext-IgG induction at 
the concentration of 10 µg/mL (Figure 2.2. b) while the expression of mRNAs for 
the venous-like endothelial gene markers CoupTFII and EphB4 remained at low 
levels of detection (Figure 2.2. b). Changes in Hey2 and CoupTFII gene 
expression at the transcript level upon Delta1ext-IgG binding were confirmed at the 
protein level (Figure 2.2. c). Immunoblot analysis indicated that the protein level 
changes of Hey2 and CoupTFII were consistent with their mRNA levels of 
change. These results demonstrated that Delta1ext-IgG was able to enhance Notch 
related gene expression in human CB ECFCs in vitro. 
 
Next, we examined whether Delta1ext-IgG -induced EphrinB2 expression could be 
suppressed if Notch signaling was blocked via the use of a γ-secretase inhibitor 
L685458. The expression of Hes1 and Hey2 mRNA decreased with the addition 
of the inhibitor to the culture (Figure. 2.4. a and b). Interestingly, the Delta1ext-IgG -
induced upregulation of mRNA for Hey2 and EphrinB2 was significantly 
decreased in the presence of 1µM L685458 for 3 days, whereas the expression 
of mRNA for CoupTFII was noticeably increased (Figure. 2.4. c). In addition, 
when control human CB ECFCs were treated with 1µM L685458 alone for 3 days, 
the expression of mRNAs for Hey2 and EphrinB2 were dramatically suppressed 
while the mRNA for CoupTFII was considerably enhanced when compared to 
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Deltaext-IgG treated cells (Figure. 2.4. c). Collectively, these observations 
demonstrated that immobilized Dll1 activated Notch signaling is able to regulate 
ECFC gene expression patterns in vitro over several days of exposure.  
  
	   48 
 
  
	   49 
Figure 2.2.  ECFCs respond to Notch signaling with increased expression 
of known downstream target genes.  The dose-dependent activation of 
endogenous Notch signaling in human cord blood derived ECFCs is indicated by 
Hey2 (a) expression after 3 days of incubation in various concentrations of 
Delta1ext-IgG. (b) Quantitative RT-PCR analysis revealed Hey2 and EphrinB2 
transcripts were significantly increased after 3 days of stimulation with 10 µg/mL 
Delta1ext-IgG, whereas the expression of CoupTFII and EphB4 were not 
significantly affected. Expression levels were presented as a fold change (in 
2logarithmic scale) compared to baseline levels and were normalized by using 
ATP5B as a housekeeping gene. The expression at day 0 in nontreated cells 
serveed as a baseline value. N=5. *P<0.05. (c) Upper panel shows 
representative immunoblots of Hey2 and CoupTFII proteins and lower panel 
shows quantification (protein expression levels were normalized by using β-actin). 
N=3. *P<0.05. Reprinted with permission from “Notch ligand Delta-like 1 
promotes in vivo vasculogenesis in human cord blood-derived endothelial colony 
forming cells” by Kim et al., 2015, Cytotherapy, 17(5):579-92. Figure 2.2. was 
from combined effort of my co-worker, Lan Huang  and me (H. Kim, Huang, et al., 
2015).  
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Figure 2.3. Alteration of Notch gene expression in ECFC response to 3 days 
of Delta1ext-IgG stimulation. Quantitative PCR analysis reveals that expression of 
mRNA levels for Dll4, Notch1, and Notch4 was unchanged upon stimulation of 
ECFC upon co-culture with Delta1ext-IgG over 3 days. Expression levels are 
presented as a fold change (in 2logarithmic scale) compared to baseline levels, 
which were normalized using ATP5B as a housekeeping gene. The expression at 
Day 0 in non-treated cells acts as baseline. N=5. *P<0.05. Reprinted with 
permission from “Notch ligand Delta-like 1 promotes in vivo vasculogenesis in 
human cord blood-derived endothelial colony forming cells” by Kim et al., 2015, 
Cytotherapy, 17(5):579-92. Figure 2.3. was from combined effort of my co-worker, 
Lan Huang  and me (H. Kim, Huang, et al., 2015). 
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Figure 2.4. The effect of γ-secretase inhibitor L685458 on Notch signaling. 
The dose-dependent inhibition of endogenous Notch signaling in human CB 
derived ECFCs is indicated by Hes1 (a) and Hey2 (b) expression after 3 days of 
incubation in various concentrations of L685458 using quantitative PCR. 
Expression levels are presented as a fold change (in 2logarithmic scale) 
compared to baseline levels, which were normalized using ATP5B as a 
housekeeping gene. The expression at Day 0 in non-treated cells acts as 
baseline. N=5. (c) Quantitative RT-PCR analysis revealed that Delta1ext-IgG-
induced upregulation of Hey2 and EphrinB2 was dramatically attenuated in the 
presence of 1µM γ-secretase inhibitor L685458 while CoupTFII was significantly 
upregulated. Expression levels are presented as a fold change (in 2logarithmic 
scale) compared to baseline levels and were normalized by using ATP5B as a 
housekeeping gene. The expression at day 0 in non-treated cells serves as a 
baseline. N=5. *P<0.05, or **P<0.01. Reprinted with permission from “Notch 
ligand Delta-like 1 promotes in vivo vasculogenesis in human cord blood-derived 
endothelial colony forming cells” by Kim et al., 2015, Cytotherapy, 17(5):579-92. 
Figure 2.4. was from combined effort of my co-worker, Lan Huang  and me (H. 
Kim, Huang, et al., 2015). 
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Dll1 expression by OP9 stromal cells significantly enhances in vivo 
postnatal vasculogenesis  
We subsequently tested whether human CB ECFCs exposed to immobilized Dll1 
(Delta1ext-IgG) would increase vasculogenesis after they were implanted in vivo. 
ECFCs were treated with 10 µg/mL of Delta1ext-IgG for 3 days in vitro, then 
suspended in a collagen-fibronectin matrix and subcutaneously implanted into 
immunodeficient mice as described (Yoder et al., 2007). After 14 days, the mice 
were euthanized, the grafts were harvested, and implants were analyzed for 
blood vessel formation (Figure 2.5. a). Our data indicated that in vitro Delta1ext-
IgG-primed human CB ECFCs were unable to enhance vessel formation in vivo, 
since the total vascular area of the human vessels was unchanged compared to 
IgG control cultured cells (Figure 2.5. a and b). These data indicate that 
preconditioning of ECFC in vitro with Notch activation fails to translate into 
enhanced vasculogenic properties in ECFC in vivo.  
 
Knowing that activation of Notch signaling is mediated by cell-cell interaction 
between Notch ligands and receptors in vitro and in vivo (Kume, 2009), we 
hypothesized that co-implantation of ECFCs with stromal cells constitutively 
expressing Dll1 may be required to enhance vasculogenesis in vivo. ECFCs 
were cultured in standard conditions and then co-implanted with OP9-Delta-like 1 
stromal cells (OP9-DL1) into immunodeficient mice. After 14 days, the mice were 
euthanized; the grafts were harvested and investigated for human blood vessel 
formation. Use of a specific anti-human CD31 antibody revealed that human CB 
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ECFCs were able to form microvessels perfused with murine red blood cells in 
the grafts (Figure 2.6. a). Of interest, the vessel number and morphology differed 
between the collagen matrices containing ECFC co-implanted with OP9-DL1 
(ECFC/OP9-DL1) cells and the control implants (the collagen matrices containing 
ECFC alone or ECFC with OP9 (ECFC/OP9)). The quantification of murine 
erythrocyte-containing human microvessels (Figure 2.6. b) revealed a 
significantly greater number of hCD31+ vessels were present in ECFC/OP9-DL1 
implants compared to the controls (ECFC alone vs. ECFC/OP9 vs. ECFC/OP9-
DL1 was 30.03 ± 8.14 vs. 53.32 ± 7.19 vs. 129.10 ± 27.80 vessels/mm2, 
respectively, P<0.05). In addition, the size distribution of hCD31+ microvessels 
was altered with the ECFC/OP9-DL1 implants compared to the control implants 
(Figure 2.6. c). Noticeably, upon Dll1 stimulation human cord blood ECFCs gave 
rise to significantly more large area microvessels (1000-4000 µm2) and less small 
ones (51-100 µm2) (Figure 2.6. c). Furthermore, the average vessel area was 
distinctly increased with the ECFC/OP9-DL1 implants compared to the control 
implants (Figure 3.6. d, ECFC alone vs. ECFC/OP9 vs. ECFC/OP9-DL1 was 
223.81 ± 15.47 vs. 266.03 ± 39.28 vs. 384.61 ± 42.73 µm2, respectively, P<0.05). 
These alterations resulted in the overall hCD31+ vascular area (=average vessel 
density x average vessel area) being significantly enhanced in the ECFC/OP9-
DL1 implants compared to the control implants (Figure 2.6. e).  
 
Notch1 and Notch2 protein levels were significantly upregulated in implants with 
OP9-DL1, but Notch4 expression level was distinctly decreased (Figure 2.6. f). In 
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addition, stimulation with the OP9-DL1 Notch ligand has been reported to cause 
rapid nuclear translocation of the cleaved domain of Notch1 (Krebs et al., 2000). 
Consistently, Notch1 activation was widely detected in nuclei of human ECFC-
derived vessels (in implants containing OP9-DL1) as shown by specific EC 
nuclear immunostaining for cleaved Notch1 (Val1744) (Figure 2.6. g). This 
observation indicated that human ECFC-derived vessels were responsive to Dll1 
ligand presentation in vivo and Notch1 signaling was persistently activated in 
ECFC/OP9-DL1 implants in vivo. Also, anti-mouse smooth muscle α actin (αSMA) 
antibody stain (red) was detected in peri-vascular cells located around human 
ECFC-derived CD31+ (brown) microvessels in co-implants with OP9-DL1 (Figure 
2.6. h). Together, these data suggest that Dll1 binding to Notch1 significantly 
modulates vasculogenesis in vivo by inducing Notch signaling and promoting 
more ECFC-derived vessel formation with an overall enlarged vascular area and 
recruitment of host murine peri-vascular cells to the human vessels.  
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Figure 2.5. In vitro Delta1ext-IgG-primed ECFCs fail to enhance 
vasculogenesis in vivo. (a) H&E staining indicates microvessel formation in 
collagen-fibronectin matrices after 14 days of implantation. Anti-human CD31 
staining further confirms the human origin of these vessels. Results suggest that 
human cord blood derived ECFCs cultured in the presence of Delta1ext-IgG retain 
vessel-forming ability in vivo. Moreover, the number of vessels formed by human 
cord blood derived ECFCs and perfused with murine red blood cells per mm2 in 
the matrix demonstrate no observable difference between Delta1ext-IgG treated 
and nontreated samples (b). In addition, the size distribution of both populations 
of microvessels is similar (c). N=6. Reprinted with permission from “Notch ligand 
Delta-like 1 promotes in vivo vasculogenesis in human cord blood-derived 
endothelial colony forming cells” by Kim et al., 2015, Cytotherapy, 17(5):579-92. 
Figure 2.5. was from combined effort of my co-worker, Lan Huang  and me (H. 
Kim, Huang, et al., 2015). 
	   58 
  
	   59 
 
	   60 
Figure 2.6. In vivo Dll1 stimulation boosts the formation of functional 
vessels. (a) Anti-human CD31 staining identified human cord blood derived 
ECFCs alone or combined with OP9 or OP9-DL1, that have formed microvessels 
in collagen matrices after 14 days of implantation. Upon the stimulation of Dll1, 
there was a significant increase in the number of vessels formed by human cord 
blood derived ECFCs and perfused with murine red blood cells per mm2 in the 
matrix (b). In addition, the size distribution of hCD31+ microvessels was 
noticeably altered (c), shifting towards larger sized vessels (1001-4000 µm2) with 
Dll1 stimulation. Moreover, vessel morphology was significantly altered by the 
presence of Dll1 with increased average vessel area (d) and total vascular areas 
(d). (f) Upper panel shows representative immunoblots of Notch1, Notch2, and 
Notch4 proteins and lower two panels show quantification of repeated 
experiments (protein expression levels were normalized using β-actin). N=3. 
*P<0.05. Anti-cleaved Notch1 (Val1744) antibody staining (g) in endothelial 
nuclei confirms that the activation of Notch1 is detected in vivo in newly-formed 
human vessels in the presence of Dll1. N=6. Scale bar represents 100 µm. (h) 
Anti-mouse smooth muscle α actin (αSMA) antibody staining (red) was detected 
in peri-vascular cells around human ECFC-derived CD31+ vessels (brown) in 
implants with OP9-DL1 stromal cells. N=3. Scale bar represents 10 µm. *P<0.05. 
Reprinted with permission from “Notch ligand Delta-like 1 promotes in vivo 
vasculogenesis in human cord blood-derived endothelial colony forming cells” by 
Kim et al., 2015, Cytotherapy, 17(5):579-92. Figure 2.6. (a-e) were performed by 
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co-worker, Lan Huang. Figure 2.6. (f-h) were from my original work (H. Kim, 
Huang, et al., 2015).  
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Dll1 expressed by OP9 stromal cells significantly reduces apoptosis of 
human cord blood ECFCs in three dimensional (3D) collagen matrices.  
To begin to understand the mechanisms through which Notch activation could 
enhance vasculogenesis of the human ECFC, we tested whether the presence of 
OP9-DL1 decreases apoptosis of human CB ECFCs in the 3D collagen implants. 
After one, two, three, or five days, the cells were recovered and assessed for 
apoptosis of ECFCs using Annexin V and propidium iodide staining. Implanted 
ECFCs started undergoing apoptosis on day 1 and a significant majority of the 
cells died on day 2 and 3 after implantation (Figure 2.7. a). ECFC co-implanted 
with OP9-DL1 (1:1 cell ratio) revealed a significantly higher percentage of the 
Annexin V-/PI- viable cell population compared to ECFC alone or ECFC with OP9 
implantation on day 1 and 3 (Figure 2.7. b and c). These results indicated that 
co-implantation of ECFC with OP9-DL1 stromal cells increased survival of ECFC 
within the 3D-collagen matrices. Since caspase activation is a hallmark of 
apoptosis, we examined ECFC for evidence of caspase activation within the 3D 
matrices.  The caspase assay we employed allowed detecting fluorescein-
labeled inhibitors that bind to activated caspase-1 and -3/7 within cells. The 
inhibitors bind with 1:1 stoichiometry to the active centers of activated caspases. 
Thus, the assay can be used for quantitative analysis of the activated caspases 
in the cells. In every experiment performed, the caspase-3/7-/PI- cell subset of 
ECFC co-implanted with OP9-DL1 was significantly higher on day 3 compared to 
implanted ECFC alone or ECFCs with OP9 implantation (Figure 2.7. d). ECFC 
co-implanted with OP9-DL1 also displayed a greater percentage of caspase-1-
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/PI- cells compared to ECFC alone or ECFC with OP9 implantation on day 2 and 
3 (Figure 2.7. e). These observations indicate that Notch activation by OP9-DL1 
stromal cells reduced activated caspase-3/7 and caspase-1 within ECFCs in 
collagen matrices. Therefore, we conclude that Notch activation of ECFC in 
collagen matrix implants enhanced survival of ECFCs by reducing activation of 
caspase-3/7 and caspase-1.  
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Figure 2.7. OP9-DL1 stimulation diminishes apoptosis of ECFCs in 3D 
collagen matrices. (a) Representative dot plots of apoptosis analysis of ECFCs 
at 30 minutes or on day 1-3. (b) Representative dot plots of apoptosis analysis of 
ECFC alone, co-implanted with OP9 or OP9-DL1 on day 1-3. (c) The Annexin V-
/PI- viable population of ECFC co-implanted with OP9-DL1 was significantly 
higher on day 1 and 3 compared to implantation of ECFC alone or ECFC with 
OP9 on day 1 and 3. (d) The percentage of the Caspase-3/7-/PI- population of 
ECFC co-implanted with OP9-DL1 was significantly greater compared to ECFC 
alone or with OP9 on day 3. (e) ECFC co-implanted with OP9-DL1 displayed a 
higher percentage of Caspase-1-/PI- cells compared to ECFC alone or ECFC 
with OP9 co-implants. N=6. *P<0.05. Reprinted with permission from “Notch 
ligand Delta-like 1 promotes in vivo vasculogenesis in human cord blood-derived 
endothelial colony forming cells” by Kim et al., 2015, Cytotherapy, 17(5):579-92. 
Figure 2.7. was from my original work (H. Kim, Huang, et al., 2015). 
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2.4. Discussion 
Vasculogenesis is the process of primary capillary plexus formation from 
angioblasts during embryogenesis. Remodeling of the capillary plexus normally 
occurs via angiogenesis and arteriogenesis to form the hierarchical mature 
systemic vasculature (Carmeliet, 2000; Hanahan, 1997). It has been well 
established that Notch signaling plays an important role in regulating vascular 
patterning and remodeling during development (Benedito et al., 2008; Copeland, 
Feng, Neradugomma, Fields, & Vivian, 2011; Y. H. Kim et al., 2008; Krebs, 
Starling, Chervonsky, & Gridley, 2010; Trindade et al., 2008; Uyttendaele, Ho, 
Rossant, & Kitajewski, 2001) and after birth (Limbourg et al., 2007; Takeshita et 
al., 2007). Previous studies in murine embryonic development showed that 
ectopic Notch1 activation in ECs caused vascular remodeling defects with 
enlarged vessel caliber (Copeland et al., 2011; Krebs et al., 2010). In contrast, 
small sized vessels were present upon loss of active Notch signaling (Benedito et 
al., 2008; Copeland et al., 2011). We report that the in vivo presence of stromal 
cell associated Notch ligand Dll1 led to enhanced vasculogenesis and vascular 
remodeling in human cord blood ECFCs, characterized by increased vessel 
density and enlarged vessel area (Figure 2.6.). Accordingly, our observations 
coincide with the previous studies indicating that Dll1-dependent Notch1 
signaling regulates vessel size and state in murine embryogenesis.  
 
A role for mesenchymal stromal cells (MSC) in promoting enhanced human 
ECFC vasculogenesis in vivo has been reported by several laboratories (P. Allen, 
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K.-T. Kang, & J. Bischoff, 2013; Au, Daheron, et al., 2008; Au, Tam, Fukumura, & 
Jain, 2008; Kang, Allen, & Bischoff, 2011; Lin, Moreno-Luna, Zhou, Pu, & 
Melero-Martin, 2012; Melero-Martin et al., 2008; Traktuev et al., 2009; X. Wu et 
al., 2004). Indeed, conditioned medium secreted by multiple tissue-derived 
cultured MSCs promotes ECFC vasculogenesis in vivo, although the specific 
molecules promoting enhanced ECFC function remain elusive (Lin et al., 2012). 
Surprisingly, we did not find a significant improvement in ECFC vasculogenic 
properties when the murine OP9 MSCs were co-implanted with the ECFC in our 
studies. We speculate that differences in the types and composition of the 3D 
scaffolding proteins and strain of immunodeficient mice may play a role in the 
extent to which MSC promote human ECFC vasculogenesis in vivo. While there 
are numerous matrices that permit ECFC and MSC, but not ECFC alone, to form 
vessels in vivo upon implantation into nude mice (Patrick Allen et al., 2013; Allen, 
Melero-Martin, & Bischoff, 2011), cord blood ECFC alone form human blood 
vessels in tissue engineered skin substitutes implanted in C.B-17 severe 
combined immunodeficient (SCID)/beige mice (Benjamin R. Shepherd et al., 
2006) or in type I collagen matrices implanted in non-obese diabetic 
(NOD)/(SCID) mice (L. Huang et al., 2011; Yoder et al., 2007). Further work to 
directly compare ECFC vasculogenesis in various matrices in several different 
immunodeficient murine hosts will be required to address the discrepancies in 
the literature.  
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VEGF plays a critical role in determining arterial-venous specification and the 
concentration of VEGF influences this determination (Lanner, Sohl, & Farnebo, 
2007). In cultured murine embryonic stem cells (ESCs), a high concentration of 
VEGF (50 ng/mL) drove an arterial-like endothelial gene expression pattern while 
a low dose encouraged venous-like endothelial gene expression (Lanner et al., 
2007). Similarly, addition of 10 ng/mL of rhVEGF-A to cultured cells upregulated 
an arterial-like endothelial gene expression pattern in hMAPCs and in hMSCs 
(Aranguren et al., 2007; Zhang et al., 2008). Recently, in the presence of 50 
ng/mL of rhVEGF-A, arterial-like endothelial genes and downstream genes of 
Notch signaling were increased in cultured ECFCs (Boyer-Di Ponio et al., 2014). 
The arterial-like endothelial genes induced by VEGF were decreased with 
treatment using γ-secretase inhibitor on cultured ECFCs (Boyer-Di Ponio et al., 
2014). This study indicated that VEGF-dependent induction leads to arterial-like 
gene expression with Notch signaling activation. Our results consistently 
confirmed prior work that rhVEGF-A at 50 ng/mL was sufficient to enhance 
expression of the arterial-like endothelial genes with activation of Notch in 
cultured CB ECFC. In addition, Notch stimulated preconditioning in vitro was able 
to induce an arterial-like gene expression pattern in vitro. However, 
preconditioning of ECFC in vitro with Notch stimulation failed to promote an 
arterial-like phenotype in vivo, suggesting that in vitro priming is not sufficient for 
in vivo specification in our experimental model. Of interest, in vivo co-
implantation of OP9-DL1 stromal cells with ECFCs significantly enhanced 
vasculogenesis in vivo by promoting more ECFC-derived vessel formation with 
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an overall enlarged vascular area and recruiting of murine peri-vascular cells 
around ECFC-derived vessels (Figure 2.6.). Shepherd et al. (B. R. Shepherd, Jay, 
Saltzman, Tellides, & Pober, 2009) reported that co-implantation of human aortic 
smooth muscle cells promoted larger vessel size with peri-endothelial investment 
at 60 days post-implantation. While we implanted the OP9-DL1 stromal cells with 
the ECFC, we observed an effect of Notch activation on human vessel size and 
recruitment of host peri-vascular cells. Future studies utilizing specific 
perivascular cell subsets may indicate whether there are cell specific influences 
provided by the mesenchymal cells on the human ECFC.  
 
In the present work, implanted human CB ECFCs started undergoing apoptosis 
on day 1. After 2-5 days of implantation, most implanted ECFCs died with only 5-
8% of total implanted cells persisting as perfused vessels. Previous studies have 
indicated that human ECFC cell-lined vessels formed within subcutaneous 
implants in mice were found as early as day 1 or 2 following implantation, but 
these lumenized structures lacked significant perfusion with murine red blood 
cells at those early time points. However, ECFC derived vessels perfused with 
host murine red blood cells (perfusion also confirmed by human specific lectin 
infusion and contrast-enhanced ultrasound flow detection) were detected after 3-
4 days of implantation in vivo (Patrick Allen et al., 2013). Thus, implanted 
endothelial cells had to survive at least 3-4 days in vivo to be able to contribute to 
a stable perfused capillary network. Given the proclivity of capillary networks to 
destabilize and regress with endothelial apoptosis in the absence of peri-
	   70 
endothelial support cells or adhesion of the endothelial cells to matrix proteins via 
cell surface integrin receptors (Brooks et al., 1994; Fukai et al., 1998; Pollman, 
Naumovski, & Gibbons, 1999; Stratman, Schwindt, Malotte, & Davis, 2010), 
understanding the importance of a balance of pro-apoptotic versus anti-apoptotic 
signals in the plasticity of the capillary plexus has become an important paradigm. 
Peri-vascular support cells can induce endothelial cells to secrete basement 
membrane proteins that enhance endothelial cell integrin mediated attachment 
and increases in Bcl-2 expression to protect cells from apoptosis (Pollman et al., 
1999; Stromblad, Becker, Yebra, Brooks, & Cheresh, 1996). While human 
umbilical vein endothelial cells (HUVECs) undergo apoptosis when implanted in 
immunodeficient mice within 24h, Bcl-2 overexpression in HUVECs rescues them 
from apoptotic death and enhances the number and complexity of human 
vessels formed (Zheng et al., 2000). Bcl-2 overexpression in HUVECs also 
increases the number of human and mouse endothelial cell-lined vessels 
(vascularization) in implants and induces maturation of vessels by increasing 
tissue perfusion (Enis et al., 2005; Benjamin R. Shepherd et al., 2006). The 
frequency of the Annexin V-/PI- viable cell population and overall hCD31+ 
vascular area in the ECFC/OP9-DL1 implants reflected a four-fold increase 
compared to the ECFC/OP9 implants (Figure. 2.6. e and 2.7. c), suggesting a 
direct effect between diminishing apoptosis and increased vessel formation by 
Notch activation in ECFC in vivo. Our results suggest that improvement of cell 
survival of ECFCs by Dll1-dependent Notch1 signaling activation (Figure. 2.6. f) 
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leads to vessel stabilization and promotes functional vessel formation in 3D 
collagen matrices.  
 
In summary, we have demonstrated that human cord blood ECFCs robustly form 
microvessels exhibiting a distinct remodeling pattern with increased vessel 
number and enlarged vessels by diminishing apoptosis of CB ECFCs during 
OP9-DL1 mediated Notch activation. While other studies have shown that 
stromal cell co-implantation with ECFCs increases vessel number and maturation 
in vivo (Melero-Martin et al., 2010; Melero-Martin et al., 2008), we did not 
observed any enhancement of vasculogenesis by co-implanting ECFCs with OP9 
stromal cells. However, co-implantation of OP9-DL1 led to constitutive ECFC 
Notch activation and resulted in greater numbers and maturation of human blood 
vessels in vivo. Further studies to present Notch activating ligands embedded 
within the matrix molecules may permit the modulation of human vessel 
formation using ECFC alone.  
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CHAPTER 3. HUMAN PLATELET LYSATE IMPROVES HUMAN CORD 
BLOOD DERIVED ECFC SURVIVAL AND VASCULOGENESIS IN THREE 
DIMENSIONAL (3D) COLLAGEN MATRICES 
 
The following chapter is reprinted with permission from “Human platelet lysate 
improves human cord blood derived ECFC survival and vasculogenesis in three 
dimensional (3D) collagen matrices” by Kim et al., 2015, Microvascular Research, 
101:72-81 (H. Kim, Prasain, et al., 2015). 
 
3.1. Introduction 
The progenitor cells for the endothelial lineage play critical roles in vascular 
homeostasis and regeneration in adult subjects (Asahara et al., 1997; Hirschi et 
al., 2008). Endothelial colony forming cells (ECFC) are derived from a rare 
circulating subset that may arise from resident endothelium of established blood 
vessels in man (Hirschi et al., 2008). We have successfully isolated human 
peripheral blood (PB) or umbilical cord blood (CB) derived circulating ECFC that 
display a hierarchy of proliferative potential through the use of single cell 
clonogenic and functional assays (L. Huang et al., 2011; Ingram et al., 2004). 
Human CB derived ECFC also display de novo vessel forming ability in nude or 
non-obese diabetic/severe combined immunodeficient mice (NOD/SCID) in vivo 
after subcutaneous implantation of ECFC in type I collagen matrices and upon 
perfusion with host murine vessels, become a part of the systemic host 
circulation (Au, Daheron, et al., 2008; Cheng et al., 2011; Critser, Kreger, Voytik-
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Harbin, & Yoder, 2010; L. Huang et al., 2011; Melero-Martin et al., 2008; Melero-
Martin et al., 2007; Reinisch et al., 2009; Whittington, Yoder, & Voytik-Harbin, 
2013; Yoder et al., 2007).   
 
Previous studies have reported that human ECFC-derived vessels formed in 
subcutaneous implants were found as early as day 1 or 2 after implantation in 
NOD/SCID mice (P. Allen et al., 2013). However, these premature vessels were 
not properly perfused with murine red blood cells of the host circulatory system at 
those early time points. Proof of human ECFC cell-lined vessel connection to 
host circulation system after 3-4 days of implantation in vivo was subsequently 
reported (P. Allen et al., 2013). It has been reported that up to 60% of human 
umbilical vein endothelial cells (HUVECs) undergo apoptosis in the first 24 hours 
after suspension in collagen gels and there is further loss of vascular structures 
in 3D type I collagen matrices after 24 hours of culture (Ilan et al., 1998). In our 
previous study, we demonstrated that implanted human CB ECFC containing 
collagen matrices displayed ECFC undergoing apoptosis on day 1 following 
implantation (H. Kim, Huang, et al., 2015). After 2-3 days of implantation, most 
implanted ECFC died with only 1-3% of the total implanted cells demonstrating 
viability in the subcutaneous implants (H. Kim, Huang, et al., 2015). Since the 
stability of newly formed vessels requires systemic blood flow, theses data 
suggest that implanted endothelial cells must survive at least 3-4 days in vivo to 
form a stable perfused capillary network connected to the host circulatory 
system.  
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The microvascular network has the intrinsic capacity to remodel itself through 
changes in endothelial cell differentiation, growth, migration, and matrix 
modification (Hanahan & Folkman, 1996; Risau, 1995). Previous studies have 
reported that cytokines, matrix proteins, and integrins are important factors in 
capillary endothelial network formation and remodeling in various matrix models 
(Matrigel and type I collagen matrix systems) (Critser et al., 2010; Fukai et al., 
1998; Hynes, 1992; Ranta, Mikkola, Ylikorkala, Viinikka, & Orpana, 1998; 
Sacharidou, Stratman, & Davis, 2012; Stratman, Davis, & Davis, 2011; 
Whittington et al., 2013). The absence of peri-endothelial support cells or lack of 
endothelial cell adhesion to matrix proteins causes destabilization and regression 
of capillary structures within Matrigel or 3D type I collagen matrices (Brooks et 
al., 1994; Fukai et al., 1998; Pollman et al., 1999; Stratman et al., 2010). 
Apoptosis of endothelial cells has been observed in the context of dynamic 
capillary network remodeling in the various matrix models both in vitro and in vivo 
and is thought to play a necessary role for optimal network formation (Brooks et 
al., 1994; Fukai et al., 1998; Pollman et al., 1999; Stratman et al., 2010). On the 
other hand, the generation of anti-apoptotic signals is also required to maintain 
integrity of the vascular network following realignment of certain matrix proteins 
and cell-cell or cell-matrix interactions during the process (Pollman et al., 1999; 
Shih et al., 2011). Thus, understanding the balance between pro-apoptotic and 
pro-survival signals is a critical point in capillary structure formation and the 
remodeling process. 
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Apoptosis is a cellular process in tissue development that generally culminates 
with the sequential activation of caspases, the cysteine proteases for cleavage of 
proteins (Duprez et al., 2009; Sprick & Walczak, 2004; Taylor et al., 2008). There 
are two pathways that result in apoptosis depending on the apoptotic signal. The 
extrinsic pathway is initiated by ligand binding to membrane receptors of the 
death receptor family, whereas the intrinsic pathway is mediated by stress-
mediated damage such as alterations in temperature, osmolality, DNA damaging 
agents, free radical generation compounds, removal of nutrients, and oxygen 
deprivation (Duprez et al., 2009; Sprick & Walczak, 2004; Taylor et al., 2008; 
Wyllie, 2010). The activation of the two pathways leads to the same type of 
apoptotic response, causing release of cytochrome c (Cyt-C) from mitochondria 
and activation of the executioner caspase-3 (Duprez et al., 2009; Sprick & 
Walczak, 2004; Taylor et al., 2008). In the normal state, Akt activation (phospho-
Akt, pAkt) by various growth factors induces cell survival via protection of 
mitochondrial integrity and inhibition of Cyt-C release (Gottlob et al., 2001; Plas 
et al., 2001; Uchiyama et al., 2004; Wyllie, 2010). Akt has also been reported to 
stimulate the expression of anti-apoptotic Bcl-2 proteins, such as Bcl-xL that 
prevents permeabilization of the mitochondrial membrane by inhibiting activation 
of Bas/Bak (Jones et al., 2000; Zong et al., 1999).  However, under apoptotic 
stimulation, pro-apoptotic members of the Bcl-2 family (Bax, Bak, and Bad) are 
activated and induce the release of Cyt-C from mitochondria by binding and 
inactivating anti-apoptotic proteins (Gustafsson & Gottlieb, 2007; Scorrano & 
Korsmeyer, 2003). As the penultimate event, caspase-3 is activated to cleaved 
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caspase-3 to generate all the biochemical and morphologic hallmarks of cell 
apoptosis.   
 
Platelets regulate the balance between apoptosis and cell survival in numerous 
cells involved in the repair of injured tissues (Freishtat et al., 2009; Gambim et 
al., 2007; Mause et al., 2010; Pakala, Willerson, & Benedict, 1994; Sharron et al., 
2012; Stellos & Gawaz, 2007). Since platelets have a critical role in regulation of 
cell death and survival and contains various growth factors and cytokines (Fekete 
et al., 2012; Shih et al., 2011), we hypothesized that human platelet lysate (HPL) 
would increase ECFC survival and enhance ECFC vascularization by modulating 
the balance between apoptosis and cell survival of ECFC in 3D collagen 
matrices.  
 
3.2. Materials And Methods 
Culture of human umbilical cord blood derived ECFC  
ECFC were isolated and cultured as previously described (Ingram et al., 2004). 
ECFC colonies appeared between 5 and 22 days of culture and were noted to 
form colonies of adherent cells with cobblestone morphology. After approximately 
10 days of culture, the ECFC-derived ECs were released from the culture dish by 
TrypLE™ Express (Gibco) and replated onto 25/75 cm2 tissue culture flasks pre-
coated with Type I rat-tail collagen (BD Biosciences) for subsequent passage.  
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Preparation of three-dimensional (3D) collagen matrices 
All of the type I collagen oligomers and associated polymerization reagents were 
purchased from GeniPhys (Bailey et al., 2011). Stock oligomer was diluted in 
0.01N hydrochloric acid (HCl) and neutralized according to manufacturer’s 
recommendations to achieve a final oligomer concentration of 1.37 mg/ml (200Pa 
matrix stiffness). ECFC (1 x 105 cells/60 µl or 1 x 106 cells/250 µl) were 
suspended in the collagen solution with or without human platelet lysate (HPL-
10% of final concentration) at 4°C.  The HPL was purchased from Gemeinnützige 
Salzburger Landeskliniken Betriebsges (SALK). The HPL was prepared from 
pooled platelet-rich plasma derived from a minimum of 40 whole blood donations 
(Schallmoser & Strunk, 2009). The collagen-cell suspensions were plated on 96-
well or 48-well plates and allowed to polymerize at 37°C for 30 minutes and 
covered with complete endothelial cell growth medium (EGM-2, Lonza) with 10% 
defined fetal bovine serum (Hyclone) for incubation for one to three days at 37°C, 
5% CO2. 
 
Toluidine blue staining of 3D collagen matrices and quantification of in 
vitro vascular structures  
For analysis of in vitro vascular structure formation in 3D collagen matrix, 
cellularized collagen matrices were fixed with 4% paraformaldehyde for 20 
minutes on Day 1 or Day 3 after implantation. The matrices were stained with 0.1% 
toluidine blue O dye (30% methanol) for 25 minutes at room temperature and 
washed with PBS for 30 minutes for three times at room temperature. Vascular 
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structures including vacuoles, lumens, and tube formation were quantified using 
ImageJ image analysis software (National Institutes of Health (NIH)). Vacuoles 
and lumens were defined as areas completely surrounded by a toluidine blue-
labeled endothelial cell membrane. A single image of the entire well was 
captured at a depth of 10 microns from the surface of the matrix and then 
additional places 150 microns apart for each of triplicate samples of each group. 
Images of vascular structures were captured at 10x and 20x levels of 
magnification using a Leica DM IRE2 microscope (Leica Microsystems) with 
attached Retiga 4000R digital camera (QImaging). 
 
Assessment of apoptosis of ECFC in 3D collagen matrices 
Apoptosis was assessed by examining the percentage of human CD31+ ECFC 
that bound Annexin V and propidium iodide and was performed as per the 
manufacturer’s instruction (Apoptosis Detection kit, eBioscience). ECFC (1 x 105 
cells/60 µl) were suspended in collagen matrices with/without HPL (10% of final 
concentration), with dimethyl sulfoxide (DMSO) vehicle (same volume of solvent 
for each inhibitor) or with signaling pathway inhibitors, plated in 96-well plates 
and incubated for one to three days as above. As previously described (H. Kim, 
Huang, et al., 2015), matrices were recovered from one to three days after 
implantation and incubated in 250 µl Collagenase Type I (0.25%) (Stemcell 
technology) for 20 minutes at 37°C. Akt1 inhibitor (A-674563) and Bcl-xL inhibitor 
(ABT-263/Navitoclax) were purchased from Selleckchem and Akt2 inhibitor 
(CCT128930) was purchased from Santa Cruz biotechnology. Cell dissociation 
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buffer was added to stop the enzymatic reaction (Invitrogen). Cells were 
centrifuged at 500 g for 5 minutes at room temperature. Cell pellets were 
suspended in staining buffer and stained with anti-human CD31 antibody 
conjugated to phycoerythrin (PE) for 15 minutes (clone WM-59, BD Biosciences 
Pharmingen). Cells were incubated and stained for Annexin V-allophycocyanin 
(APC) and propidium iodide (PI) in binding buffer for 10 minutes at room 
temperature in the dark. Stained cells were analyzed by FlowJo software. Three 
different clones of ECFCs were analyzed in each experiment and each 
experiment repeated one or two times. 
 
Western blot 
Cellular protein lysates were extracted from the ECFC collagen matrix implants 
and electrophoresed using sodium dodecyl sulfate–polyacrylamide matrix 
electrophoresis (SDS-PAGE), transferred to nitrocellulose, and probed with 
monoclonal antibodies that included anti-human Bcl-xL (clone 54H6, Cell 
signaling), cleaved caspase-3 (clone 3G2, Cell signaling), Akt1 (clone 2H10, Cell 
signaling), Akt2 (clone L79B2, Cell signaling), phospho-Akt1 (pAkt1 Ser473) 
(clone D7F10, Cell signaling), phospho-Akt2 (pAkt2 Ser474) (clone D3H2, Cell 
signaling), and phospho-Bad (pBad Ser136) (clone D25H8, Cell signaling). Anti-
human β-actin (mAbcam 8226, Abcam) and GAPDH (clone 14C10, Cell signaling) 
antibodies were used to probe for loading control proteins. Three different clones 
of ECFCs were analyzed in each experiment on at least two occasions. 
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Implantation of human cord blood derived ECFC into NOD/SCID mice  
Cellularized matrix implants were cast as noted above. Cultured ECFC (1 x 106 
cells/250 µl) were suspended in the collagen mixture with or without HPL (10% of 
final concentration). Then 250 µL of the cell suspension was pipetted into one 
well of a 48-well tissue culture plate, allowed to polymerize at 37°C for 30 
minutes, and covered with 500 µL EGM-2 medium for 30 minute incubation at 
37°C, in 5% CO2. Matrices were implanted into the flanks of anesthetized 6-9-
week-old NOD/SCID mice. After 5 days or 14 days, the mice were sacrificed; the 
grafts were excised and analyzed by histology and immunohistochemistry (N=6 
each group) as previously described (L. Huang et al., 2011; Yoder et al., 2007).  
 
Histology and immunohistochemistry 
Sections were stained as previously described (Yoder et al., 2007). Briefly, 
paraffin-embedded tissue sections were deparaffinized and then either directly 
stained with hematoxylin and eosin (H&E) or immersed in retrieval solution (Dako) 
for 20 minutes at 90–99°C. Slides were incubated at room temperature for 30 
minutes with anti-human CD31 antibody (clone JC70/A, Abcam) followed by a 
10-minute incubation with LASB2 link-biotin and streptavidin-HRP (Vector 
Laboratories), then developed with DAB (Vector Laboratories) solution for 5 
minutes. Slides were analyzed by microscope under 20x magnification using a 
Leica DM 4000B microscope (Leica Microsystems) with attached Spot-KE digital 
camera (Diagnostic Instruments).  
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Statistical analysis 
Results are expressed as mean ± the standard error of the mean (SEM) for the 
study variables. The assessment of apoptosis of ECFC, in vitro vascular 
structure quantification and the quantification of western blot data points (ECFC 
versus ECFC+HPL), western blot data points (ECFC treated with DMSO, Akt1 
inhibitor, Akt2 inhibitor, or Bcl-xL inhibitor) were assessed by unpaired t-test. A 
statistically significant difference was set at *P<0.05, **P<0.001, or ***P<0.0001. 
 
3.3. Results 
Human cord blood (CB) derived ECFC with human platelet lysate (HPL) 
significantly reduces apoptosis of ECFC in three dimensional (3D) collagen 
matrices.  
Our previous study demonstrated that implanted ECFC started undergoing 
apoptosis on day 1 and a significant majority of ECFC died on day 2 and 3 in 3D 
collagen matrices after implantation (H. Kim, Huang, et al., 2015). We tested 
whether the co-implantation of ECFC with HPL would decrease apoptosis of 
human CB ECFC in the 3D collagen implants in vitro. After 1-3 days, ECFC were 
recovered from 3D collagen matrices and assessed for apoptosis of ECFC 
stained with anti-human CD31, Annexin V and propidium iodide (PI). CD31+ 
ECFC were selected from the total cell population and separated into Annexin 
V+/- and PI+/- expressing subsets (Figure 3.1.). Implanted ECFC without HPL 
started undergoing apoptosis on day 1 and a significant amount of the cells died 
by day 3 after matrix formation in vitro (Figure 3.2. a). In contrast, ECFC co-
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implants with HPL revealed a significantly higher percentage of the Annexin V-
/PI- viable cell population compared to the control (ECFC alone) (Figure 3.2. a). 
We investigated whether co-implantation of ECFC with HPL would enhance more 
vascular structures in 3D collagen matrices in vitro. ECFC-derived vascular 
structures were defined as endothelial cells with vacuoles and lumenized 
structures were defined as areas completely surrounded by a toluidine blue-
labeled endothelial cell membrane (Figure 3.2. b). A significantly greater average 
number of vascular structures (Figure 3.2. c) and total luminal area of vascular 
structures (mm2) (Figure 3.2. d) were quantified in ECFC+HPL implants 
compared to the control implants on both day 1 and 3 of the in vitro study. These 
data suggest that ECFC+HPL co-implantation significantly promotes 
vasculogenesis by inducing greater cell survival of ECFC in 3D collagen matrices 
in vitro.  
 
	   83 
  
	   84 
Figure 3.1. Co-implantation of ECFC with HPL promotes cell survival of 
ECFC in 3D collagen matrices. Representative dot plots of apoptosis analysis 
of co-implant of ECFC alone and ECFC with HPL on day 1 and 3 of in vitro 
culture. Reprinted with permission from “Human platelet lysate improves human 
cord blood derived ECFC survival and vasculogenesis in three dimensional (3D) 
collagen matrices” by Kim et al., 2015, Microvascular Research, 101:72-81. 
Figure 3.1. was from my original work (H. Kim, Prasain, et al., 2015). 
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Figure 3.2. Co-implantation of ECFC with HPL diminishes apoptosis of 
ECFC in 3D collagen matrices in vitro. (a) The Annexin V-/PI- viable population 
of co-implanted ECFC with HPL was significantly higher on day 1 and 3 
compared to implantation of ECFC alone. N=3. *P<0.05. (b) Representative 
images of vascular structures of ECFC implanted with or without HPL in collagen 
matrices on day 1 and 3 (white arrows indicate the structures and small boxes 
indicates representative counted structures). Scale bar represents 50 µm. Co-
implantation of ECFC with HPL was resulted in a significant increase in (c) the 
average number of vascular structures per collagen matrix surface area and (d) 
total luminal area of vascular structures per matrix surface area (mm2) compared 
to controls. N=10 each group. *P<0.05, **P<0.001, or ***P<0.0001. Reprinted 
with permission from “Human platelet lysate improves human cord blood derived 
ECFC survival and vasculogenesis in three dimensional (3D) collagen matrices” 
by Kim et al., 2015, Microvascular Research, 101:72-81. Figure 3.2. was from my 
original work (H. Kim, Prasain, et al., 2015). 
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Co-implantation of ECFC with HPL modulates the balance between 
apoptosis and cell survival in 3D collagen matrices.  
Knowing that HPL treatment can modulate the balance between apoptosis and 
cell survival (Freishtat et al., 2009; Gambim et al., 2007; Mause et al., 2010; 
Pakala et al., 1994; Sharron et al., 2012; Stellos & Gawaz, 2007), we 
subsequently tested whether ECFC implantation with HPL would alter the protein 
expression level of pro-apoptotic, anti-apoptotic, and pro-survival molecules in 
vitro. On day 1 and 3 after casting the matrices, expression of pro-survival 
molecules (Akt1 and phosphorylated Akt1 (pAkt1)) and an anti-apoptotic 
molecule (Bcl-xL) were upregulated in implants of ECFC with HPL compared to 
ECFC implants without HPL (Figure 3.3. a and b). The pro-apoptotic molecule, 
Bad was phosphorylated (pBad) to an inactive form that blocks apoptosis and the 
expression level of pBad was upregulated in ECFC implants with HPL compared 
to control implants on day 1 and 3 in vitro (Figure 3.3. a and b). The expression 
level of active cleaved caspase-3 was enhanced in co-implants of ECFC with 
HPL compared to control samples on day 1 and 3 (Figure 3.3. a and b). We also 
examined protein expression level of Akt2 and pAkt2, but these proteins were not 
detected in either group on day 1 or 3 (date not shown). Since HPL contains 
various cytokines and growth factors that are involved in pro-survival and anti-
apoptotic signaling (Bendinelli et al., 2010; El-Sharkawy et al., 2007; Fekete et 
al., 2012), HPL may induce more pro-survival/anti-apoptotic signaling to resist 
the apoptotic stimuli that stimulate activation of caspasae-3 (cleaved caspase-3). 
These data suggest that co-implantation of ECFC with HPL in vitro promotes cell 
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survival of ECFC by modulating the balance between pro-apoptotic and anti-
apoptotic/pro-survival molecules.  
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Figure 3.3. HPL in ECFC implant stimulates protein expression of 
apoptotic/cell survival related molecules. (a) Representative immunoblots of 
pro-survival (Akt1, pAkt1, pBad, and Bcl-xL) and apoptotic (cleaved caspase-3) 
proteins from implants of ECFC and ECFC with HPL. Lower panels show 
quantification of repeated experiments on day 1 (b) and day 3(c) after 
implantation (protein expression levels were normalized using β-actin). Pro-
survival molecules and apoptotic molecule were significantly upregulated on co-
implantation of ECFC with HPL compared to ECFC alone on day 1 and day 3. 
N=2 each group. ns=no significance. *P<0.05 or **P<0.001. Reprinted with 
permission from “Human platelet lysate improves human cord blood derived 
ECFC survival and vasculogenesis in three dimensional (3D) collagen matrices” 
by Kim et al., 2015, Microvascular Research, 101:72-81. Figure 3.3. was from my 
original work (H. Kim, Prasain, et al., 2015). 
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Co-implantation of ECFC with HPL significantly enhances vasculogenesis 
of ECFC in vivo. 
ECFC implantation with HPL induced more formation of vascular structures in 
vitro in 3D collagen matrices compared to control matrices (Figure 3.2.). We 
subsequently tested whether co-implantation of ECFC with HPL would promote 
vasculogenesis in an in vivo model. Specific anti-human CD31 antibody staining 
revealed human CB ECFC cell-lined microvessels that were perfused with 
murine red blood cells in the grafts (Figure 3.4. a).  The quantification of murine 
erythrocyte-containing human CD31+ microvessels revealed a significant 
increase of average vessel numbers (Figure 3.4. b) and total vessel area (mm2) 
(Figure 3.4. c) in ECFC+HPL implants compared to ECFC alone implants. In 
addition, the size distribution of the microvessels differed between ECFC 
implants with HPL and ECFC alone implants (Figure 3.4. d). Noticeably, only co-
implantation of ECFC with HPL gave rise to the largest vascular elements (1001-
4000 µm2). These data suggest that co-implantation of ECFC with HPL 
enhanced vasculogenesis in vivo as evidenced by more ECFC-derived vessel 
formation with an enlarged vascular bed area.  
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Figure 3.4. Co-implantation of ECFC with HPL induces the formation of 
functional vessels in vivo. (a) Human ECFC-derived vessels were identified by 
rat anti-human CD31 staining (white arrows indicate ECFC-derived CD31+ 
vessels). The two top panel images show representative images of ECFC-
derived human CD31+ vessels. The two lower panel images show representative 
images of ECFC with HPL derived human CD31+ vessels. Scale bar represents 
10µm. There was a significant increase in (b) average vessel numbers per unit 
sectional area and (c) total vessel area (mm2) per unit sectional area in the ECFC 
with HPL co-implants. (d) In addition, only co-implants of ECFC with HPL formed 
the largest sized vessels (# indicates 1001-4000 µm2) in the size distribution of 
hCD31+ microvessels perfused with murine red blood cells. N=10 mice each 
group. *P<0.05 or **P<0.001. Reprinted with permission from “Human platelet 
lysate improves human cord blood derived ECFC survival and vasculogenesis in 
three dimensional (3D) collagen matrices” by Kim et al., 2015, Microvascular 
Research, 101:72-81. Figure 3.4. was from my original work (H. Kim, Prasain, et 
al., 2015). 
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Inhibition of pro-survival/anti-apoptotic signaling enhances apoptosis of 
ECFC by modulating protein expression of pro-survival molecules in 3D 
collagen matrices  
Since ECFC cell survival was significantly increased when ECFC were co-
implanted with HPL by balancing the anti-apoptotic/pro-survival (Akt1, pAkt1, 
pBad, and Bcl-xL) and pro-apoptotic signals (cleaved caspase-3), we evaluated 
whether inhibition of these pro-survival and anti-apoptotic molecules would alter 
cell survival of ECFC in 3D collagen matrices. Akt is a critical regulator of PI3K-
mediated cell survival (Franke et al., 1995; Yao & Cooper, 1995). Since, Akt1 
and Akt2 are the upstream molecules in PI3K-mediated cell survival and have 
been reported to display compensatory functions between isoforms (W. S. Chen 
et al., 2001; Paradis & Ruvkun, 1998), Akt1 and Akt2 inhibitors were selected to 
examine the importance of these signaling pathways on ECFC pro-survival 
signaling. Akt1 inhibitor blocks the phosphorylation of the Akt downstream target 
pBad to result in increased apoptosis (Luo et al., 2005; Zhu et al., 2008). Akt2 
inhibitor has been reported as a novel small molecule that inhibits cell 
proliferation by inducing cell cycle arrest and thereby triggering apoptosis (Yap et 
al., 2011).  Also, the inhibitor of Bcl-xL was selected for blocking anti-apoptotic 
signaling in ECFC implants. Bcl-xL inhibitor binds to apoptosis suppressor Bcl-xL 
and prevents binding to the apoptotic effectors Bax and Bak proteins 
(Shoemaker et al., 2008; Tse et al., 2008). The concentration of each inhibitor 
was chosen based on dose-dependent optimization experiments (Figure. 3.5.).   
ECFC and ECFC+HPL implants were treated with DMSO as vehicle control, 2 
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µm of Akt1 inhibitor (Figure 3.6. a), 2 µm of Akt2 inhibitor (Figure 3.6. b), and 20 
nM of Bcl-xL inhibitor (Figure 3.6. c). The percentage of the Annexin V-/PI- viable 
population was significantly reduced in both implants of ECFC alone and ECFC 
with HPL when exposed to the Akt1 inhibitor on both day 1 and 3 of culture. 
While cell survival of ECFC alone implants were significantly decreased on day 1, 
both implants of ECFC and ECFC+HPL displayed zero cell survival on day 3 
when treated with the Bcl-xL inhibitor. Akt2 inhibitor treatment significantly 
reduced cell survival of ECFC alone in implants on day 1 and 3. However, there 
was not a statistical significant difference in cell survival of ECFC in the 
ECFC+HPL implants when treated with Akt2 inhibitor on day 1 and 3 because of 
high variability among the repeated experiments. As a result, only Akt1 inhibition 
of ECFC displayed a significant reduction of ECFC cell survival in both implants 
on day 1 following implantation. These results implicate the Akt1 pathway as the 
most important pro-survival pathway promoting ECFC survival in the 3D matrices. 
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Figure 3.5. The effect of inhibitors of Akt1, Akt2, and Bcl-xL on ECFC in 3D 
collagen matrices on day1 and day3. Percentage of the Annexin V-/PI- viable 
population indicates the dose-dependent inhibition of cell survival in ECFC via 
treatment of DMSO, (a) Akt1 inhibitor, (b) Akt2 inhibitor, or (c) Bcl-xL inhibitor. 
Reprinted with permission from “Human platelet lysate improves human cord 
blood derived ECFC survival and vasculogenesis in three dimensional (3D) 
collagen matrices” by Kim et al., 2015, Microvascular Research, 101:72-81. 
Figure 3.5. was from my original work (H. Kim, Prasain, et al., 2015). 
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Figure 3.6. Inhibition of pro-survival molecules reduces cell survival in 3D 
collagen matrices on day 1 and day 3. The Annexin V-/PI- viable population of 
inhibitor treatment of ECFC alone or ECFC with HPL in 3D collagen matrices on 
day 1 and day 3: DMSO as vehicle control, (a) Akt1 inhibitor, 2 µm, (b) Akt2 
inhibitor, 2 µm, and (c) Bcl-xL inhibitor, 20 nM. Percentage of Annexin V-/PI- 
viable population was significantly decreased by inhibition of Akt1, Akt2, and Bcl-
xL.  Of note, the most profound decrease in viability was observed in the 
ECFC+HPL matrices that contained the Akt1 inhibitor on day 1. N=3 each group. 
*P<0.05 or **P<0.001. Reprinted with permission from “Human platelet lysate 
improves human cord blood derived ECFC survival and vasculogenesis in three 
dimensional (3D) collagen matrices” by Kim et al., 2015, Microvascular Research, 
101:72-81. Figure 3.6. was from my original work (H. Kim, Prasain, et al., 2015). 
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Next, we examined whether the inhibitor treatments would alter the protein 
expression level of pro-survival/anti-apoptotic or pro-apoptotic molecules in 
ECFC in 3D collagen matrices on day 1. We tested only day 1 implants because 
cell survival of ECFC was close to zero by all inhibitor treatments on day 3. When 
treated with the Akt1 inhibitor, pBad (inactive form that blocks apoptosis) was 
barely detected in ECFC alone implants and significantly decreased in 
ECFC+HPL implants compared to DMSO control groups. The level of Bcl-xL 
(anti-apoptotic molecule) was not changed in both implantation of ECFC and 
ECFC+HPL matrices compared to DMSO control samples. When exposed to the 
Bcl-xL inhibitor, the level of pBad and Bcl-xL was significantly decreased in the 
both groups compared to DMSO controls. On the other hand, Akt2 inhibition 
caused a significant increase of expression level of Akt1/pAkt1, Bcl-xL (anti-
apoptotic molecule), and pBad (inactivated pro-apoptotic molecule) in both 
groups compared to DMSO groups (Figure 3.7.). Cleaved caspase-3 (pro-
apoptotic molecule) was increased with treatment of the three inhibitors in 
implants of ECFC alone compared to ECFC implants with DMSO (Figure 3.7. b). 
However, cleaved caspase-3 expression was not changed in ECFC+HPL 
implants with the three inhibitors compared to ECFC+HPL implants treated with 
DMSO samples (Figure 3.7. c). Thus, inhibition of Akt1 and Bcl-xL (pro-
survival/anti-apoptotic molecules) promotes apoptosis of ECFC by decreasing 
pBad (inactivated pro-apoptotic molecule) and Bcl-xL (pro-survival molecule), 
which are Akt downstream substrates, in both ECFC alone and ECFC+HPL 3D 
implants. In summary, only Akt1 inhibition significantly diminished cell survival of 
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ECFC by decreasing protein level of pBad in ECFC implants with HPL, even 
though cleaved caspase-3 expression was not concomitantly changed.  
 
In addition, we also determined that ECFC treated with the Akt1, Akt2, and Bcl-
xL inhibitors on day 1 and 3 displayed significantly diminished vascular structures 
on day 1 and absence of vascular structures on day 3 (date not shown). 
Collectively, these observations have demonstrated that inhibition of the Akt1 
signaling pathway significantly diminished cell survival and vasculogenesis of 
ECFC by altering expression level of pro-apoptotic and anti-apoptotic/pro-survival 
molecules. 
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Figure 3.7. Inhibition of pro-survival molecules affects protein expression 
of molecules involved in the apoptotic/cell survival signaling in 3D collagen 
matrices. (a) Representative immunoblots of inhibitor treatment of ECFC or 
ECFC with HPL in 3D collagen matrices (DMSO as vehicle control, Akt1 inhibitor, 
2 µm, Akt2 inhibitor 2 µm, and Bcl-xL inhibitor 20 nM). Lower panels show 
quantification of repeated experiments of the inhibitor treatment ECFC alone (b) 
and ECFC with HPL (c) in 3D collagen matrix on day 1 after implantation (protein 
expression levels were normalized using GAPDH). Y axis=Normalized optical 
density N=2 each group. *P<0.05, **P<0.001, or ***P<0.0001. Reprinted with 
permission from “Human platelet lysate improves human cord blood derived 
ECFC survival and vasculogenesis in three dimensional (3D) collagen matrices” 
by Kim et al., 2015, Microvascular Research, 101:72-81. Figure 3.7. was from my 
original work (H. Kim, Prasain, et al., 2015). 
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3.4. Discussion 
The microvascular network has dynamic structural plasticity. Vasculogenesis, 
angiogenesis, and microvascular remodeling are complex processes following 
endothelial cell growth, migration, and differentiation (Adams & Alitalo, 2007; 
Bader, Rayburn, Crowley, & Hynes, 1998; Carmeliet, 2000; Carmeliet et al., 1996; 
Coultas et al., 2005; Ferrara, 1999; Ferrara et al., 1996; Hanahan & Folkman, 
1996; Lamalice et al., 2007; Risau, 1995, 1997; Shalaby et al., 1997). Many of 
theses in vivo processes can be modeled and examined in vitro. Human CB 
ECFC or human umbilical vein endothelial cells (HUVEC) participate in cell-cell 
and/or cell-matrix interactions and form capillary network within the first 24hrs on 
2D Matrigel coated dishes. The capillary network formation shows tremendous 
structural plasticity and dynamic processes of not only new network formation but 
also network regression. By blocking cell-matrix interactions with colchicine or 
anti-human avb3 antibody, HUVEC failed to form a capillary network, and a 
significant increase of endothelial cell death was observed (Pollman et al., 1999). 
Thus, cell-matrix interactions are necessary for cell viability and the formation of 
a capillary network on Matrigel coated dishes (Pollman et al., 1999; Shih et al., 
2011). Bcl-2 over expression in HUVEC enhanced cell viability and promoted 
stabilization of the capillary network formed on Matrigel (Pollman et al., 1999). 
This study suggested that the formation of capillary networks is dependent on the 
balance between pro-apoptotic and pro-survival of endothelial cells on 2D 
Matrigel substrates. We suggest that the balance between pro-apoptotic and 
anti-apoptotic/pro-survival signals play a critical role in promoting cell survival of 
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ECFC and enhancing vasculogenesis when ECFC are co-implanted with HPL in 
in vitro and in vivo models (Figure 3.2., 3.3., and 3.4.).  
 
Previous studies have been reported that HPL contains various cytokines and 
growth factors that are involved in various cellular events, particularly cellular 
migration, proliferation, differentiation, extracellular matrix organization and 
remodeling, and cell survival (Aarabi et al., 2007; Fekete et al., 2012; Shih et al., 
2011; Singer & Clark, 1999). Growth factors in HPL, especially, VEGF and 
angiopoietin-1, stimulate Akt to promote cell survival and ensure adequate 
vascular development in cardiovascular functions (Carmeliet et al., 1999; Fujio & 
Walsh, 1999; Gerber et al., 1998; I. Kim et al., 2000; Kontos et al., 1998; 
Papapetropoulos et al., 2000). Akt also has been reported to stimulate the 
expression of anti-apoptotic Bcl-2 proteins, such as Bcl-xL through the activation 
of NF-κB (I. Kim et al., 2000; Zong et al., 1999). Constitutive activation of Akt 
signaling protects cardiomyocytes against apoptosis (Fujio et al., 2000). In 
addition, chronic activation of Akt/PI3K pathway in endothelial cells enhances cell 
survival of endothelial cells (ECs) and promotes more vasculogenesis of ECs in 
absence of growth factors and serum (Seandel et al., 2008). Since Akt1 is 
generally the predominant expressed isoform (Akt1, Akt2, and Akt3) and 
compensates Akt2 functions for the inhibition of Akt2 (Ak2 knockout) (W. S. Chen 
et al., 2001; Paradis & Ruvkun, 1998), such compensation may explain the why 
inhibition of Akt2 may not effectively alter expression of pro-survival/anti-
apoptotic survival signaling molecules in the ECFC in 3D matrices (Figure 3.6. 
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and 3.7.). Only Akt1 inhibition significantly decreased the downstream targets, 
pBad and significantly diminished cell survival of ECFC on both day 1 and day 3 
in our in vitro model. Thus, growth factors in HPL may enhance cell survival of 
ECFC by activating Akt1 and enhancing expression of pro-survival/anti-apoptotic 
molecules (pAkt1, pBad, and Bcl-xL) against the apoptotic signal (cleaved 
caspase-3) mediated by environmental stress in our experimental models.   
In summary, we have demonstrated that co-implantation of human cord blood 
ECFCs with HPL improves cell survival of ECFC and promotes robust formation 
of human ECFC-derived microvessels with increased average vessel number, 
total vessel area, and enlarged vessel sizes in vivo.  By activating Akt1 pro-
survival signaling in the ECFC, HPL modifies the balance of pro-apoptotic and 
anti-apoptotic/cell survival signaling in the implanted cells to enhance 
vasculogenesis. 
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CHAPTER 4. INHIBITION OF APOPTOSIS OF ECFC ENHANCES HUMAN 
CORD BLOOD DERIVED ECFC SURVIVAL AND VASCULOGENESIS IN 
THREE DIMENSIONAL (3D) MATRICES 
 
4.1 Introduction 
Endothelial progenitor cells (EPCs) play critical roles in the formation of new 
vessels or the recovery of damaged vascular endothelium through angiogenesis 
and vasculogenesis (Asahara et al., 1997; Rafii et al., 2002; Shi et al., 1998). 
Endothelial colony forming cells (ECFC) are derived from a rare circulating 
subset of EPCs that may arise from resident endothelium of established blood 
vessels in man (Hirschi et al., 2008). We have successfully isolated ECFC from 
human peripheral blood (PB) or umbilical cord blood (CB) and identified a 
hierarchy of proliferative potential in ECFC through the use of single cell 
clonogenic and functional assays (L. Huang et al., 2011; Ingram et al., 2004). 
Human CB derived ECFC also display de novo vessel forming ability in 
immunodeficient mice in vivo after subcutaneous implantation of ECFC in 
collagen-fibronectin matrices and upon inosculation with host murine vessels, 
become a part of the systemic host circulation (Au, Daheron, et al., 2008; Cheng 
et al., 2011; Critser et al., 2010; L. Huang et al., 2011; Melero-Martin et al., 2008; 
Melero-Martin et al., 2007; Reinisch et al., 2009; Whittington et al., 2013; Yoder 
et al., 2007).   
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In subcutaneous implants, human ECFC-derived vessels were detected as early 
as day 1 or 2 after implantation in non-obese diabetic/severe combined 
immunodeficient mice (NOD/SCID) but these nascent vessels were not properly 
perfused with the host circulatory system at these early time points (P. Allen et 
al., 2013). After 3-4 days of implantation in vivo, however, human ECFC-derived 
vessels display robust connection with the host circulatory system (P. Allen et al., 
2013). Previous studies have noted that up to 60% of human umbilical vein 
endothelial cells (HUVECs) undergo apoptosis in the first 24 hours following 
suspension in collagen matrices in vitro and there is further loss of vascular 
structures in 3D type I collagen matrices after 24 hours of culture (Ilan et al., 
1998). Moreover, in our previous study, we reported that > 80% of human CB 
ECFC suspended in collagen matrices underwent apoptosis on day 1 after 
implantation (H. Kim, Huang, et al., 2015). After 2-3 days of implantation, only 1-
3% of the total ECFC cells demonstrated viability in the subcutaneous implants 
(H. Kim, Huang, et al., 2015). Since the stability of newly formed vessels requires 
systemic blood flow, theses data suggest that implanted endothelial cells must 
survive at least 3-4 days in vivo to form and stabilize a capillary network that is 
connected to the host circulatory system.  
 
Vasculogenesis, angiogenesis, and microvascular remodeling during embryonic 
development and in adult are complex and dynamic processes requiring 
endothelial cell growth, migration, and differentiation (Adams & Alitalo, 2007; 
Bader et al., 1998; Carmeliet, 2000; Carmeliet et al., 1996; Coultas et al., 2005; 
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Ferrara, 1999; Ferrara et al., 1996; Hanahan & Folkman, 1996; Lamalice et al., 
2007; Risau, 1995, 1997; Shalaby et al., 1997). Human ECFC or HUVEC form a 
primary capillary network via cell-cell and/or cell-matrix interactions on 2D 
Matrigel coated dishes (Pollman et al., 1999). The formation of a capillary 
network is a highly dynamic process requiring both new network formation and 
concomitant network regression via apoptosis (Pollman et al., 1999). Thus, 
apoptosis of endothelial cells has been observed in the context of dynamic 
capillary network remodeling in vitro and in vivo and is thought to play a 
necessary role for optimal network formation (Brooks et al., 1994; Fukai et al., 
1998; Pollman et al., 1999; Stratman et al., 2010). On the other hand, Bcl-2 over 
expression in HUVEC enhanced cell viability and promoted stabilization of the 
capillary network on Matrigel coated dishes. Therefore, the generation of anti-
apoptotic signals is also required to maintain integrity of the vascular network 
following realignment of certain matrix proteins and cell-cell or cell-matrix 
interactions during the process (Pollman et al., 1999; Shih et al., 2011). Thus, 
understanding the balance between pro-apoptotic and pro-survival signals is a 
critical point in capillary structure formation and the remodeling process. 
 
Apoptosis is a highly conserved cellular process in tissue development and 
homeostasis that generally culminates with the sequential activation of caspases 
(Duprez et al., 2009; Sprick & Walczak, 2004; Taylor et al., 2008). There are two 
pathways; the extrinsic pathway (death receptor pathway) and intrinsic pathway 
(mitochondrial pathway) that result in apoptosis depending on the apoptotic 
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signal. The extrinsic pathway is initiated by ligand binding to the death receptor 
family on the cell membrane, whereas the intrinsic pathway is triggered by 
stress-mediated damage such as alterations in temperature, osmolality, DNA 
damaging agents, free radical generation compounds, removal of nutrients, and 
oxygen deprivation (Duprez et al., 2009; Sprick & Walczak, 2004; Taylor et al., 
2008; Wyllie, 2010). The activation of both pathways merges to generate the 
release of cytochrome c (Cyt-C) from the mitochondria and activation of the 
caspase cascade including executioner (effector) caspase-3 (Duprez et al., 2009; 
Sprick & Walczak, 2004; Taylor et al., 2008). Caspase-3 is activated to cleaved 
caspase-3 to generate all the biochemical and morphologic hallmarks of cell 
apoptosis (Duprez et al., 2009; Sprick & Walczak, 2004; Taylor et al., 2008). 
Caspases are a family of cytosolic aspartate-specific cysteine proteases involved 
in the initiation and execution of apoptosis (Duprez et al., 2009; Sprick & 
Walczak, 2004; Taylor et al., 2008). They are activated by an autoproteolytic 
mechanism or by cleavage by other proteases (frequently other caspases). We 
hypothesized that inhibition of caspases would increase ECFC survival and 
enhance ECFC vascularization in 3D collagen matrices.  
 
4.2. Materials And Methods 
Culture of human umbilical cord blood derived ECFC  
ECFC were isolated and cultured as previously described (Ingram et al., 2004). 
ECFC colonies appeared between 5 and 22 days of culture and were indicated to 
form colonies of adherent cells with cobblestone morphology. The ECFC-derived 
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ECs were released from the culture plate by TrypLE™ Express (Gibco) and 
replated onto 25 or 75 cm2 tissue culture flasks pre-coated with Type I rat-tail 
collagen (BD Biosciences) for subsequent passage after approximately 10-14 
days of culture.  
 
Two dimensional Matrigel assays in vitro 
Tissue culture 96-well plates were coated with 50 µl of growth factor reduced 
Matrigel (BD Biosciences Pharmingen) and incubated for 30 minutes at 37°C, 5% 
CO2. ECFC (1 x 104 cells) were resuspended in EGM-2 media with DMSO, Z-
YVAD-FMK (0.5 mM, caspase-1/4 inhibitor), or Z-DEVD-FMK (0.5 mM, capase-3 
inhibitor) and plated on Matrigel coated 96-well plates. The Z-YVAD-FMK and Z-
DEVD-FMK were purchased from R&D system. ECFC plated on Matrigel was 
incubated for 24 hours, 48 hours and 72 hours. Images of tube-like structures 
were captured at 10x magnification after 24 hours, 48 hours, and 72 hours using 
a Leica DM IRE2 microscope (Leica Microsystems) with attached Retiga 4000R 
digital camera (QImaging). 
 
Preparation of three dimensional (3D) collagen matrices assay 
All of the type I collagen oligomers and associated polymerization reagents were 
purchased from GeniPhys. Zionsville, IN (Bailey et al., 2011). Stock oligomer was 
diluted in 0.01N hydrochloric acid (HCl) and neutralized according to 
manufacturer’s recommendations to achieve a final oligomer concentration of 
1.37 mg/ml (200Pa matrix stiffness). ECFC (1 x 105 cells/60 µl or 1 x 106 
	   112 
cells/250 µl) were suspended in the collagen solution with/without human platelet 
lysate (HPL-10% of final concentration), with DMSO vehicle (same amount of 
each inhibitor), Z-YVAD-FMK (0.5 mM, caspase-1/4 inhibitor), or Z-DEVD-FMK 
(0.5 mM, capase-3 inhibitor) at 4°C. The HPL was purchased from 
Gemeinnützige Salzburger Landeskliniken Betriebsges (SALK) in Graz, Austria. 
The HPL was prepared from pooled platelet-rich plasma derived from a minimum 
of 40 whole blood donations (Schallmoser & Strunk, 2009). The collagen-cell 
suspensions were plated on 96-well or 48-well plates, allowed to polymerize at 
37°C for 30 minutes, and covered with complete endothelial cell growth medium 
(EGM-2, Lonza) with 10% defined fetal bovine serum (Hyclone) for incubation for 
one to three days in a tissue culture incubator at 37°C, 5% CO2. 
 
Toluidine blue staining of 3D collagen matrices and quantification of in 
vitro vascular structures  
For analysis of in vitro vascular structure formation in 3D collagen matrix, 
cellularized collagen matrices were fixed with 4% paraformaldehyde for 20 
minutes on Day 1 or Day 3 post-matrix formation. The matrices were stained with 
0.1% toluidine blue O dye (30% methanol) for 25 minutes at room temperature 
and washed with PBS for 30 minutes for three times at room temperature (as 
previously described (Critser et al., 2010)). Vascular structures (Vacuoles, 
Lumens, and tube formation) were quantified using ImageJ image analysis 
software (National Institutes of Health (NIH)). Vacuoles and lumens were defined 
as areas completely surrounded by a toluidine blue stained endothelial cell 
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membrane. A single image of the entire well was captured at a depth of 100 
microns from the surface of the matrix for each of triplicate samples of each 
group. Images of vascular structures were captured at 10x magnification using a 
Leica DM IRE2 microscope (Leica Microsystems) with attached Retiga 4000R 
digital camera (QImaging). 
 
Assessment of apoptosis of ECFC in 3D collagen matrices 
Apoptosis was assessed by examining the percentage of human CD31+ ECFC 
that bound Annexin V and propidium iodide and was performed as per the 
manufacturer’s instruction (Apoptosis Detection kit, eBioscience). ECFC (1 x 105 
cells/60 µl) were suspended in collagen matrices with/without HPL, with DMSO 
vehicle (same volume of each inhibitor), Z-YVAD-FMK, or Z-DEVD-FMK, plated 
in 96-well plates, and incubated for one to three days as above. As previously 
described (H. Kim, Huang, et al., 2015), matrices were recovered from one to 
three days after implantation and incubated in 250 µl Collagenase Type I (0.25%) 
(Stemcell technology) for 20 minutes at 37°C. Cell dissociation buffer was added 
to stop the enzymatic reaction (Invitrogen). Cells were centrifuged at 500 g for 5 
minutes at room temperature. Cell pellets were suspended in staining buffer and 
stained with anti-human CD31 antibody conjugated to phycoerythrin (PE) for 15 
minutes (clone WM-59, BD Biosciences Pharmingen). Cells were incubated and 
stained for Annexin V-allophycocyanin (APC) and propidium iodide (PI) in binding 
buffer for 10 minutes at room temperature in the dark. Stained cells were 
analyzed by FlowJo software. 
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Western blot 
Cellular protein lysates were extracted from the ECFC collagen matrix implants 
and electrophoresed using sodium dodecyl sulfate–polyacrylamide matrix 
electrophoresis (SDS-PAGE), transferred to nitrocellulose, and probed with 
monoclonal antibodies that included anti-human cleaved caspase-1 (clone 
D7F10, Cell signaling) and cleaved caspase-3 (clone 3G2, Cell signaling). Anti-
human GAPDH (clone 14C10, Cell signaling) antibody was used to probe for 
loading control proteins (as previously described (H. Kim, Huang, et al., 2015)).  
 
Histology and immunohistochemistry 
Sections were stained as previously described (Yoder et al., 2007). Briefly, 
paraffin-embedded tissue sections were deparaffinized and then either directly 
stained with hematoxylin and eosin (H&E) or immersed in retrieval solution (Dako) 
for 20 minutes at 90–99°C. Slides were incubated at room temperature for 30 
minutes with anti-human CD31 antibody (clone JC70/A, Abcam) followed by a 
10-minute incubation with LASB2 link-biotin and streptavidin-HRP (Vector 
Laboratories), then developed with DAB (Vector Laboratories) solution for 5 
minutes. Slides were analyzed by microscope under 20x magnification using a 
Leica DM 4000B microscope (Leica Microsystems, Bannockburn) with attached 
Spot-KE digital camera (Diagnostic Instruments, Sterling Heights).  
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Statistical analysis 
Results are expressed as mean ± the standard error of the mean (SEM) for the 
study variables. The assessment of apoptosis of ECFC, in vitro vascular 
structure quantification and the quantification of western blot data points (ECFC 
treated with DMSO, Z-YVAD-FMK, or Z-DEVD-FMK) were assessed by unpaired 
t-test. A statistically significant difference was set at *P<0.05, **P<0.001, or 
***P<0.0001. 
 
4.3. Results 
Caspase inhibitors reduce vasculogenesis of human CB derived ECFC on 
2D Matrigel in vitro. 
Consistent with prior reports, inhibition of programmed cell death significantly 
decreased vasculogenesis of endothelial cells (EC) via various types of caspase 
inhibitors (Rohban et al., 2013; Segura et al., 2002). We first examined whether 
the presence of Z-YVAD-FMK (0.5 mM, caspase-1/4 inhibitor) or Z-DEVD-FMK 
(0.5 mM, capase-3 inhibitor) alters ECFC vasculogenesis on 2D Matrigel coated 
dishes. The concentration (0.5 mM) of the caspase inhibitors was selected based 
upon two previous studies that reported these concentrations decreased 
vasculogenesis (Rohban et al., 2013; Segura et al., 2002). Both ECFC alone 
(Figure 4.1. a) and ECFC with the control solvent DMSO (Figure 4.1. D) formed 
tube-like structures on the Matrigel coating at 24 hours after cell deposition. The 
ECFC alone group formed and maintained the tube-like structures on the 
Matrigel coated dishes at 24, 48, and 72 hours of culture (Fig. 1A-C). Tube-like 
	   116 
structures of the ECFC with DMSO (vehicle control) group were slightly 
regressed through 48 and 72 hours of culture (Figure 4.1. D-F). However, the 
presence of caspase-1 inhibitor (0.5 mM) (Figure 4.1. G-I) and caspase-3 
inhibitor (0.5 mM) (Figure 4.1. J-L) blocked the formation, elongation, and 
branching of tube-like structures during vasculogenesis of ECFC on 2D Matrigel 
coated dishes. The caspase-3 inhibitor group displayed the most dramatic 
capillary tube-like regression and loss of the tube-like structures over time. These 
data confirm that effector caspase inhibition in ECFC significantly impairs 
vasculogenesis of ECFC on 2D Matrigel coated dishes in vitro as recently 
reported (Rohban et al., 2013; Segura et al., 2002).  
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Figure 4.1. Inhibition of caspases in ECFC diminishes vasculogenic activity 
of ECFC on 2D Matrigel in vitro. The Images show representative images of 
tube-like structure formation of untreated control ECFC (a-c), ECFC with DMSO 
(d-f), with caspase-1 inhibitor (g-i), and with caspase-3 inhibitor (j-l).  
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Inhibition of caspase promotes vasculogenesis of human CB derived ECFC 
in 3D collagen matrices in vitro.  
We next investigated whether co-implantation of ECFC with caspase inhibitors 
(same concentration as above with 2D Matrigel coated dishes) would also impair 
vasculogenic activity of ECFC in 3D collagen matrices. ECFC-derived vascular 
structures were defined as endothelial cells with vacuoles and lumenized 
structures were defined as areas completely surrounded by a toluidine blue 
stained endothelial cell membrane (Figure 4.2. a and b). A significantly greater 
average number of vascular structures per surface area of the matrix (Figure 4.2. 
c) and total luminal area of vascular structures per surface area of the matrix 
(mm2) (Figure 4.2. d) were quantified in ECFC incubated with caspase-1 inhibitor 
and caspase-3 inhibitor compared to the control groups on day 1 and 3 of the in 
vitro study. Moreover, Caspase-3 inhibition displayed the greatest average 
number of vascular structures per surface area of the matrix and total luminal 
area of vascular structures per surface area of the matrix (mm2) among the 
experimental groups on day 3 of culture.   
 
We subsequently tested whether caspase inhibitors alter the protein expression 
level of cleaved caspase-1 or cleaved caspase-3 in ECFC in 3D collagen 
matrices in vitro. Cleaved caspases are the active forms that promote apoptosis. 
In the presence of caspase-3 inhibitor, cleaved caspase-3 was appropriately 
diminished in collagen gels containing ECFC alone and ECFC with added human 
platelet lysate (HPL) compared to the DMSO control group gels (Figure 4.2. e 
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and f). Inhibition of caspase-1 decreased cleaved caspase-1 in ECFC alone and 
ECFC with HPL group gels compared to DMSO containing gels (Figure 4.2. e 
and f). Thus, these data demonstrate that ECFC incubated with two selective 
caspase inhibitors significantly promotes vasculogenesis in 3D collagen matrices 
by blocking caspase-1 and -3 activity in vitro.  
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Figure 4.2. ECFC with caspase inhibitors induces the formation of vascular 
structures in 3D collagen matrices in vitro. (a) Representative images of 
vascular structures of ECFC with or without HPL and with DMSO, caspase-1 
inhibitor, or caspase-3 inhibitor in collagen matrices on day 1 and 3 (white arrows 
indicate the structures and small boxes indicates representative counted 
structures). Scale bar represents 0.05 µm. ECFC with caspase-1 inhibitor or 
caspase-3 inhibitor was resulted in a significant increase in (c) the average 
number of vascular structures per collagen matrix surface area and (d) total 
luminal area of vascular structures per matrix surface area (mm2) compared to 
controls. N=10 each group. *P<0.05, **P<0.001, or ***P<0.0001. Top panel (e) 
displays representative immunoblots of cleaved caspase-1 and cleaved caspase-
3 proteins from ECFC with DMSO, caspase-1 inhibitor, or caspase-3 inhibitor in 
3D matrices. Bottom panel (f) shows quantification of repeated experiments on 
day 1 and day 3 after incubation (protein expression levels were normalized 
using GAPDH). N=2 each group. *P<0.05 or **P<0.001. 
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Human CB derived ECFC incubated with caspase inhibitors significantly 
enhanced cell survival of ECFC in 3D collagen matrices.  
Our previous study demonstrated that activation of the Notch pathway by OP9-
Delta like ligand 1 (DL1) stromal cells or co-implantation of ECFC with HPL 
enhances vasculogenesis and augments blood vessel formation by diminishing 
apoptosis of the implanted ECFC (H. Kim, Huang, et al., 2015). We subsequently 
tested whether the presence of caspase inhibitors diminishes apoptosis of ECFC 
in 3D collagen matrices. After 1-3 days, ECFCs were recovered from 3D collagen 
matrices and assessed for apoptosis of ECFC stained with anti-human CD31, 
Annexin V and propidium iodide (PI).  The CD31+ ECFC population was selected 
from the total cell population and separated into Annexin V+/- and PI+/- expressing 
subsets. The concentration of caspase-1 inhibitor and caspase-3 inhibitor in the 
3D collagen matrices were titrated based on the percentage of viable cells 
(Annexin V-/PI-) (Figure 4.3.). ECFC incubated with DMSO started undergoing 
apoptosis on day 1 and a significant population of the cells died by day 3 in the 
collagen matrices in vitro (Figure 4.4.). In contrast, ECFC with added caspase-1 
inhibitor or caspase-3 inhibitor revealed a significantly higher percentage of 
viable cells (Annexin V-/PI-) at the highest concentration of inhibitor (0.5 mM) 
compared to the control group. The addition of the caspase-3 inhibitor (0.5 mM) 
displayed the greatest percentage of viable cells compared to ECFC with added 
DMSO or caspase-1 inhibitor (0.5 mM). These data suggest significantly 
enhanced cell survival of ECFC in 3D collagen matrices in vitro in the presence 
of caspase-1 or -3 inhibitor.   
	   124 
 
	   125 
 
 
c. 
	   126 
  
d. 
	   127 
Figure 4.3. The effect of caspase inhibitors on ECFC in 3D collagen 
matrices in vitro. Percentage of the Annexin V-/PI- viable population indicates 
the dose-dependent inhibition of apoptosis in ECFC treated with DMSO,  (a) 
caspase-1 inhibitor, or (b) caspase-3 inhibitor. (c and d) Representative dot plots 
of apoptosis analysis of ECFC with DMSO, caspase-1 inhibitor, or caspase-3 
inhibitor on day 1 and 3 (only two concentrations of each inhibitor).  
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Figure 4.4. Incubation of ECFC with caspase inhibitors diminishes 
apoptosis of ECFC in 3D collagen matrices in vitro. The Annexin V-/PI- viable 
population of ECFC with (a) caspase-3 inhibitor and (b) caspase-1 inhibitor was 
significantly higher on day 1 and 3 compared to ECFC with DMSO in culture. 
N=3. *P<0.05. 
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4.4 Discussion 
The balance between apoptosis and cell survival is an important variable during 
vasculogenesis, angiogenesis, and microvascular remodeling during embryonic 
development and in adult organisms (Jacobson, Weil, & Raff, 1997). Earlier 
reports showed that activation of apoptosis pathways by blocking cell-cell and/or 
cell-matrix interactions blocks vessel formation (Brooks et al., 1994; Fukai et al., 
1998; Pollman et al., 1999; Stratman et al., 2010). Our previous studies also 
have demonstrated that activation of the Notch pathway by OP9-DL1 stromal 
cells or co-implantation of ECFC with HPL enhances vasculogenesis and 
augments blood vessel formation by diminishing apoptosis of the implanted 
ECFC. In contrast, some studies have been reported that caspase inhibition 
reduces adhesion and migration of endothelial cells (EC) and significantly 
decreases the vasculogenic activities of EC in a 2D Matrigel model (Rohban et 
al., 2013; Segura et al., 2002). Thus, the roles of apoptosis in vasculogenesis of 
EC are controversial and have not been well studied. The aim of this study was 
to examine whether inhibition of the apoptosis pathway via caspase inhibitors 
alters the early phase of vasculogenesis of ECFC when plated on 2D Matrigel or 
in 3D collagen matrices. When ECFC are plated on the 2D Matrigel, inhibition of 
activation of caspase-1 and caspase-3 significantly reduced vasculogenic 
activities of EC (Figure 4.1.), whereas ECFC with caspase-1 or caspase-3 
inhibitors significantly increased vasculogenesis in 3D collagen matrices (Figure 
4.2.).  
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In this report, we have provided evidence that 2D Matrigel and 3D collagen 
matrix environments revealed totally opposite results in ECFC survival and 
vasculogenic ability in vitro. At present we cannot determine whether the 
differences in ECFC survival and function were due to caspase inhibition in the 
context of the 2D or 3D environment or in response to the Matrigel or collagen 
matrix. For proper comparisons of each matrix model, in future studies we will 
examine cell survival and vasculogenesis of ECFC with caspase-1 and caspase-
3 inhibitor in Matrigel and collagen matrices in both 2D and 3D formats. 
 
We have previously published that non-human primate peripheral blood ECFC 
display vessel forming ability from newborn animals throughout adulthood in vitro 
and in vivo upon implantation in immunodeficient mice. Interestingly ECFC from 
those oldest animals failed to form non-human primate-derived ECFC-lined 
vessels when implanted in vivo, whereas the same ECFC formed capillary 
structures when plated in vitro on Matrigel coated dishes (Shelley et al., 2012). 
Thus, the responses of the ECFC derived from the oldest monkeys displayed 
differences in capillary tube formation depending on whether they were plated in 
a 2D Matrigel or a 3D collagen environment. Therefore, we cannot simply 
assume that in vivo vasculogenesis of ECFC will be promoted by inhibition of 
caspase-3, even though ECFC with caspase-3 inhibitor enhanced 
vasculogenesis in 3D collagen matrices in vitro. Thus, in future studies we will 
examine in vivo vessel forming ability of ECFC with caspase-3 inhibitor upon 
implantation in NOD/SCID mice.  
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CHAPTER 5. SUMMARY 
In the adult organism, endothelial progenitor cells (EPCs) have been reported to 
contribute to neovascularization in the recovery of damaged vascular 
endothelium through the processes of angiogenesis and vasculogenesis 
(Asahara et al., 1997; Rafii et al., 2002; Shi et al., 1998). Reports over 5 decades 
have reported that some circulating mammalian ECs attach and proliferate to 
form colonies of endothelium that coat intravascular suspended biomaterials 
(Stump et al., 1963) while the majority of circulating human ECs are senescent 
sloughed cells undergoing anoikis (Woywodt et al., 2006). In 1997, Asahara 
reported that circulating endothelial progenitors could be isolated from human 
adult peripheral blood and participate in revascularization in vivo in response to 
acute tissue ischemia (Asahara et al., 1997). EPCs have been subsequently 
reported to contribute to new vessel formation in adult subjects (Asahara et al., 
1997; Shi et al., 1998). For example, blood vessel damage leads to an increase 
in the number of circulating EPCs in patients with peripheral artery disease (PAD) 
(Hill et al., 2003; Rafii & Lyden, 2003; Urbich & Dimmeler, 2004).  
 
Only certain subsets of circulating EPCs are recruited into areas of vascular 
injury to promote vascular repair (Urbich & Dimmeler, 2004; Werner et al., 2005). 
In immunodeficient mouse vascular injury models, human endothelial colony 
forming cells (ECFCs) integrate into injured vessels to relieve tissue ischemia 
(Schwarz et al., 2012) and have been reported to improve blood flow in various 
diseases, such as ischemic retinopathy, limb ischemia, myocardial infarction, and 
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stroke (X. T. Huang et al., 2013; Kang et al., 2013; Medina et al., 2010; Moubarik 
et al., 2011; Schwarz et al., 2012; Stroncek et al., 2012). Thus, ECFC may serve 
as a novel cell therapy for these disorders in human subjects.  
 
We have isolated endothelial colony forming cells (ECFCs) from human 
peripheral blood and cord blood (Au, Daheron, et al., 2008; Ingram et al., 2004; 
Melero-Martin et al., 2007). ECFCs express cell surface proteins (KDR, CD34, 
vWF, eNOS, VE-cadherin, and others) similar to those on primary ECs (Ingram 
et al., 2004; Yoder et al., 2007). ECFCs have a high proliferative potential and 
are able to form human blood vessel de novo in vivo when implanted in 
immnunodeficient mice (Yoder et al., 2007). However, there is still a great need 
for further refinement of methods and identifying the molecular mechanisms that 
regulate and facilitate vascularization of ECFC in in vitro and in vivo matrices.  
 
Human ECFC-derived vessels form after implantation in NOD/SCID mice, but 
inosculation to the host circulatory system does not occur until after 3-4 days of 
implantation (P. Allen et al., 2013). It has been known that up to 60% of human 
umbilical vein endothelial cells (HUVECs) undergo apoptosis in the first 24 hours 
after suspension in collagen gels (Ilan et al., 1998). We have also reported that 
most human CB ECFC suspended in 3D collagen matrices displayed apoptosis 
on day 1 post-implantation (H. Kim, Huang, et al., 2015). After 2-3 days of 
incubation, the majority of ECFC died. Only 1-3% of the total implanted cells 
were alive in the subcutaneous implants (H. Kim, Huang, et al., 2015). Since 
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systemic blood flow is required to stabilize newly formed vessels, these data 
suggest that implanted endothelial cells must survive at least 3-4 days in vivo to 
form a stable perfused capillary network that can be perfused by the host 
circulatory system.  
 
Notch1 activation has been involved in inhibiting cell death in a cell type specific 
manner (Beverly et al., 2005; Jehn et al., 1999; MacKenzie et al., 2004; Sade et 
al., 2004). Notch 1 and a downstream mediator, Hes1, in human iliac artery 
endothelial cells (HIAECs) caused growth suppression but improved cell survival 
of the cultured cells. Also, activated Notch1 in HIAECs formed a more stabilized 
network and cord formation on Matrigel substrate in the presence of VEGF (Z. J. 
Liu et al., 2003). Delta like ligand 1 (Dll1)-dependent Notch signaling mediated by 
EphrinB2 has been reported to induce branching morphogenesis and network 
formation by human arterial endothelial cells (HAECs) plated on Matrigel 
(Limbourg et al., 2007). These reports have indicated that Notch1 signaling plays 
a role in regulating endothelial cell survival and network and cord formation in 
vitro. Since Notch signaling is a critical for embryonic blood vessel formation, we 
hypothesized that activation of Notch signaling in ECFC would enhance cultured 
ECFC vasculogenic abilities in vitro and in vivo. We report that preconditioning of 
ECFC with Notch activation is not sufficient to promote in vivo vasculogenesis, 
whereas co-implantation of ECFC with Notch ligand Delta-like 1 (DL1) 
expressing OP9 stromal cells (OP9-DL1) significantly increased vasculogenesis 
of ECFC by diminishing ECFC apoptosis in vivo.  
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Human platelet lysate (HPL) contains various cytokines and growth factors that 
are involved in the balance between apoptosis and cell survival in numerous cells 
involved in the repair of injured tissues (Freishtat et al., 2009; Gambim et al., 
2007; Mause et al., 2010; Pakala et al., 1994; Sharron et al., 2012; Stellos & 
Gawaz, 2007). VEGF and angiopoietin-1 in HPL promote protein kinase B (Akt) 
activation that enhances cell survival and contributes to vascular development 
(Carmeliet et al., 1999; Fujio & Walsh, 1999; Gerber et al., 1998; I. Kim et al., 
2000; Kontos et al., 1998; Papapetropoulos et al., 2000). Constitutive activation 
of the Akt/phosphoinositol-3-kinase (PI3K) pathway in endothelial cells stimulates 
cell survival of EC and promotes more vasculogenesis of ECs in serum free 
conditions (Seandel et al., 2008). Since platelets have a critical role in regulation 
of cell death and survival and contain granules filled with various growth factors 
and cytokines (Fekete et al., 2012; Shih et al., 2011), we hypothesized that HPL 
would diminish apoptosis of ECFC and promote ECFC vascularization by 
modulating the balance between apoptosis and cell survival of ECFC in 3D 
collagen matrices. We report that ECFC mixed with HPL in collagen matrices 
decreased apoptosis of ECFC by altering the expression of pro-survival 
molecules (pAkt1, pBad, and Bcl-xL) in vitro and stimulated vasculogenesis of 
human EC-derived vessels both in vitro and in vivo. 
 
Apoptosis is a highly conserved cellular process in tissue development and 
homeostasis that generally culminates with the sequential activation of effector 
caspases (Duprez et al., 2009; Sprick & Walczak, 2004; Taylor et al., 2008). 
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There are two pathways; the extrinsic pathway (death receptor pathway) and 
intrinsic pathway (mitochondrial pathway) that result in apoptosis depending on 
the apoptotic signal. The activation of both pathways leads to release of 
cytochrome c (Cyt-C) from mitochondria and activation of the executioner 
caspase-3 (Duprez et al., 2009; Sprick & Walczak, 2004; Taylor et al., 2008). 
Caspase-3 is activated to cleaved caspase-3 that generates all the biochemical 
and morphologic hallmarks of cell apoptosis (Duprez et al., 2009; Sprick & 
Walczak, 2004; Taylor et al., 2008). However, numerous reports have highlighted 
that capillary tube formation by EC plated on Matrigel in vitro is dependent on 
some level of caspase activation and apoptosis induction (Rohban et al., 2013; 
Segura et al., 2002). We hypothesized that inhibition of apoptosis via caspase 
inhibitors would increase ECFC survival and enhance ECFC vascularization in 
3D collagen matrices in vitro. We report that inhibition of caspase-1 and -3 in 
ECFC significantly enhanced cell survival of ECFC and dramatically increased 
vascular formation of ECFC by decreasing cleaved caspase-1 and cleaved 
caspase-3 in 3D collagen matrices in vitro.  
 
We hypothesized that in vivo vasculogenesis of ECFC would be enhanced by 
inhibition of caspase-3, since ECFC with caspase-3 inhibitor promoted the most 
vasculogenesis in 3D collagen matrices in vitro. We examined in vivo vessel 
forming ability of ECFC with caspase-3 inhibitor upon implantation in NOD/SCID 
mice. The inhibitor was injected into an implanted osmotic pump for constant 
delivery for 3 days post-implantation. The first set of mice receiving implants 
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showed increased vessel forming ability of ECFC in implants that included 
caspase-3 inhibitor compared to ECFC implants with DMSO control. However, in 
the second experiment, no difference in vessel forming ability of ECFC was 
observed in the two study groups. Kinetics of caspase-3 inhibitor release from 
the osmotic pump has not been well studied following implantation in mice. 
Further studies will be required to define kinetics of release of the caspase-3 
inhibitor in vivo before repeating the ECFC implants studies.  
 
In future studies, we can also examine combinational treatment of caspase-3 
inhibitor with other drugs. For example, since ECFCs are in a hypoxic 
microenvironment following implantation, pre-conditioning of ECFC with hypoxia-
inducible factor (HIF) inducers might lead to hypoxia tolerance to enhance cell 
survival of ECFC in vivo. 
 
  
  
	   137 
REFERENCES 
Aarabi, S., Longaker, M. T., & Gurtner, G. C. (2007). Hypertrophic scar formation 
following burns and trauma: new approaches to treatment. PLoS Med, 
4(9), e234. doi: 10.1371/journal.pmed.0040234 
Ables, J. L., Breunig, J. J., Eisch, A. J., & Rakic, P. (2011). Not(ch) just 
development: Notch signalling in the adult brain. Nat Rev Neurosci, 12(5), 
269-283. doi: nrn3024 [pii]10.1038/nrn3024 
Achen, M. G., Jeltsch, M., Kukk, E., Makinen, T., Vitali, A., Wilks, A. F., . . . 
Stacker, S. A. (1998). Vascular endothelial growth factor D (VEGF-D) is a 
ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 
3 (Flt4). Proc Natl Acad Sci U S A, 95(2), 548-553.  
Adams, R. H., & Alitalo, K. (2007). Molecular regulation of angiogenesis and 
lymphangiogenesis. Nat Rev Mol Cell Biol, 8(6), 464-478. doi: nrm2183 
[pii]10.1038/nrm2183 
Allen, P., Kang, K.-T., & Bischoff, J. (2013). Rapid onset of perfused blood 
vessels after implantation of ECFCs and MPCs in collagen, PuraMatrix 
and fibrin provisional matrices. Journal of Tissue Engineering and 
Regenerative Medicine, n/a-n/a. doi: 10.1002/term.1803 
Allen, P., Kang, K. T., & Bischoff, J. (2013). Rapid onset of perfused blood 
vessels after implantation of ECFCs and MPCs in collagen, PuraMatrix 
and fibrin provisional matrices. J Tissue Eng Regen Med. doi: 
10.1002/term.1803 
Allen, P., Melero-Martin, J., & Bischoff, J. (2011). Type I collagen, fibrin and 
PuraMatrix matrices provide permissive environments for human 
endothelial and mesenchymal progenitor cells to form neovascular 
networks. J Tissue Eng Regen Med, 5(4), e74-86. doi: 10.1002/term.389 
Alva, J. A., & Iruela-Arispe, M. L. (2004). Notch signaling in vascular 
morphogenesis. Curr Opin Hematol, 11(4), 278-283.  
Amaya, E., Musci, T. J., & Kirschner, M. W. (1991). Expression of a dominant 
negative mutant of the FGF receptor disrupts mesoderm formation in 
Xenopus embryos. Cell, 66(2), 257-270.  
Aplin, A. C., Fogel, E., Zorzi, P., & Nicosia, R. F. (2008). The aortic ring model of 
angiogenesis. Methods Enzymol, 443, 119-136. doi: 10.1016/S0076-
6879(08)02007-7 
Aranguren, X. L., Luttun, A., Clavel, C., Moreno, C., Abizanda, G., Barajas, M. A., 
. . . Prosper, F. (2007). In vitro and in vivo arterial differentiation of human 
multipotent adult progenitor cells. Blood, 109(6), 2634-2642. doi: blood-
2006-06-030411 [pii]10.1182/blood-2006-06-030411 
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., . . . 
Isner, J. M. (1997). Isolation of putative progenitor endothelial cells for 
angiogenesis. Science, 275(5302), 964-967.  
Au, P., Daheron, L. M., Duda, D. G., Cohen, K. S., Tyrrell, J. A., Lanning, R. M., . 
. . Jain, R. K. (2008). Differential in vivo potential of endothelial progenitor 
cells from human umbilical cord blood and adult peripheral blood to form 
	   138 
functional long-lasting vessels. Blood, 111(3), 1302-1305. doi: blood-2007-
06-094318 [pii]10.1182/blood-2007-06-094318 
Au, P., Tam, J., Fukumura, D., & Jain, R. K. (2008). Bone marrow-derived 
mesenchymal stem cells facilitate engineering of long-lasting functional 
vasculature. Blood, 111(9), 4551-4558. doi: blood-2007-10-118273 [pii] 
10.1182/blood-2007-10-118273 
Auguste, P., Gursel, D. B., Lemiere, S., Reimers, D., Cuevas, P., Carceller, F., . . 
. Bikfalvi, A. (2001). Inhibition of fibroblast growth factor/fibroblast growth 
factor receptor activity in glioma cells impedes tumor growth by both 
angiogenesis-dependent and -independent mechanisms. Cancer Res, 
61(4), 1717-1726.  
Bader, B. L., Rayburn, H., Crowley, D., & Hynes, R. O. (1998). Extensive 
vasculogenesis, angiogenesis, and organogenesis precede lethality in 
mice lacking all alpha v integrins. Cell, 95(4), 507-519.  
Bailey, J. L., Critser, P. J., Whittington, C., Kuske, J. L., Yoder, M. C., & Voytik-
Harbin, S. L. (2011). Collagen oligomers modulate physical and biological 
properties of three-dimensional self-assembled matrices. Biopolymers, 
95(2), 77-93. doi: 10.1002/bip.21537 
Barry, O. P., Pratico, D., Savani, R. C., & FitzGerald, G. A. (1998). Modulation of 
monocyte-endothelial cell interactions by platelet microparticles. J Clin 
Invest, 102(1), 136-144. doi: 10.1172/JCI2592 
Bayless, K. J., & Davis, G. E. (2002). The Cdc42 and Rac1 GTPases are 
required for capillary lumen formation in three-dimensional extracellular 
matrices. J Cell Sci, 115(Pt 6), 1123-1136.  
Bayless, K. J., & Davis, G. E. (2003). Sphingosine-1-phosphate markedly 
induces matrix metalloproteinase and integrin-dependent human 
endothelial cell invasion and lumen formation in three-dimensional 
collagen and fibrin matrices. Biochem Biophys Res Commun, 312(4), 903-
913.  
Bayless, K. J., Salazar, R., & Davis, G. E. (2000). RGD-dependent vacuolation 
and lumen formation observed during endothelial cell morphogenesis in 
three-dimensional fibrin matrices involves the alpha(v)beta(3) and 
alpha(5)beta(1) integrins. Am J Pathol, 156(5), 1673-1683.  
Beckers, J., Clark, A., Wunsch, K., Hrabe De Angelis, M., & Gossler, A. (1999). 
Expression of the mouse Delta1 gene during organogenesis and fetal 
development. Mech Dev, 84(1-2), 165-168.  
Bendinelli, P., Matteucci, E., Dogliotti, G., Corsi, M. M., Banfi, G., Maroni, P., & 
Desiderio, M. A. (2010). Molecular basis of anti-inflammatory action of 
platelet-rich plasma on human chondrocytes: mechanisms of NF-kappaB 
inhibition via HGF. J Cell Physiol, 225(3), 757-766. doi: 10.1002/jcp.22274 
Benedito, R., Roca, C., Sorensen, I., Adams, S., Gossler, A., Fruttiger, M., & 
Adams, R. H. (2009). The notch ligands Dll4 and Jagged1 have opposing 
effects on angiogenesis. Cell, 137(6), 1124-1135. doi: 
10.1016/j.cell.2009.03.025 
Benedito, R., Trindade, A., Hirashima, M., Henrique, D., da Costa, L. L., Rossant, 
J., . . . Duarte, A. (2008). Loss of Notch signalling induced by Dll4 causes 
	   139 
arterial calibre reduction by increasing endothelial cell response to 
angiogenic stimuli. BMC Dev Biol, 8, 117. doi: 1471-213X-8-117 [pii] 
10.1186/1471-213X-8-117 
Beverly, L. J., Felsher, D. W., & Capobianco, A. J. (2005). Suppression of p53 by 
Notch in lymphomagenesis: implications for initiation and regression. 
Cancer Res, 65(16), 7159-7168. doi: 10.1158/0008-5472.CAN-05-1664 
Boyer-Di Ponio, J., El-Ayoubi, F., Glacial, F., Ganeshamoorthy, K., Driancourt, 
C., Godet, M., . . . Uzan, G. (2014). Instruction of circulating endothelial 
progenitors in vitro towards specialized blood-brain barrier and arterial 
phenotypes. PLoS One, 9(1), e84179. doi: 10.1371/journal.pone.0084179 
Breier, G., Albrecht, U., Sterrer, S., & Risau, W. (1992). Expression of vascular 
endothelial growth factor during embryonic angiogenesis and endothelial 
cell differentiation. Development, 114(2), 521-532.  
Breier, G., & Risau, W. (1996). The role of vascular endothelial growth factor in 
blood vessel formation. Trends Cell Biol, 6(12), 454-456.  
Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, 
G., & Cheresh, D. A. (1994). Integrin alpha v beta 3 antagonists promote 
tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 
79(7), 1157-1164.  
Carmeliet, P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nat Med, 
6(4), 389-395. doi: 10.1038/74651 
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, 
M., . . . Nagy, A. (1996). Abnormal blood vessel development and lethality 
in embryos lacking a single VEGF allele. Nature, 380(6573), 435-439. doi: 
10.1038/380435a0 
Carmeliet, P., Lampugnani, M. G., Moons, L., Breviario, F., Compernolle, V., 
Bono, F., . . . Dejana, E. (1999). Targeted deficiency or cytosolic 
truncation of the VE-cadherin gene in mice impairs VEGF-mediated 
endothelial survival and angiogenesis. Cell, 98(2), 147-157.  
Chen, W. S., Xu, P. Z., Gottlob, K., Chen, M. L., Sokol, K., Shiyanova, T., . . . 
Hay, N. (2001). Growth retardation and increased apoptosis in mice with 
homozygous disruption of the Akt1 gene. Genes Dev, 15(17), 2203-2208. 
doi: 10.1101/gad.913901 
Chen, Y., Jacamo, R., Shi, Y. X., Wang, R. Y., Battula, V. L., Konoplev, S., . . . 
Andreeff, M. (2012). Human extramedullary bone marrow in mice: a novel 
in vivo model of genetically controlled hematopoietic microenvironment. 
Blood, 119(21), 4971-4980. doi: 10.1182/blood-2011-11-389957 
Cheng, G., Liao, S., Kit Wong, H., Lacorre, D. A., di Tomaso, E., Au, P., . . . 
Munn, L. L. (2011). Engineered blood vessel networks connect to host 
vasculature via wrapping-and-tapping anastomosis. Blood, 118(17), 4740-
4749. doi: 10.1182/blood-2011-02-338426 
Copeland, J. N., Feng, Y., Neradugomma, N. K., Fields, P. E., & Vivian, J. L. 
(2011). Notch signaling regulates remodeling and vessel diameter in the 
extraembryonic yolk sac. BMC Dev Biol, 11, 12. doi: 1471-213X-11-12 [pii] 
10.1186/1471-213X-11-12 
	   140 
Cornell, R. A., & Kimelman, D. (1994a). Activin-mediated mesoderm induction 
requires FGF. Development, 120(2), 453-462.  
Cornell, R. A., & Kimelman, D. (1994b). Combinatorial signaling in development. 
Bioessays, 16(8), 577-581. doi: 10.1002/bies.950160811 
Coultas, L., Chawengsaksophak, K., & Rossant, J. (2005). Endothelial cells and 
VEGF in vascular development. Nature, 438(7070), 937-945. doi: 
10.1038/nature04479 
Critser, P. J., Kreger, S. T., Voytik-Harbin, S. L., & Yoder, M. C. Collagen matrix 
physical properties modulate endothelial colony forming cell-derived 
vessels in vivo. Microvasc Res, 80(1), 23-30. doi: S0026-2862(10)00046-4 
[pii]10.1016/j.mvr.2010.03.001 
Critser, P. J., Kreger, S. T., Voytik-Harbin, S. L., & Yoder, M. C. (2010). Collagen 
matrix physical properties modulate endothelial colony forming cell-
derived vessels in vivo. Microvasc Res, 80(1), 23-30. doi: 
10.1016/j.mvr.2010.03.001 
Crowley, S. T., Dempsey, E. C., Horwitz, K. B., & Horwitz, L. D. (1994). Platelet-
induced vascular smooth muscle cell proliferation is modulated by the 
growth amplification factors serotonin and adenosine diphosphate. 
Circulation, 90(4), 1908-1918.  
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. 
E. (1997). Akt phosphorylation of BAD couples survival signals to the cell-
intrinsic death machinery. Cell, 91(2), 231-241.  
Davis, G. E., Bayless, K. J., & Mavila, A. (2002). Molecular basis of endothelial 
cell morphogenesis in three-dimensional extracellular matrices. Anat Rec, 
268(3), 252-275. doi: 10.1002/ar.10159 
Davis, G. E., & Camarillo, C. W. (1996). An alpha 2 beta 1 integrin-dependent 
pinocytic mechanism involving intracellular vacuole formation and 
coalescence regulates capillary lumen and tube formation in three-
dimensional collagen matrix. Exp Cell Res, 224(1), 39-51. doi: 
10.1006/excr.1996.0109 
Davis, G. E., Koh, W., & Stratman, A. N. (2007). Mechanisms controlling human 
endothelial lumen formation and tube assembly in three-dimensional 
extracellular matrices. Birth Defects Res C Embryo Today, 81(4), 270-285. 
doi: 10.1002/bdrc.20107 
Davis, G. E., & Senger, D. R. (2005). Endothelial extracellular matrix: 
biosynthesis, remodeling, and functions during vascular morphogenesis 
and neovessel stabilization. Circ Res, 97(11), 1093-1107. doi: 
10.1161/01.RES.0000191547.64391.e3 
de Boer, H. C., Verseyden, C., Ulfman, L. H., Zwaginga, J. J., Bot, I., Biessen, E. 
A., . . . van Zonneveld, A. J. (2006). Fibrin and activated platelets 
cooperatively guide stem cells to a vascular injury and promote 
differentiation towards an endothelial cell phenotype. Arterioscler Thromb 
Vasc Biol, 26(7), 1653-1659. doi: 10.1161/01.ATV.0000222982.55731.f1 
De Moerlooze, L., Spencer-Dene, B., Revest, J. M., Hajihosseini, M., Rosewell, 
I., & Dickson, C. (2000). An important role for the IIIb isoform of fibroblast 
	   141 
growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling 
during mouse organogenesis. Development, 127(3), 483-492.  
de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., & Williams, L. T. 
(1992). The fms-like tyrosine kinase, a receptor for vascular endothelial 
growth factor. Science, 255(5047), 989-991.  
Delaney, C., Varnum-Finney, B., Aoyama, K., Brashem-Stein, C., & Bernstein, I. 
D. (2005). Dose-dependent effects of the Notch ligand Delta1 on ex vivo 
differentiation and in vivo marrow repopulating ability of cord blood cells. 
Blood, 106(8), 2693-2699. doi: 2005-03-1131 [pii]10.1182/blood-2005-03-
1131 
Deng, C. X., Wynshaw-Boris, A., Shen, M. M., Daugherty, C., Ornitz, D. M., & 
Leder, P. (1994). Murine FGFR-1 is required for early postimplantation 
growth and axial organization. Genes Dev, 8(24), 3045-3057.  
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. 
(1999). Activation of nitric oxide synthase in endothelial cells by Akt-
dependent phosphorylation. Nature, 399(6736), 601-605. doi: 
10.1038/21224 
Djonov, V., & Makanya, A. N. (2005). New insights into intussusceptive 
angiogenesis. EXS(94), 17-33.  
Duarte, A., Hirashima, M., Benedito, R., Trindade, A., Diniz, P., Bekman, E., . . . 
Rossant, J. (2004). Dosage-sensitive requirement for mouse Dll4 in artery 
development. Genes Dev, 18(20), 2474-2478. doi: 10.1101/gad.1239004 
Dummler, B., Tschopp, O., Hynx, D., Yang, Z. Z., Dirnhofer, S., & Hemmings, B. 
A. (2006). Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are 
viable but display impaired glucose homeostasis and growth deficiencies. 
Mol Cell Biol, 26(21), 8042-8051. doi: 10.1128/MCB.00722-06 
Dumont, D. J., Fong, G. H., Puri, M. C., Gradwohl, G., Alitalo, K., & Breitman, M. 
L. (1995). Vascularization of the mouse embryo: a study of flk-1, tek, tie, 
and vascular endothelial growth factor expression during development. 
Dev Dyn, 203(1), 80-92. doi: 10.1002/aja.1002030109 
Duprez, L., Wirawan, E., Vanden Berghe, T., & Vandenabeele, P. (2009). Major 
cell death pathways at a glance. Microbes Infect, 11(13), 1050-1062. doi: 
10.1016/j.micinf.2009.08.013 
Eichmann, A., Marcelle, C., Breant, C., & Le Douarin, N. M. (1993). Two 
molecules related to the VEGF receptor are expressed in early endothelial 
cells during avian embryonic development. Mech Dev, 42(1-2), 33-48.  
El-Sharkawy, H., Kantarci, A., Deady, J., Hasturk, H., Liu, H., Alshahat, M., & 
Van Dyke, T. E. (2007). Platelet-rich plasma: growth factors and pro- and 
anti-inflammatory properties. J Periodontol, 78(4), 661-669. doi: 
10.1902/jop.2007.060302 
Enis, D. R., Shepherd, B. R., Wang, Y., Qasim, A., Shanahan, C. M., Weissberg, 
P. L., . . . Schechner, J. S. (2005). Induction, differentiation, and 
remodeling of blood vessels after transplantation of Bcl-2-transduced 
endothelial cells. Proc Natl Acad Sci U S A, 102(2), 425-430. doi: 
0408357102 [pii]10.1073/pnas.0408357102 
	   142 
Eswarakumar, V. P., Monsonego-Ornan, E., Pines, M., Antonopoulou, I., Morriss-
Kay, G. M., & Lonai, P. (2002). The IIIc alternative of Fgfr2 is a positive 
regulator of bone formation. Development, 129(16), 3783-3793.  
Fekete, N., Gadelorge, M., Furst, D., Maurer, C., Dausend, J., Fleury-
Cappellesso, S., . . . Rojewski, M. T. (2012). Platelet lysate from whole 
blood-derived pooled platelet concentrates and apheresis-derived platelet 
concentrates for the isolation and expansion of human bone marrow 
mesenchymal stromal cells: production process, content and identification 
of active components. Cytotherapy, 14(5), 540-554. doi: 
10.3109/14653249.2012.655420 
Feldman, B., Poueymirou, W., Papaioannou, V. E., DeChiara, T. M., & Goldfarb, 
M. (1995). Requirement of FGF-4 for postimplantation mouse 
development. Science, 267(5195), 246-249.  
Ferrara, N. (1996). Vascular endothelial growth factor. Eur J Cancer, 32A(14), 
2413-2422.  
Ferrara, N. (1999). Role of vascular endothelial growth factor in the regulation of 
angiogenesis. Kidney Int, 56(3), 794-814. doi: 10.1046/j.1523-
1755.1999.00610.x 
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., . . . 
Moore, M. W. (1996). Heterozygous embryonic lethality induced by 
targeted inactivation of the VEGF gene. Nature, 380(6573), 439-442. doi: 
10.1038/380439a0 
Flamme, I., Breier, G., & Risau, W. (1995). Vascular endothelial growth factor 
(VEGF) and VEGF receptor 2 (flk-1) are expressed during vasculogenesis 
and vascular differentiation in the quail embryo. Dev Biol, 169(2), 699-712. 
doi: 10.1006/dbio.1995.1180 
Flamme, I., & Risau, W. (1992). Induction of vasculogenesis and hematopoiesis 
in vitro. Development, 116(2), 435-439.  
Fong, G. H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995). Role of the 
Flt-1 receptor tyrosine kinase in regulating the assembly of vascular 
endothelium. Nature, 376(6535), 66-70. doi: 10.1038/376066a0 
Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., 
. . . Tsichlis, P. N. (1995). The protein kinase encoded by the Akt proto-
oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. 
Cell, 81(5), 727-736.  
Freishtat, R. J., Natale, J., Benton, A. S., Cohen, J., Sharron, M., Wiles, A. A., . . 
. Hoffman, E. P. (2009). Sepsis alters the megakaryocyte-platelet 
transcriptional axis resulting in granzyme B-mediated lymphotoxicity. Am J 
Respir Crit Care Med, 179(6), 467-473. doi: 10.1164/rccm.200807-
1085OC 
Fujio, Y., Nguyen, T., Wencker, D., Kitsis, R. N., & Walsh, K. (2000). Akt 
promotes survival of cardiomyocytes in vitro and protects against 
ischemia-reperfusion injury in mouse heart. Circulation, 101(6), 660-667.  
Fujio, Y., & Walsh, K. (1999). Akt mediates cytoprotection of endothelial cells by 
vascular endothelial growth factor in an anchorage-dependent manner. J 
Biol Chem, 274(23), 16349-16354.  
	   143 
Fukai, F., Mashimo, M., Akiyama, K., Goto, T., Tanuma, S., & Katayama, T. 
(1998). Modulation of apoptotic cell death by extracellular matrix proteins 
and a fibronectin-derived antiadhesive peptide. Exp Cell Res, 242(1), 92-
99.  
Fulton, D., Gratton, J. P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., . . . 
Sessa, W. C. (1999). Regulation of endothelium-derived nitric oxide 
production by the protein kinase Akt. Nature, 399(6736), 597-601. doi: 
10.1038/21218 
Gabler, C., Plath-Gabler, A., Killian, G. J., Berisha, B., & Schams, D. (2004). 
Expression pattern of fibroblast growth factor (FGF) and vascular 
endothelial growth factor (VEGF) system members in bovine corpus 
luteum endothelial cells during treatment with FGF-2, VEGF or oestradiol. 
Reprod Domest Anim, 39(5), 321-327. doi: 10.1111/j.1439-
0531.2004.00517.x 
Gale, N. W., Dominguez, M. G., Noguera, I., Pan, L., Hughes, V., Valenzuela, D. 
M., . . . Yancopoulos, G. D. (2004). Haploinsufficiency of delta-like 4 ligand 
results in embryonic lethality due to major defects in arterial and vascular 
development. Proc Natl Acad Sci U S A, 101(45), 15949-15954. doi: 
0407290101 [pii]10.1073/pnas.0407290101 
Gambim, M. H., do Carmo Ade, O., Marti, L., Verissimo-Filho, S., Lopes, L. R., & 
Janiszewski, M. (2007). Platelet-derived exosomes induce endothelial cell 
apoptosis through peroxynitrite generation: experimental evidence for a 
novel mechanism of septic vascular dysfunction. Crit Care, 11(5), R107. 
doi: 10.1186/cc6133 
Gerber, H. P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & 
Ferrara, N. (1998). Vascular endothelial growth factor regulates 
endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt 
signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol 
Chem, 273(46), 30336-30343.  
Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, 
A., . . . Betsholtz, C. (2003). VEGF guides angiogenic sprouting utilizing 
endothelial tip cell filopodia. J Cell Biol, 161(6), 1163-1177. doi: 
10.1083/jcb.200302047 
Gottlob, K., Majewski, N., Kennedy, S., Kandel, E., Robey, R. B., & Hay, N. 
(2001). Inhibition of early apoptotic events by Akt/PKB is dependent on the 
first committed step of glycolysis and mitochondrial hexokinase. Genes 
Dev, 15(11), 1406-1418. doi: 10.1101/gad.889901 
Gridley, T. (2007). Notch signaling in vascular development and physiology. 
Development, 134(15), 2709-2718. doi: 10.1242/dev.004184 
Gridley, T. (2010). Notch signaling in the vasculature. Curr Top Dev Biol, 92, 
277-309. doi: 10.1016/S0070-2153(10)92009-7 
Gurtner, G. C., Werner, S., Barrandon, Y., & Longaker, M. T. (2008). Wound 
repair and regeneration. Nature, 453(7193), 314-321. doi: 
10.1038/nature07039 
	   144 
Gustafsson, A. B., & Gottlieb, R. A. (2007). Bcl-2 family members and apoptosis, 
taken to heart. Am J Physiol Cell Physiol, 292(1), C45-51. doi: 
10.1152/ajpcell.00229.2006 
Hanahan, D. (1997). Signaling vascular morphogenesis and maintenance. 
Science, 277(5322), 48-50.  
Hanahan, D., & Folkman, J. (1996). Patterns and emerging mechanisms of the 
angiogenic switch during tumorigenesis. Cell, 86(3), 353-364.  
Hannan, K. M., & Little, P. J. (1998). Mechanisms regulating the vascular smooth 
muscle Na/H exchanger (NHE-1) in diabetes. Biochem Cell Biol, 76(5), 
751-759.  
Hellstrom, M., Phng, L. K., Hofmann, J. J., Wallgard, E., Coultas, L., Lindblom, 
P., . . . Betsholtz, C. (2007). Dll4 signalling through Notch1 regulates 
formation of tip cells during angiogenesis. Nature, 445(7129), 776-780. 
doi: 10.1038/nature05571 
Hill, J. M., Zalos, G., Halcox, J. P., Schenke, W. H., Waclawiw, M. A., Quyyumi, 
A. A., & Finkel, T. (2003). Circulating endothelial progenitor cells, vascular 
function, and cardiovascular risk. N Engl J Med, 348(7), 593-600. doi: 
10.1056/NEJMoa022287 
Hirschi, K. K., Ingram, D. A., & Yoder, M. C. (2008). Assessing identity, 
phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb 
Vasc Biol, 28(9), 1584-1595. doi: 10.1161/ATVBAHA.107.155960 
Hisano, N., Yatomi, Y., Satoh, K., Akimoto, S., Mitsumata, M., Fujino, M. A., & 
Ozaki, Y. (1999). Induction and suppression of endothelial cell apoptosis 
by sphingolipids: a possible in vitro model for cell-cell interactions between 
platelets and endothelial cells. Blood, 93(12), 4293-4299.  
Hofmann, J. J., & Iruela-Arispe, M. L. (2007). Notch signaling in blood vessels: 
who is talking to whom about what? Circ Res, 100(11), 1556-1568. doi: 
10.1161/01.RES.0000266408.42939.e4 
Holderfield, M. T., & Hughes, C. C. (2008). Crosstalk between vascular 
endothelial growth factor, notch, and transforming growth factor-beta in 
vascular morphogenesis. Circ Res, 102(6), 637-652. doi: 
10.1161/CIRCRESAHA.107.167171 
Hrabe de Angelis, M., McIntyre, J., 2nd, & Gossler, A. (1997). Maintenance of 
somite borders in mice requires the Delta homologue DII1. Nature, 
386(6626), 717-721. doi: 10.1038/386717a0 
Huang, L., Critser, P. J., Grimes, B. R., & Yoder, M. C. (2011). Human umbilical 
cord blood plasma can replace fetal bovine serum for in vitro expansion of 
functional human endothelial colony-forming cells. Cytotherapy, 13(6), 
712-721. doi: 10.3109/14653249.2010.548380 
Huang, X. T., Zhang, Y. Q., Li, S. J., Li, S. H., Tang, Q., Wang, Z. T., . . . Zhang, 
J. N. (2013). Intracerebroventricular transplantation of ex vivo expanded 
endothelial colony-forming cells restores blood-brain barrier integrity and 
promotes angiogenesis of mice with traumatic brain injury. J Neurotrauma, 
30(24), 2080-2088. doi: 10.1089/neu.2013.2996 
Huppert, S. S., Le, A., Schroeter, E. H., Mumm, J. S., Saxena, M. T., Milner, L. 
A., & Kopan, R. (2000). Embryonic lethality in mice homozygous for a 
	   145 
processing-deficient allele of Notch1. Nature, 405(6789), 966-970. doi: 
10.1038/35016111 
Hynes, R. O. (1992). Integrins: versatility, modulation, and signaling in cell 
adhesion. Cell, 69(1), 11-25.  
Ilan, N., Mahooti, S., & Madri, J. A. (1998). Distinct signal transduction pathways 
are utilized during the tube formation and survival phases of in vitro 
angiogenesis. J Cell Sci, 111 ( Pt 24), 3621-3631.  
Ingram, D. A., Mead, L. E., Moore, D. B., Woodard, W., Fenoglio, A., & Yoder, M. 
C. (2005). Vessel wall-derived endothelial cells rapidly proliferate because 
they contain a complete hierarchy of endothelial progenitor cells. Blood, 
105(7), 2783-2786. doi: 10.1182/blood-2004-08-3057 
Ingram, D. A., Mead, L. E., Tanaka, H., Meade, V., Fenoglio, A., Mortell, K., . . . 
Yoder, M. C. (2004). Identification of a novel hierarchy of endothelial 
progenitor cells using human peripheral and umbilical cord blood. Blood, 
104(9), 2752-2760. doi: 10.1182/blood-2004-04-1396 
Jacobson, M. D., Weil, M., & Raff, M. C. (1997). Programmed cell death in 
animal development. Cell, 88(3), 347-354.  
Janiszewski, M., Do Carmo, A. O., Pedro, M. A., Silva, E., Knobel, E., & 
Laurindo, F. R. (2004). Platelet-derived exosomes of septic individuals 
possess proapoptotic NAD(P)H oxidase activity: A novel vascular redox 
pathway. Crit Care Med, 32(3), 818-825.  
Jehn, B. M., Bielke, W., Pear, W. S., & Osborne, B. A. (1999). Cutting edge: 
protective effects of notch-1 on TCR-induced apoptosis. J Immunol, 
162(2), 635-638.  
Jeltsch, M., Kaipainen, A., Joukov, V., Meng, X., Lakso, M., Rauvala, H., . . . 
Alitalo, K. (1997). Hyperplasia of lymphatic vessels in VEGF-C transgenic 
mice. Science, 276(5317), 1423-1425.  
Jin, S. W., Beis, D., Mitchell, T., Chen, J. N., & Stainier, D. Y. (2005). Cellular 
and molecular analyses of vascular tube and lumen formation in zebrafish. 
Development, 132(23), 5199-5209. doi: 10.1242/dev.02087 
Jones, R. G., Parsons, M., Bonnard, M., Chan, V. S., Yeh, W. C., Woodgett, J. 
R., & Ohashi, P. S. (2000). Protein kinase B regulates T lymphocyte 
survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J 
Exp Med, 191(10), 1721-1734.  
Joutel, A., Andreux, F., Gaulis, S., Domenga, V., Cecillon, M., Battail, N., . . . 
Tournier-Lasserve, E. (2000). The ectodomain of the Notch3 receptor 
accumulates within the cerebrovasculature of CADASIL patients. J Clin 
Invest, 105(5), 597-605. doi: 10.1172/JCI8047 
Kanda, S., Miyata, Y., & Kanetake, H. (2004). Fibroblast growth factor-2-
mediated capillary morphogenesis of endothelial cells requires signals via 
Flt-1/vascular endothelial growth factor receptor-1: possible involvement of 
c-Akt. J Biol Chem, 279(6), 4007-4016. doi: 10.1074/jbc.M307569200 
Kang, K. T., Allen, P., & Bischoff, J. (2011). Bioengineered human vascular 
networks transplanted into secondary mice reconnect with the host 
vasculature and re-establish perfusion. Blood, 118(25), 6718-6721. doi: 
10.1182/blood-2011-08-375188 
	   146 
Kang, K. T., Coggins, M., Xiao, C., Rosenzweig, A., & Bischoff, J. (2013). Human 
vasculogenic cells form functional blood vessels and mitigate adverse 
remodeling after ischemia reperfusion injury in rats. Angiogenesis, 16(4), 
773-784. doi: 10.1007/s10456-013-9354-9 
Kanzawa, S., Endo, H., & Shioya, N. (1993). Improved in vitro angiogenesis 
model by collagen density reduction and the use of type III collagen. Ann 
Plast Surg, 30(3), 244-251.  
Kazemi, S., Wenzel, D., Kolossov, E., Lenka, N., Raible, A., Sasse, P., . . . Bloch, 
W. (2002). Differential role of bFGF and VEGF for vasculogenesis. Cell 
Physiol Biochem, 12(2-3), 55-62. doi: 63781 
Kim, H., Huang, L., Critser, P. J., Yang, Z., Chan, R. J., Wang, L., . . . Yoder, M. 
C. (2015). Notch ligand Delta-like 1 promotes in vivo vasculogenesis in 
human cord blood-derived endothelial colony forming cells. Cytotherapy, 
17(5), 579-592. doi: 10.1016/j.jcyt.2014.12.003 
Kim, H., Prasain, N., Vemula, S., Ferkowicz, M. J., Yoshimoto, M., Voytik-Harbin, 
S. L., & Yoder, M. C. (2015). Human platelet lysate improves human cord 
blood derived ECFC survival and vasculogenesis in three dimensional 
(3D) collagen matrices. Microvasc Res, 101, 72-81. doi: 
10.1016/j.mvr.2015.06.006 
Kim, I., Kim, H. G., So, J. N., Kim, J. H., Kwak, H. J., & Koh, G. Y. (2000). 
Angiopoietin-1 regulates endothelial cell survival through the 
phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. Circ Res, 
86(1), 24-29.  
Kim, Y. H., Hu, H., Guevara-Gallardo, S., Lam, M. T., Fong, S. Y., & Wang, R. A. 
(2008). Artery and vein size is balanced by Notch and ephrin B2/EphB4 
during angiogenesis. Development, 135(22), 3755-3764. doi: 135/22/3755 
[pii]10.1242/dev.022475 
Koh, W., Mahan, R. D., & Davis, G. E. (2008). Cdc42- and Rac1-mediated 
endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-
dependent signaling. J Cell Sci, 121(Pt 7), 989-1001. doi: 
10.1242/jcs.020693 
Koh, W., Stratman, A. N., Sacharidou, A., & Davis, G. E. (2008). In vitro three 
dimensional collagen matrix models of endothelial lumen formation during 
vasculogenesis and angiogenesis. Methods Enzymol, 443, 83-101. doi: 
10.1016/S0076-6879(08)02005-3 
Kontos, C. D., Stauffer, T. P., Yang, W. P., York, J. D., Huang, L., Blanar, M. A., . 
. . Peters, K. G. (1998). Tyrosine 1101 of Tie2 is the major site of 
association of p85 and is required for activation of phosphatidylinositol 3-
kinase and Akt. Mol Cell Biol, 18(7), 4131-4140.  
Korff, T., & Augustin, H. G. (1999). Tensional forces in fibrillar extracellular 
matrices control directional capillary sprouting. J Cell Sci, 112 ( Pt 19), 
3249-3258.  
Kotani, K., Ogawa, W., Hino, Y., Kitamura, T., Ueno, H., Sano, W., . . . Kasuga, 
M. (1999). Dominant negative forms of Akt (protein kinase B) and atypical 
protein kinase Clambda do not prevent insulin inhibition of 
	   147 
phosphoenolpyruvate carboxykinase gene transcription. J Biol Chem, 
274(30), 21305-21312.  
Krebs, L. T., Starling, C., Chervonsky, A. V., & Gridley, T. (2010). Notch1 
activation in mice causes arteriovenous malformations phenocopied by 
ephrinB2 and EphB4 mutants. Genesis, 48(3), 146-150. doi: 
10.1002/dvg.20599 
Krebs, L. T., Xue, Y., Norton, C. R., Shutter, J. R., Maguire, M., Sundberg, J. P., . 
. . Gridley, T. (2000). Notch signaling is essential for vascular 
morphogenesis in mice. Genes Dev, 14(11), 1343-1352.  
Kume, T. (2009). Novel insights into the differential functions of Notch ligands in 
vascular formation. J Angiogenes Res, 1, 8. doi: 10.1186/2040-2384-1-8 
Kurz, H., Gartner, T., Eggli, P. S., & Christ, B. (1996). First blood vessels in the 
avian neural tube are formed by a combination of dorsal angioblast 
immigration and ventral sprouting of endothelial cells. Dev Biol, 173(1), 
133-147. doi: 10.1006/dbio.1996.0012 
LaBonne, C., & Whitman, M. (1994). Mesoderm induction by activin requires 
FGF-mediated intracellular signals. Development, 120(2), 463-472.  
Lamalice, L., Le Boeuf, F., & Huot, J. (2007). Endothelial cell migration during 
angiogenesis. Circ Res, 100(6), 782-794. doi: 
10.1161/01.RES.0000259593.07661.1e 
Langer, H. F., Stellos, K., Steingen, C., Froihofer, A., Schonberger, T., Kramer, 
B., . . . Gawaz, M. (2009). Platelet derived bFGF mediates vascular 
integrative mechanisms of mesenchymal stem cells in vitro. J Mol Cell 
Cardiol, 47(2), 315-325. doi: 10.1016/j.yjmcc.2009.03.011 
Lanner, F., Sohl, M., & Farnebo, F. (2007). Functional arterial and venous fate is 
determined by graded VEGF signaling and notch status during embryonic 
stem cell differentiation. Arterioscler Thromb Vasc Biol, 27(3), 487-493. 
doi: 01.ATV.0000255990.91805.6d [pii] 
10.1161/01.ATV.0000255990.91805.6d 
Lawson, N. D., Scheer, N., Pham, V. N., Kim, C. H., Chitnis, A. B., Campos-
Ortega, J. A., & Weinstein, B. M. (2001). Notch signaling is required for 
arterial-venous differentiation during embryonic vascular development. 
Development, 128(19), 3675-3683.  
Lawson, N. D., Vogel, A. M., & Weinstein, B. M. (2002). sonic hedgehog and 
vascular endothelial growth factor act upstream of the Notch pathway 
during arterial endothelial differentiation. Dev Cell, 3(1), 127-136. doi: 
S1534580702001983 [pii] 
Lee, M. Y., Luciano, A. K., Ackah, E., Rodriguez-Vita, J., Bancroft, T. A., 
Eichmann, A., . . . Sessa, W. C. (2014). Endothelial Akt1 mediates 
angiogenesis by phosphorylating multiple angiogenic substrates. Proc Natl 
Acad Sci U S A, 111(35), 12865-12870. doi: 10.1073/pnas.1408472111 
Lee, S. H., Schloss, D. J., & Swain, J. L. (2000). Maintenance of vascular 
integrity in the embryo requires signaling through the fibroblast growth 
factor receptor. J Biol Chem, 275(43), 33679-33687. doi: 
10.1074/jbc.M004994200 
	   148 
Leslie, J. D., Ariza-McNaughton, L., Bermange, A. L., McAdow, R., Johnson, S. 
L., & Lewis, J. (2007). Endothelial signalling by the Notch ligand Delta-like 
4 restricts angiogenesis. Development, 134(5), 839-844. doi: 
10.1242/dev.003244 
Lev, E. I., Estrov, Z., Aboulfatova, K., Harris, D., Granada, J. F., Alviar, C., . . . 
Dong, J. F. (2006). Potential role of activated platelets in homing of human 
endothelial progenitor cells to subendothelial matrix. Thromb Haemost, 
96(4), 498-504.  
Limbourg, A., Ploom, M., Elligsen, D., Sorensen, I., Ziegelhoeffer, T., Gossler, A., 
. . . Limbourg, F. P. (2007). Notch ligand Delta-like 1 is essential for 
postnatal arteriogenesis. Circ Res, 100(3), 363-371. doi: 
10.1161/01.RES.0000258174.77370.2c 
Lin, R. Z., Moreno-Luna, R., Zhou, B., Pu, W. T., & Melero-Martin, J. M. (2012). 
Equal modulation of endothelial cell function by four distinct tissue-specific 
mesenchymal stem cells. Angiogenesis, 15(3), 443-455. doi: 
10.1007/s10456-012-9272-2 
Liu, Y., & Senger, D. R. (2004). Matrix-specific activation of Src and Rho initiates 
capillary morphogenesis of endothelial cells. FASEB J, 18(3), 457-468. 
doi: 10.1096/fj.03-0948com 
Liu, Z. J., Shirakawa, T., Li, Y., Soma, A., Oka, M., Dotto, G. P., . . . Herlyn, M. 
(2003). Regulation of Notch1 and Dll4 by vascular endothelial growth 
factor in arterial endothelial cells: implications for modulating 
arteriogenesis and angiogenesis. Mol Cell Biol, 23(1), 14-25.  
Llevadot, J., & Asahara, T. (2002). [Effects of statins on angiogenesis and 
vasculogenesis]. Rev Esp Cardiol, 55(8), 838-844.  
Lobov, I. B., Renard, R. A., Papadopoulos, N., Gale, N. W., Thurston, G., 
Yancopoulos, G. D., & Wiegand, S. J. (2007). Delta-like ligand 4 (Dll4) is 
induced by VEGF as a negative regulator of angiogenic sprouting. Proc 
Natl Acad Sci U S A, 104(9), 3219-3224. doi: 10.1073/pnas.0611206104 
Luo, Y., Shoemaker, A. R., Liu, X., Woods, K. W., Thomas, S. A., de Jong, R., . . 
. Giranda, V. L. (2005). Potent and selective inhibitors of Akt kinases slow 
the progress of tumors in vivo. Mol Cancer Ther, 4(6), 977-986. doi: 
10.1158/1535-7163.MCT-05-0005 
MacKenzie, F., Duriez, P., Wong, F., Noseda, M., & Karsan, A. (2004). Notch4 
inhibits endothelial apoptosis via RBP-Jkappa-dependent and -
independent pathways. J Biol Chem, 279(12), 11657-11663. doi: 
10.1074/jbc.M312102200 
Magnusson, P., Rolny, C., Jakobsson, L., Wikner, C., Wu, Y., Hicklin, D. J., & 
Claesson-Welsh, L. (2004). Deregulation of Flk-1/vascular endothelial 
growth factor receptor-2 in fibroblast growth factor receptor-1-deficient 
vascular stem cell development. J Cell Sci, 117(Pt 8), 1513-1523. doi: 
10.1242/jcs.00999 
Matsumura, T., Wolff, K., & Petzelbauer, P. (1997). Endothelial cell tube 
formation depends on cadherin 5 and CD31 interactions with filamentous 
actin. J Immunol, 158(7), 3408-3416.  
	   149 
Mause, S. F., Ritzel, E., Liehn, E. A., Hristov, M., Bidzhekov, K., Muller-Newen, 
G., . . . Weber, C. (2010). Platelet microparticles enhance the 
vasoregenerative potential of angiogenic early outgrowth cells after 
vascular injury. Circulation, 122(5), 495-506. doi: 
10.1161/CIRCULATIONAHA.109.909473 
Mause, S. F., von Hundelshausen, P., Zernecke, A., Koenen, R. R., & Weber, C. 
(2005). Platelet microparticles: a transcellular delivery system for RANTES 
promoting monocyte recruitment on endothelium. Arterioscler Thromb 
Vasc Biol, 25(7), 1512-1518. doi: 10.1161/01.ATV.0000170133.43608.37 
Medina, R. J., O'Neill, C. L., Humphreys, M. W., Gardiner, T. A., & Stitt, A. W. 
(2010). Outgrowth endothelial cells: characterization and their potential for 
reversing ischemic retinopathy. Invest Ophthalmol Vis Sci, 51(11), 5906-
5913. doi: 10.1167/iovs.09-4951 
Melero-Martin, J. M., De Obaldia, M. E., Allen, P., Dudley, A. C., Klagsbrun, M., 
& Bischoff, J. (2010). Host myeloid cells are necessary for creating 
bioengineered human vascular networks in vivo. Tissue Eng Part A, 16(8), 
2457-2466. doi: 10.1089/ten.TEA.2010.0024 
Melero-Martin, J. M., De Obaldia, M. E., Kang, S. Y., Khan, Z. A., Yuan, L., 
Oettgen, P., & Bischoff, J. (2008). Engineering robust and functional 
vascular networks in vivo with human adult and cord blood-derived 
progenitor cells. Circ Res, 103(2), 194-202. doi: 
10.1161/CIRCRESAHA.108.178590 CIRCRESAHA.108.178590 [pii] 
Melero-Martin, J. M., Khan, Z. A., Picard, A., Wu, X., Paruchuri, S., & Bischoff, J. 
(2007). In vivo vasculogenic potential of human blood-derived endothelial 
progenitor cells. Blood, 109(11), 4761-4768. doi: 10.1182/blood-2006-12-
062471 
Ment, L. R., Stewart, W. B., Scaramuzzino, D., & Madri, J. A. (1997). An in vitro 
three-dimensional coculture model of cerebral microvascular angiogenesis 
and differentiation. In Vitro Cell Dev Biol Anim, 33(9), 684-691. doi: 
10.1007/s11626-997-0126-y 
Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., & Ullrich, A. (1994). 
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 
mutant. Nature, 367(6463), 576-579. doi: 10.1038/367576a0 
Millauer, B., Wizigmann-Voos, S., Schnurch, H., Martinez, R., Moller, N. P., 
Risau, W., & Ullrich, A. (1993). High affinity VEGF binding and 
developmental expression suggest Flk-1 as a major regulator of 
vasculogenesis and angiogenesis. Cell, 72(6), 835-846.  
Miller, D. L., Ortega, S., Bashayan, O., Basch, R., & Basilico, C. (2000). 
Compensation by fibroblast growth factor 1 (FGF1) does not account for 
the mild phenotypic defects observed in FGF2 null mice. Mol Cell Biol, 
20(6), 2260-2268.  
Morales-Ruiz, M., Fulton, D., Sowa, G., Languino, L. R., Fujio, Y., Walsh, K., & 
Sessa, W. C. (2000). Vascular endothelial growth factor-stimulated actin 
reorganization and migration of endothelial cells is regulated via the 
serine/threonine kinase Akt. Circ Res, 86(8), 892-896.  
	   150 
Moubarik, C., Guillet, B., Youssef, B., Codaccioni, J. L., Piercecchi, M. D., 
Sabatier, F., . . . Pisano, P. (2011). Transplanted late outgrowth 
endothelial progenitor cells as cell therapy product for stroke. Stem Cell 
Rev, 7(1), 208-220. doi: 10.1007/s12015-010-9157-y 
Mund, J. A., Estes, M. L., Yoder, M. C., Ingram, D. A., Jr., & Case, J. (2012). 
Flow cytometric identification and functional characterization of immature 
and mature circulating endothelial cells. Arterioscler Thromb Vasc Biol, 
32(4), 1045-1053. doi: 10.1161/ATVBAHA.111.244210 
Nakamura, T., Teramoto, H., & Ichihara, A. (1986). Purification and 
characterization of a growth factor from rat platelets for mature 
parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci U S A, 
83(17), 6489-6493.  
Neufeld, G., Cohen, T., Gengrinovitch, S., & Poltorak, Z. (1999). Vascular 
endothelial growth factor (VEGF) and its receptors. FASEB J, 13(1), 9-22.  
Ng, C. P., Helm, C. L., & Swartz, M. A. (2004). Interstitial flow differentially 
stimulates blood and lymphatic endothelial cell morphogenesis in vitro. 
Microvasc Res, 68(3), 258-264. doi: 10.1016/j.mvr.2004.08.002 
Niessen, K., & Karsan, A. (2008). Notch signaling in cardiac development. Circ 
Res, 102(10), 1169-1181. doi: 102/10/1169 [pii] 
10.1161/CIRCRESAHA.108.174318 
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, 
N. W., . . . Thurston, G. (2006). Blockade of Dll4 inhibits tumour growth by 
promoting non-productive angiogenesis. Nature, 444(7122), 1032-1037. 
doi: 10.1038/nature05355 
Ohishi, K., Varnum-Finney, B., Flowers, D., Anasetti, C., Myerson, D., & 
Bernstein, I. D. (2000). Monocytes express high amounts of Notch and 
undergo cytokine specific apoptosis following interaction with the Notch 
ligand, Delta-1. Blood, 95(9), 2847-2854.  
Olofsson, B., Pajusola, K., Kaipainen, A., von Euler, G., Joukov, V., Saksela, O., 
. . . Eriksson, U. (1996). Vascular endothelial growth factor B, a novel 
growth factor for endothelial cells. Proc Natl Acad Sci U S A, 93(6), 2576-
2581.  
Ornitz, D. M., & Itoh, N. (2001). Fibroblast growth factors. Genome Biol, 2(3), 
REVIEWS3005.  
Pajusola, K., Aprelikova, O., Pelicci, G., Weich, H., Claesson-Welsh, L., & Alitalo, 
K. (1994). Signalling properties of FLT4, a proteolytically processed 
receptor tyrosine kinase related to two VEGF receptors. Oncogene, 9(12), 
3545-3555.  
Pakala, R., Willerson, J. T., & Benedict, C. R. (1994). Mitogenic effect of 
serotonin on vascular endothelial cells. Circulation, 90(4), 1919-1926.  
Papapetropoulos, A., Fulton, D., Mahboubi, K., Kalb, R. G., O'Connor, D. S., Li, 
F., . . . Sessa, W. C. (2000). Angiopoietin-1 inhibits endothelial cell 
apoptosis via the Akt/survivin pathway. J Biol Chem, 275(13), 9102-9105.  
Paradis, S., & Ruvkun, G. (1998). Caenorhabditis elegans Akt/PKB transduces 
insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 
transcription factor. Genes Dev, 12(16), 2488-2498.  
	   151 
Peng, X. D., Xu, P. Z., Chen, M. L., Hahn-Windgassen, A., Skeen, J., Jacobs, J., 
. . . Hay, N. (2003). Dwarfism, impaired skin development, skeletal muscle 
atrophy, delayed bone development, and impeded adipogenesis in mice 
lacking Akt1 and Akt2. Genes Dev, 17(11), 1352-1365. doi: 
10.1101/gad.1089403 
Petrova, T. V., Makinen, T., & Alitalo, K. (1999). Signaling via vascular 
endothelial growth factor receptors. Exp Cell Res, 253(1), 117-130. doi: 
10.1006/excr.1999.4707 
Pfaffl, M. W. (2001). A new mathematical model for relative quantification in real-
time RT-PCR. Nucleic Acids Res, 29(9), e45.  
Phng, L. K., & Gerhardt, H. (2009). Angiogenesis: a team effort coordinated by 
notch. Dev Cell, 16(2), 196-208. doi: 10.1016/j.devcel.2009.01.015 
Plas, D. R., Talapatra, S., Edinger, A. L., Rathmell, J. C., & Thompson, C. B. 
(2001). Akt and Bcl-xL promote growth factor-independent survival 
through distinct effects on mitochondrial physiology. J Biol Chem, 276(15), 
12041-12048. doi: 10.1074/jbc.M010551200 
Pollman, M. J., Naumovski, L., & Gibbons, G. H. (1999). Endothelial cell 
apoptosis in capillary network remodeling. J Cell Physiol, 178(3), 359-370. 
doi: 10.1002/(SICI)1097-4652(199903)178:3<359::AID-JCP10>3.0.CO;2-
O 
Prindull, G. (1995). Apoptosis in the embryo and tumorigenesis. Eur J Cancer, 
31A(1), 116-123.  
Radtke, F., Fasnacht, N., & Macdonald, H. R. (2010). Notch signaling in the 
immune system. Immunity, 32(1), 14-27. doi: S1074-7613(10)00005-1 [pii] 
10.1016/j.immuni.2010.01.004 
Rafii, S., & Lyden, D. (2003). Therapeutic stem and progenitor cell 
transplantation for organ vascularization and regeneration. Nat Med, 9(6), 
702-712. doi: 10.1038/nm0603-702 
Rafii, S., Lyden, D., Benezra, R., Hattori, K., & Heissig, B. (2002). Vascular and 
haematopoietic stem cells: novel targets for anti-angiogenesis therapy? 
Nat Rev Cancer, 2(11), 826-835. doi: 10.1038/nrc925 
Ranta, V., Mikkola, T., Ylikorkala, O., Viinikka, L., & Orpana, A. (1998). Reduced 
viability of human vascular endothelial cells cultured on Matrigel. J Cell 
Physiol, 176(1), 92-98. doi: 10.1002/(SICI)1097-
4652(199807)176:1<92::AID-JCP11>3.0.CO;2-Q 
Reinisch, A., Hofmann, N. A., Obenauf, A. C., Kashofer, K., Rohde, E., 
Schallmoser, K., . . . Strunk, D. (2009). Humanized large-scale expanded 
endothelial colony-forming cells function in vitro and in vivo. Blood, 
113(26), 6716-6725. doi: 10.1182/blood-2008-09-181362 
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W. C., Chanthery, Y., . . . 
Yan, M. (2006). Inhibition of Dll4 signalling inhibits tumour growth by 
deregulating angiogenesis. Nature, 444(7122), 1083-1087. doi: 
10.1038/nature05313 
Risau, W. (1995). Differentiation of endothelium. FASEB J, 9(10), 926-933.  
Risau, W. (1997). Mechanisms of angiogenesis. Nature, 386(6626), 671-674. 
doi: 10.1038/386671a0 
	   152 
Risau, W., & Flamme, I. (1995). Vasculogenesis. Annu Rev Cell Dev Biol, 11, 73-
91. doi: 10.1146/annurev.cb.11.110195.000445 
Roca, C., & Adams, R. H. (2007). Regulation of vascular morphogenesis by 
Notch signaling. Genes Dev, 21(20), 2511-2524. doi: 
10.1101/gad.1589207 
Rocha, S. F., & Adams, R. H. (2009). Molecular differentiation and specialization 
of vascular beds. Angiogenesis, 12(2), 139-147. doi: 10.1007/s10456-009-
9132-x 
Rohban, R., Reinisch, A., Etchart, N., Schallmoser, K., Hofmann, N. A., Szoke, 
K., . . . Strunk, D. (2013). Identification of an effective early signaling 
signature during neo-vasculogenesis in vivo by ex vivo proteomic profiling. 
PLoS One, 8(6), e66909. doi: 10.1371/journal.pone.0066909 
Roman, B. L., & Weinstein, B. M. (2000). Building the vertebrate vasculature: 
research is going swimmingly. Bioessays, 22(10), 882-893. doi: 
10.1002/1521-1878(200010)22:10<882::AID-BIES3>3.0.CO;2-J 
Rossant, J., & Howard, L. (2002). Signaling pathways in vascular development. 
Annu Rev Cell Dev Biol, 18, 541-573. doi: 
10.1146/annurev.cellbio.18.012502.105825012502.105825 [pii] 
Rozmyslowicz, T., Majka, M., Kijowski, J., Murphy, S. L., Conover, D. O., Poncz, 
M., . . . Ratajczak, M. Z. (2003). Platelet- and megakaryocyte-derived 
microparticles transfer CXCR4 receptor to CXCR4-null cells and make 
them susceptible to infection by X4-HIV. AIDS, 17(1), 33-42. doi: 
10.1097/01.aids.0000042948.95433.3d 
Sacharidou, A., Stratman, A. N., & Davis, G. E. (2012). Molecular mechanisms 
controlling vascular lumen formation in three-dimensional extracellular 
matrices. Cells Tissues Organs, 195(1-2), 122-143. doi: 
10.1159/000331410 
Sade, H., Krishna, S., & Sarin, A. (2004). The anti-apoptotic effect of Notch-1 
requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol 
Chem, 279(4), 2937-2944. doi: 10.1074/jbc.M309924200 
Sainson, R. C., Aoto, J., Nakatsu, M. N., Holderfield, M., Conn, E., Koller, E., & 
Hughes, C. C. (2005). Cell-autonomous notch signaling regulates 
endothelial cell branching and proliferation during vascular tubulogenesis. 
FASEB J, 19(8), 1027-1029. doi: 10.1096/fj.04-3172fje 
Salazar, R., Bell, S. E., & Davis, G. E. (1999). Coordinate induction of the actin 
cytoskeletal regulatory proteins gelsolin, vasodilator-stimulated 
phosphoprotein, and profilin during capillary morphogenesis in vitro. Exp 
Cell Res, 249(1), 22-32. doi: 10.1006/excr.1999.4460 
Savill, J., & Fadok, V. (2000). Corpse clearance defines the meaning of cell 
death. Nature, 407(6805), 784-788. doi: 10.1038/35037722 
Schallmoser, K., & Strunk, D. (2009). Preparation of pooled human platelet lysate 
(pHPL) as an efficient supplement for animal serum-free human stem cell 
cultures. J Vis Exp(32). doi: 10.3791/1523 
Schechner, J. S., Nath, A. K., Zheng, L., Kluger, M. S., Hughes, C. C., Sierra-
Honigmann, M. R., . . . Pober, J. S. (2000). In vivo formation of complex 
microvessels lined by human endothelial cells in an immunodeficient 
	   153 
mouse. Proc Natl Acad Sci U S A, 97(16), 9191-9196. doi: 
10.1073/pnas.150242297 
Schmitt, T. M., & Zuniga-Pflucker, J. C. (2002). Induction of T cell development 
from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity, 
17(6), 749-756. doi: S1074761302004740 [pii] 
Schwarz, T. M., Leicht, S. F., Radic, T., Rodriguez-Araboalaza, I., Hermann, P. 
C., Berger, F., . . . Heeschen, C. (2012). Vascular incorporation of 
endothelial colony-forming cells is essential for functional recovery of 
murine ischemic tissue following cell therapy. Arterioscler Thromb Vasc 
Biol, 32(2), e13-21. doi: 10.1161/ATVBAHA.111.239822 
Scorrano, L., & Korsmeyer, S. J. (2003). Mechanisms of cytochrome c release by 
proapoptotic BCL-2 family members. Biochem Biophys Res Commun, 
304(3), 437-444.  
Seandel, M., Butler, J. M., Kobayashi, H., Hooper, A. T., White, I. A., Zhang, F., . 
. . Rafii, S. (2008). Generation of a functional and durable vascular niche 
by the adenoviral E4ORF1 gene. Proc Natl Acad Sci U S A, 105(49), 
19288-19293. doi: 10.1073/pnas.0805980105 
Seghezzi, G., Patel, S., Ren, C. J., Gualandris, A., Pintucci, G., Robbins, E. S., . . 
. Mignatti, P. (1998). Fibroblast growth factor-2 (FGF-2) induces vascular 
endothelial growth factor (VEGF) expression in the endothelial cells of 
forming capillaries: an autocrine mechanism contributing to angiogenesis. 
J Cell Biol, 141(7), 1659-1673.  
Segura, I., Serrano, A., De Buitrago, G. G., Gonzalez, M. A., Abad, J. L., 
Claveria, C., . . . Riese, H. H. (2002). Inhibition of programmed cell death 
impairs in vitro vascular-like structure formation and reduces in vivo 
angiogenesis. FASEB J, 16(8), 833-841. doi: 10.1096/fj.01-0819com 
Shalaby, F., Ho, J., Stanford, W. L., Fischer, K. D., Schuh, A. C., Schwartz, L., . . 
. Rossant, J. (1997). A requirement for Flk1 in primitive and definitive 
hematopoiesis and vasculogenesis. Cell, 89(6), 981-990.  
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., 
Breitman, M. L., & Schuh, A. C. (1995). Failure of blood-island formation 
and vasculogenesis in Flk-1-deficient mice. Nature, 376(6535), 62-66. doi: 
10.1038/376062a0 
Sharron, M., Hoptay, C. E., Wiles, A. A., Garvin, L. M., Geha, M., Benton, A. S., . 
. . Freishtat, R. J. (2012). Platelets induce apoptosis during sepsis in a 
contact-dependent manner that is inhibited by GPIIb/IIIa blockade. PLoS 
One, 7(7), e41549. doi: 10.1371/journal.pone.0041549 
Shawber, C. J., & Kitajewski, J. (2004). Notch function in the vasculature: 
insights from zebrafish, mouse and man. Bioessays, 26(3), 225-234. doi: 
10.1002/bies.20004 
Shelley, W. C., Leapley, A. C., Huang, L., Critser, P. J., Zeng, P., Prater, D., . . . 
Yoder, M. C. (2012). Changes in the frequency and in vivo vessel-forming 
ability of rhesus monkey circulating endothelial colony-forming cells across 
the lifespan (birth to aged). Pediatr Res, 71(2), 156-161. doi: 
10.1038/pr.2011.22 
	   154 
Shepherd, B. R., Enis, D. R., Wang, F., Suarez, Y., Pober, J. S., & Schechner, J. 
S. (2006). Vascularization and engraftment of a human skin substitute 
using circulating progenitor cell-derived endothelial cells. The FASEB 
Journal, 20(10), 1739-1741. doi: 10.1096/fj.05-5682fje 
Shepherd, B. R., Jay, S. M., Saltzman, W. M., Tellides, G., & Pober, J. S. (2009). 
Human aortic smooth muscle cells promote arteriole formation by 
coengrafted endothelial cells. Tissue Eng Part A, 15(1), 165-173. doi: 
10.1089/ten.tea.2008.0010 
Shi, Q., Rafii, S., Wu, M. H., Wijelath, E. S., Yu, C., Ishida, A., . . . Hammond, W. 
P. (1998). Evidence for circulating bone marrow-derived endothelial cells. 
Blood, 92(2), 362-367.  
Shih, D. T., Chen, J. C., Chen, W. Y., Kuo, Y. P., Su, C. Y., & Burnouf, T. (2011). 
Expansion of adipose tissue mesenchymal stromal progenitors in serum-
free medium supplemented with virally inactivated allogeneic human 
platelet lysate. Transfusion, 51(4), 770-778. doi: 10.1111/j.1537-
2995.2010.02915.x 
Shoemaker, A. R., Mitten, M. J., Adickes, J., Ackler, S., Refici, M., Ferguson, D., 
. . . Elmore, S. W. (2008). Activity of the Bcl-2 family inhibitor ABT-263 in a 
panel of small cell lung cancer xenograft models. Clin Cancer Res, 14(11), 
3268-3277. doi: 10.1158/1078-0432.CCR-07-4622 
Siekmann, A. F., Covassin, L., & Lawson, N. D. (2008). Modulation of VEGF 
signalling output by the Notch pathway. Bioessays, 30(4), 303-313. doi: 
10.1002/bies.20736 
Siekmann, A. F., & Lawson, N. D. (2007). Notch signalling limits angiogenic cell 
behaviour in developing zebrafish arteries. Nature, 445(7129), 781-784. 
doi: 10.1038/nature05577 
Sieminski, A. L., Hebbel, R. P., & Gooch, K. J. (2004). The relative magnitudes of 
endothelial force generation and matrix stiffness modulate capillary 
morphogenesis in vitro. Exp Cell Res, 297(2), 574-584. doi: 
10.1016/j.yexcr.2004.03.035 
Singer, A. J., & Clark, R. A. (1999). Cutaneous wound healing. N Engl J Med, 
341(10), 738-746. doi: 10.1056/NEJM199909023411006 
Slack, J. M., Darlington, B. G., Heath, J. K., & Godsave, S. F. (1987). Mesoderm 
induction in early Xenopus embryos by heparin-binding growth factors. 
Nature, 326(6109), 197-200. doi: 10.1038/326197a0 
Sorensen, I., Adams, R. H., & Gossler, A. (2009). DLL1-mediated Notch 
activation regulates endothelial identity in mouse fetal arteries. Blood, 
113(22), 5680-5688. doi: blood-2008-08-174508 [pii]10.1182/blood-2008-
08-174508 
Sprick, M. R., & Walczak, H. (2004). The interplay between the Bcl-2 family and 
death receptor-mediated apoptosis. Biochim Biophys Acta, 1644(2-3), 
125-132. doi: 10.1016/j.bbamcr.2003.11.002 
Stellos, K., & Gawaz, M. (2007). Platelets and stromal cell-derived factor-1 in 
progenitor cell recruitment. Semin Thromb Hemost, 33(2), 159-164. doi: 
10.1055/s-2007-969029 
	   155 
Stratman, A. N., Davis, M. J., & Davis, G. E. (2011). VEGF and FGF prime 
vascular tube morphogenesis and sprouting directed by hematopoietic 
stem cell cytokines. Blood, 117(14), 3709-3719. doi: 10.1182/blood-2010-
11-316752 
Stratman, A. N., Saunders, W. B., Sacharidou, A., Koh, W., Fisher, K. E., 
Zawieja, D. C., . . . Davis, G. E. (2009). Endothelial cell lumen and 
vascular guidance tunnel formation requires MT1-MMP-dependent 
proteolysis in 3-dimensional collagen matrices. Blood, 114(2), 237-247. 
doi: 10.1182/blood-2008-12-196451 
Stratman, A. N., Schwindt, A. E., Malotte, K. M., & Davis, G. E. (2010). 
Endothelial-derived PDGF-BB and HB-EGF coordinately regulate pericyte 
recruitment during vasculogenic tube assembly and stabilization. Blood, 
116(22), 4720-4730. doi: 10.1182/blood-2010-05-286872 
Stromblad, S., Becker, J. C., Yebra, M., Brooks, P. C., & Cheresh, D. A. (1996). 
Suppression of p53 activity and p21WAF1/CIP1 expression by vascular 
cell integrin alphaVbeta3 during angiogenesis. J Clin Invest, 98(2), 426-
433. doi: 10.1172/JCI118808 
Stroncek, J. D., Ren, L. C., Klitzman, B., & Reichert, W. M. (2012). Patient-
derived endothelial progenitor cells improve vascular graft patency in a 
rodent model. Acta Biomater, 8(1), 201-208. doi: 
10.1016/j.actbio.2011.09.002 
Stump, M. M., Jordan, G. L., Jr., Debakey, M. E., & Halpert, B. (1963). 
Endothelium Grown from Circulating Blood on Isolated Intravascular 
Dacron Hub. Am J Pathol, 43, 361-367.  
Suchting, S., Freitas, C., le Noble, F., Benedito, R., Breant, C., Duarte, A., & 
Eichmann, A. (2007). The Notch ligand Delta-like 4 negatively regulates 
endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S 
A, 104(9), 3225-3230. doi: 10.1073/pnas.0611177104 
Swift, M. R., & Weinstein, B. M. (2009). Arterial-venous specification during 
development. Circ Res, 104(5), 576-588. doi: 104/5/576 [pii] 
10.1161/CIRCRESAHA.108.188805 
Takeshita, K., Satoh, M., Ii, M., Silver, M., Limbourg, F. P., Mukai, Y., . . . Liao, J. 
K. (2007). Critical role of endothelial Notch1 signaling in postnatal 
angiogenesis. Circ Res, 100(1), 70-78. doi: 01.RES.0000254788.47304.6 
[pii] 10.1161/01.RES.0000254788.47304.6e 
Taylor, R. C., Cullen, S. P., & Martin, S. J. (2008). Apoptosis: controlled 
demolition at the cellular level. Nat Rev Mol Cell Biol, 9(3), 231-241. doi: 
10.1038/nrm2312 
Tobe, T., Ortega, S., Luna, J. D., Ozaki, H., Okamoto, N., Derevjanik, N. L., . . . 
Campochiaro, P. A. (1998). Targeted disruption of the FGF2 gene does 
not prevent choroidal neovascularization in a murine model. Am J Pathol, 
153(5), 1641-1646. doi: 10.1016/S0002-9440(10)65753-7 
Traktuev, D. O., Prater, D. N., Merfeld-Clauss, S., Sanjeevaiah, A. R., 
Saadatzadeh, M. R., Murphy, M., . . . March, K. L. (2009). Robust 
functional vascular network formation in vivo by cooperation of adipose 
	   156 
progenitor and endothelial cells. Circ Res, 104(12), 1410-1420. doi: 
10.1161/CIRCRESAHA.108.190926 
Trindade, A., Kumar, S. R., Scehnet, J. S., Lopes-da-Costa, L., Becker, J., Jiang, 
W., . . . Duarte, A. (2008). Overexpression of delta-like 4 induces 
arterialization and attenuates vessel formation in developing mouse 
embryos. Blood, 112(5), 1720-1729. doi: blood-2007-09-112748 [pii] 
10.1182/blood-2007-09-112748 
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., . . . 
Elmore, S. W. (2008). ABT-263: a potent and orally bioavailable Bcl-2 
family inhibitor. Cancer Res, 68(9), 3421-3428. doi: 10.1158/0008-
5472.CAN-07-5836 
Uchiyama, T., Engelman, R. M., Maulik, N., & Das, D. K. (2004). Role of Akt 
signaling in mitochondrial survival pathway triggered by hypoxic 
preconditioning. Circulation, 109(24), 3042-3049. doi: 
10.1161/01.CIR.0000130647.29030.90 
Urbich, C., & Dimmeler, S. (2004). Endothelial progenitor cells: characterization 
and role in vascular biology. Circ Res, 95(4), 343-353. doi: 
10.1161/01.RES.0000137877.89448.78 
Uyttendaele, H., Ho, J., Rossant, J., & Kitajewski, J. (2001). Vascular patterning 
defects associated with expression of activated Notch4 in embryonic 
endothelium. Proc Natl Acad Sci U S A, 98(10), 5643-5648. doi: 
10.1073/pnas.09158459898/10/5643 [pii] 
VanWijk, M. J., VanBavel, E., Sturk, A., & Nieuwland, R. (2003). Microparticles in 
cardiovascular diseases. Cardiovasc Res, 59(2), 277-287.  
Varnum-Finney, B., Wu, L., Yu, M., Brashem-Stein, C., Staats, S., Flowers, D., . . 
. Bernstein, I. D. (2000). Immobilization of Notch ligand, Delta-1, is 
required for induction of notch signaling. J Cell Sci, 113 Pt 23, 4313-4318.  
Vasina, E. M., Cauwenberghs, S., Staudt, M., Feijge, M. A., Weber, C., Koenen, 
R. R., & Heemskerk, J. W. (2013). Aging- and activation-induced platelet 
microparticles suppress apoptosis in monocytic cells and differentially 
signal to proinflammatory mediator release. Am J Blood Res, 3(2), 107-
123.  
Vernon, R. B., & Sage, E. H. (1999). A novel, quantitative model for study of 
endothelial cell migration and sprout formation within three-dimensional 
collagen matrices. Microvasc Res, 57(2), 118-133. doi: 
10.1006/mvre.1998.2122 
Villa, N., Walker, L., Lindsell, C. E., Gasson, J., Iruela-Arispe, M. L., & 
Weinmaster, G. (2001). Vascular expression of Notch pathway receptors 
and ligands is restricted to arterial vessels. Mech Dev, 108(1-2), 161-164.  
Werner, N., Kosiol, S., Schiegl, T., Ahlers, P., Walenta, K., Link, A., . . . Nickenig, 
G. (2005). Circulating endothelial progenitor cells and cardiovascular 
outcomes. N Engl J Med, 353(10), 999-1007. doi: 
10.1056/NEJMoa043814 
Whittington, C. F., Yoder, M. C., & Voytik-Harbin, S. L. (2013). Collagen-polymer 
guidance of vessel network formation and stabilization by endothelial 
	   157 
colony forming cells in vitro. Macromol Biosci, 13(9), 1135-1149. doi: 
10.1002/mabi.201300128 
Wilting, J., & Christ, B. (1996). Embryonic angiogenesis: a review. 
Naturwissenschaften, 83(4), 153-164.  
Woywodt, A., Erdbruegger, U., & Haubitz, M. (2006). Circulating endothelial cells 
and endothelial progenitor cells after angioplasty: news from the 
endothelial rescue squad. J Thromb Haemost, 4(5), 976-978. doi: 
10.1111/j.1538-7836.2006.01920.x 
Wu, J., & Bresnick, E. H. (2007). Glucocorticoid and growth factor synergism 
requirement for Notch4 chromatin domain activation. Mol Cell Biol, 27(6), 
2411-2422. doi: 10.1128/MCB.02152-06 
Wu, J., Iwata, F., Grass, J. A., Osborne, C. S., Elnitski, L., Fraser, P., . . . 
Bresnick, E. H. (2005). Molecular determinants of NOTCH4 transcription 
in vascular endothelium. Mol Cell Biol, 25(4), 1458-1474. doi: 
10.1128/MCB.25.4.1458-1474.2005 
Wu, X., Rabkin-Aikawa, E., Guleserian, K. J., Perry, T. E., Masuda, Y., 
Sutherland, F. W., . . . Bischoff, J. (2004). Tissue-engineered microvessels 
on three-dimensional biodegradable scaffolds using human endothelial 
progenitor cells. Am J Physiol Heart Circ Physiol, 287(2), H480-487. doi: 
10.1152/ajpheart.01232.2003 
Wyllie, A. H. (2010). "Where, O death, is thy sting?" A brief review of apoptosis 
biology. Mol Neurobiol, 42(1), 4-9. doi: 10.1007/s12035-010-8125-5 
Xu, X., Weinstein, M., Li, C., Naski, M., Cohen, R. I., Ornitz, D. M., . . . Deng, C. 
(1998). Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal 
regulation loop between FGF8 and FGF10 is essential for limb induction. 
Development, 125(4), 753-765.  
Xue, Y., Gao, X., Lindsell, C. E., Norton, C. R., Chang, B., Hicks, C., . . . Gridley, 
T. (1999). Embryonic lethality and vascular defects in mice lacking the 
Notch ligand Jagged1. Hum Mol Genet, 8(5), 723-730.  
Yamaguchi, T. P., Dumont, D. J., Conlon, R. A., Breitman, M. L., & Rossant, J. 
(1993). flk-1, an flt-related receptor tyrosine kinase is an early marker for 
endothelial cell precursors. Development, 118(2), 489-498.  
Yamaguchi, T. P., Harpal, K., Henkemeyer, M., & Rossant, J. (1994). fgfr-1 is 
required for embryonic growth and mesodermal patterning during mouse 
gastrulation. Genes Dev, 8(24), 3032-3044.  
Yang, S., Graham, J., Kahn, J. W., Schwartz, E. A., & Gerritsen, M. E. (1999). 
Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube 
assembly and lumen formation in three-dimensional collagen gels. Am J 
Pathol, 155(3), 887-895. doi: 10.1016/S0002-9440(10)65188-7 
Yang, Z., Kondo, T., Voorhorst, C. S., Nabinger, S. C., Ndong, L., Yin, F., . . . 
Chan, R. J. (2009). Increased c-Jun expression and reduced GATA2 
expression promote aberrant monocytic differentiation induced by 
activating PTPN11 mutants. Mol Cell Biol, 29(16), 4376-4393. doi: 
MCB.01330-08 [pii]10.1128/MCB.01330-08 
Yang, Z. Z., Tschopp, O., Di-Poi, N., Bruder, E., Baudry, A., Dummler, B., . . . 
Hemmings, B. A. (2005). Dosage-dependent effects of Akt1/protein kinase 
	   158 
Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and 
cardiovascular and nervous system development in mice. Mol Cell Biol, 
25(23), 10407-10418. doi: 10.1128/MCB.25.23.10407-10418.2005 
Yao, R., & Cooper, G. M. (1995). Requirement for phosphatidylinositol-3 kinase 
in the prevention of apoptosis by nerve growth factor. Science, 267(5206), 
2003-2006.  
Yap, T. A., Walton, M. I., Hunter, L. J., Valenti, M., de Haven Brandon, A., Eve, 
P. D., . . . Garrett, M. D. (2011). Preclinical pharmacology, antitumor 
activity, and development of pharmacodynamic markers for the novel, 
potent AKT inhibitor CCT128930. Mol Cancer Ther, 10(2), 360-371. doi: 
10.1158/1535-7163.MCT-10-0760 
Yoder, M. C., Mead, L. E., Prater, D., Krier, T. R., Mroueh, K. N., Li, F., . . . 
Ingram, D. A. (2007). Redefining endothelial progenitor cells via clonal 
analysis and hematopoietic stem/progenitor cell principals. Blood, 109(5), 
1801-1809. doi: 10.1182/blood-2006-08-043471 
Zernecke, A., Schober, A., Bot, I., von Hundelshausen, P., Liehn, E. A., Mopps, 
B., . . . Weber, C. (2005). SDF-1alpha/CXCR4 axis is instrumental in 
neointimal hyperplasia and recruitment of smooth muscle progenitor cells. 
Circ Res, 96(7), 784-791. doi: 10.1161/01.RES.0000162100.52009.38 
Zhang, G., Zhou, J., Fan, Q., Zheng, Z., Zhang, F., Liu, X., & Hu, S. (2008). 
Arterial-venous endothelial cell fate is related to vascular endothelial 
growth factor and Notch status during human bone mesenchymal stem 
cell differentiation. FEBS Lett, 582(19), 2957-2964. doi: S0014-
5793(08)00622-4 [pii]10.1016/j.febslet.2008.07.031 
Zheng, L., Dengler, T. J., Kluger, M. S., Madge, L. A., Schechner, J. S., Maher, 
S. E., . . . Bothwell, A. L. (2000). Cytoprotection of human umbilical vein 
endothelial cells against apoptosis and CTL-mediated lysis provided by 
caspase-resistant Bcl-2 without alterations in growth or activation 
responses. J Immunol, 164(9), 4665-4671.  
Zhong, T. P., Childs, S., Leu, J. P., & Fishman, M. C. (2001). Gridlock signalling 
pathway fashions the first embryonic artery. Nature, 414(6860), 216-220. 
doi: 10.1038/3510259935102599 [pii] 
Zhou, M., Sutliff, R. L., Paul, R. J., Lorenz, J. N., Hoying, J. B., Haudenschild, C. 
C., . . . Doetschman, T. (1998). Fibroblast growth factor 2 control of 
vascular tone. Nat Med, 4(2), 201-207.  
Zhu, Q. S., Ren, W., Korchin, B., Lahat, G., Dicker, A., Lu, Y., . . . Lev, D. (2008). 
Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for 
p53-independent up-regulation of GADD45 alpha. Cancer Res, 68(8), 
2895-2903. doi: 10.1158/0008-5472.CAN-07-6268 
Zong, W. X., Edelstein, L. C., Chen, C., Bash, J., & Gelinas, C. (1999). The 
prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-
kappaB that blocks TNFalpha-induced apoptosis. Genes Dev, 13(4), 382-
387.  
Zorn, A. M., & Wells, J. M. (2009). Vertebrate endoderm development and organ 
formation. Annu Rev Cell Dev Biol, 25, 221-251. doi: 
10.1146/annurev.cellbio.042308.113344 
	  	  
CURRICULUM VITAE 
Hyojin Kim 
EDUCATION 
Doctor of Philosophy, Biochemistry and Molecular Biology  2015 
Indiana University 
Bachelor of Science, Genetic Engineering  2006 
Sung Kyun Kwan University 
 
PROFESSIONAL EXPERIENCE 
Ph.D. (2008-2015) 
Indiana University, School of Medicine, Department of Biochemistry and 
Molecular Biology 
• Enhanced cell survival and vessel forming ability of endothelial colony 
forming cell (ECFC) by using human platelet lysates (HPL) and Caspase 
inhibitors in a three dimensional (3D) collagen matrix model of 
vasculogenesis in vivo and in vitro. Cell survival rates and vessel forming 
ability were analyzed by using multi-color flow cytometry and additional 
molecular analysis techniques. 
• Improved cell survival and vessel forming ability of ECFC by activating 
Notch signaling with Dll1 stromal cells in a 3D collagen matrix model of 
vasculogenesis in vivo and in vitro. Multi-color flow cytometry and 
	  	  
additional molecular analysis techniques were used to analyze cell 
survival rates and vasculogenesis.  
• Developed methods to identify and isolate highly proliferative ECFC using 
multi-color flow cytometry, multispectral imaging flow cytometry, confocal 
microscopy and additional molecular analysis techniques.  
• Published two manuscripts and two scientific abstracts as a first author. 
• Under revision of one manuscript and process in writing one manuscript 
for submission in 2015 
Research Assistant (2007-2008) 
University of Utah, School of Medicine, Division of Hematology 
• Cloned Guinea pig and Octodon degus Epo and EpoR genes and 
compared to human Epo and EpoR genes to compare and demonstrate 
the animals’ genetic adaptability of the two species to altitude through high 
oxygen affinity in blood. Analyzed the molecular mechanism of Hypoxia 
Responsive Elements (HREs) in mouse Epo genome from various organs 
by chromatin immunoprecipitation assay (ChIP) to demonstrate the 
regulatory elements of EPO gene response to hypoxic condition in various 
organs.  
• Demonstrated accelerated differentiation of erythropoiesis and gene 
expressions in polycythemia vera (PV) by molecular analysis of PV in in 
vitro differentiated erythroid progenitors. 
	  	  
• Published two scientific abstracts for conference presentations as a 
contributing author. 
Research Assistant (2004-2005) 
Nation Institute of Agricultural Biotechnology, Department of Microbial Genetics 
• Developed an isolation method and functional assay to define 
mechanisms of drug candidates, antifungal materials, from Enterobacter 
sp. B54 to demonstrate antifungal activities against to Phytophthora 
Capsici. 
Research Assistant (2003-2004) 
Sung Kyun Kwan University, Department of Genetic Engineering  
• Cloned regulatory genes and downstream genes of the Quorum sensing 
region of Bacillus subtills genome to characterize Quorum-sensing 
pheromones signal molecules secreted from Gram-positive bacteria.
 
PUBLICATIONS AND PRESENTATIONS 
Peer-Reviewed 
• Hyojin Kim, Lan Huang, Paul J. Critser, Zhenyun Yang, Rebecca J. Chan, 
Lin Wang, Nadia Carlesso, Sherry L. Voytik-Harbin, Irwin D. Bernstein, 
and Mervin C. Yoder, “Notch ligand Delta-like 1 (Dll1) promotes in vivo 
vasculogenesis in human cord blood derived endothelial colony forming 
cells (ECFCs)”, Cytotherapy, 2015 pii: S1465-3249 (14) 00883-4.  
	  	  	  
• Hyojin Kim, Nutan Prasain, Sasidhar Vemula, Michael J. Ferkowicz, 
Momoko Yoshimoto, Sherry L. Voytik-Harbin, and Mervin C. Yoder, 
“Human platelet lysate improves human cord blood derived ECFC survival 
and vasculogenesis in three dimensional (3D) collagen matrices”, 
Microvascular research, 2015 pii: S0026-2862(15)00064-3. 
Under-Revision 
• Garbacea I, O’Reilly M, Ionescu L, Alphonse RS, Shelley WC, Hyojin 
Kim, Rajabali S, Yoder MC, Thebaud B., “Functional differences between 
placental micro- and macro-vascular endothelial colony forming cells”, 
Placenta. 
In preparation 
• Hyojin Kim, Nutan Prasain, Sherry L. Voytik-Harbin, and Mervin C. 
Yoder, “Inhibition of apoptosis of ECFC enhances human cord blood 
derived ECFC survival and vasculogenesis in three dimensional (3D) 
matrices”.  
Conference Presentations 
• Hyojin Kim, Nutan Prasain, Sasidhar Vemula and Mervin C. Yoder, 
“Methods to improve ECFC survival in 3D collagen gels in vitro and 
promotion of ECFC vascularization in vivo”, Abstract of NAVBO Vascular 
Biology meeting 2014. Abstract and Poster presentation P04. 
• Hyojin Kim, Ben Wilson, Lan Huang, Irwin Berstein, Lin Wang, Nadia 
Carlesso and Mervin C. Yoder, “Notch signaling enhances in vivo 
vasculogenic function of human cord blood endothelial colony forming 
	  	  	  
cells”, Abstract of NAVBO Vascular Matrix Biology and Bioengineering 
Workshop 2011 Vascular Networks program, Abstract and Poster 
presentation 053-013. 
• Donghoon Yoon, PhD, Jihyun Song, MS, Hyojin Kim, Bumjun Kim, PhD, 
Hyejin Shin, MS, Gregory Arnold, PhD, Steven Elliott, PhD, and Josef T. 
Prchal, MD, “Tissue-Specific HIF-1 and HIF-2 Regulatory Elements and 
Their Roles in Erythropoietin Gene Expression”, Blood, 2011, 112:1303.  
• Hana Bruchova, PhD, Donghoon Yoon, PhD, Archana Agarwal, MD, Eva 
Otahalova, Hyojin Kim and Josef T. Prchal, MD, “Erythropoiesis in 
Polycythemia Vera Is Hyper-proliferative and Has Accelerated 
Differentiation during in vitro Erythroid Expansion and Is Associated with 
Higher Expressions of cMYB and EPOR at Early Erythroid Progenitors”, 
Blood, 2007, 110: Abstract 1549. 
 
TECHNICAL SKILLS 
Cell biology 
Mammalian (human) cell/tissue culture, Immunohistochemistry, Frozen tissue 
sectioning, Tissue homogenization and cell extraction, Fluorescent 
microscopy and confocal microscopy, Multi-color (>5) flow cytometry and 
Multi-color (>5) imaging flow cytometry (Amnis), Annexin V/PI apoptosis 
assay and Caspase-1 and -3/7 assay, MTT assay, Mouse tissue extraction, in 
vitro and in vivo hypoxia treatment of Guinea pig, Implantation of human 
	  	  	  
endothelial cell-seeded collagen constructs into NOD/SCID mice, Chromatin 
immunoprecipitation assay (ChIP)  
Computer 
FlowJo, Cell Quest, ImageJ, Macintosh and Windows operating systems, 
Microsoft Office, Photoshop 
 
VOLUNTEER EXPERIENCE 
• Trained and managed projects for summer/intern students (undergraduate 
students and medical students) 2013-2015 
• Volunteer to lead and answer questions for Indiana high school students 
and teachers at Molecular Medicine in Action (MMIA) 2012 
• Volunteer to help registration and technical support at US-Korea 
Conference (UKC) 2011 
• Manager of the student’s association in Sung Kyun Kwan University 
